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Abstract 
Cancer and its anti-neoplastic treatment are frequently complicated by venous 
thromboembolism (VTE) occurrence. Multiple myeloma (MM), a haematological malignancy 
and Pancreatic cancer (PC), a solid tumour are two common malignancies with similarly high 
VTE incidence, which worsens during treatment. Thrombin production is a key step in the 
pathologic evolution of VTE and may play an important role in determining VTE risk in cancer 
patients. The calibrated automated thrombography (CAT) assay is emerging as a reliable tool 
for real time estimation of thrombin generation (TG) potential, and there is a clinical need for 
such knowledge on the dynamic pathways underlying the thrombotic phenotype of various 
malignancies. Hypothetically, TG measurement may also provide a view of the haemostatic 
variances that exist in MM and PC as cancers with high VTE incidences. Therefore, this thesis 
aimed to explore the TG changes that exist in both malignancies in patients before, during 
and after treatment. It also explores the interaction of Tissue Factor (TF) associated with 
Microvesicles (MVs) or TFMVs with tumour stroma especially the endothelium, or any 
procoagulant changes such as thrombin production due to this interaction; and thus, aimed 
to study TFMVs involvement through the disruption of endothelial haemostasis. The results 
presented in this thesis demonstrate that solid and haematological malignant cells have 
significantly differing TG kinetics that may correlate with TF expression levels, and that TG 
parameters identified changes in MM during treatment, specifically the Lag times and Times-
to-Peak parameters were progressively elevated until the third chemotherapy cycle. 
In summary, procoagulant activity on the endothelium can be stimulated by TFMVs produced 
by cancer cells in vitro, and this study of thrombin as a procoagulant factor in MM and PC and 
its relationship to TFMVs may lead to future understanding of their important role in cancer 
VTE development, and thus merits further study. 
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Chapter:1  General Introduction 
 
 
 
1.1  Cancer  
 
 
The occurrence of cancer is a global problem. Of all non-communicable diseases 
(NCDs) worldwide, cancer was the second highest cause of deaths in 2015 second 
only to cardiovascular disorders, and it accounted for 8.8 million deaths (22% of 
NCDs), and nearly 1 out of every 6 deaths, with worse outcomes in low-income 
countries (World Health Organization (WHO) Global Health Observatory Cancer Fact 
sheet, 2017). Latest WHO data shows that in the UK, the age-standardized incidence 
rate (per 100 000 population) from cancer is 272.9 in both sexes. 
 
 
Historically, cancer is a disease of the elderly, with over half of the incidence in the 
UK in people aged 70 and above. In England, there were 299,923 new cancer 
registrations in 2015 equivalent to 822 per day, which represented an increase of 
4,183 registrations from the same point in the previous year, with incidence in males 
slightly higher than in females (Office of National statistics, 2015). In this survey, 
breast (15.4%), prostate (13.4%), lung (12.5%) and colorectal (11.6%) cancer continue 
to account for more than half of the malignant cancer registrations in England for all 
ages combined. In the same year, the number of registrations of Pancreatic cancer 
(PC) cases was in 4,175 males and 4,144 females (2.8% in total) while Multiple 
myeloma (MM) recorded 2,686 male and 1,946 female cases (1.5%) (Office of 
National statistics, 2015). 
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1.1.1  Cancer biology and haemostasis 
 
The haemostatic system is a complex series of biological processes that governs blood 
flow and coagulation, and it is often disrupted in many diseases. Various 
epidemiologic studies have identified several mechanisms that contribute to arterial 
or venous coagulopathy which includes abnormal levels of coagulation factors such 
as prothrombin(Poort et al., 1996), fibrinogen(van Hylckama Vlieg & Rosendaal, 
2003) and other pro-/anticoagulant proteins (Griffin et al., 1981; Pabinger & 
Schneider, 1996; Kamphuisen et al., 2001; Danesh et al., 2005; Wolberg et al., 2005; 
Allen et al., 2007). Other mechanisms involve dysfunction in thrombin generation 
(TG)(Macfarlane & Biggs, 1953; Butenas et al., 2000; Hron et al., 2006), tissue factor 
(TF) clotting activity and resistance to inactivation(Bertina et al., 1994; Zoller et al., 
1994), fibrinolysis inhibition(Fay et al., 1997; Meltzer et al., 2010). In cancer, there is 
a marked departure from normal homeostatic maintenance to prothrombotic states, 
which results in hypercoagulable disorders that are linked to its progress (Trousseau, 
1865; Lee, 2002). There is a spectrum of clinical manifestations of haemostatic 
dysfunctions that can be observed in cancer patients; from venous thromboembolic 
(VTE) events in patients being treated with chemotherapy, to arterial embolism and 
disseminated intravascular coagulation (DIC), mostly in patients with haematological 
malignancies or metastatic cancer(Prandoni et al., 2007).  
 
1.1.2  Cancer VTE: occurrence, risk and clinical implications 
 
VTE is a cumulative term for pulmonary embolism (PE) and deep venous thrombosis 
(DVT), which are both thrombotic disorders that may occur as an early manifestation 
of cancer, and are important causes of cancer treatment compromise that results in 
high mortality rates(Khorana et al., 2007). PE develops because of small or large 
blood clots (thrombi) that travels as emboli to disrupt lung vessel function, while DVT 
occurs due to clot formation located most commonly in the deep vessels of the legs.  
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Virchow’s triad, developed by Rudolph Virchow in 1884 has been fundamental to 
understanding the pathogenesis of blood clot formation in cancer patients (Virchow, 
1856; Rickles & Falanga, 2009). The triad identified three specific attributes in normal 
homeostasis, which interplay to provide a suitable environment for thrombosis 
development. Similarly, cancer VTE is of multifactorial aetiology, and develops as an 
interplay of these three main attributes of Virchow’s: blood stasis in blood vessels 
(due to prolonged immobilization, vascular compression), endothelium dysfunction 
(from direct neoplastic invasion, chemotherapy damage) and hypercoagulability 
(induced by cancer cell prothrombotic properties as shown in figure 1.1) that may 
occur in the background of genetic abnormalities(Paskauskas et al., 2008).  
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Figure 1.1 The hypercoagulable state due to prothrombotic attributes of cancer cells. 
Prothrombotic expressions of cancer cells such as release of inflammatory cytokines, 
angiogenic molecules, membrane adhesion receptors, TFMVs result in the 
production of thrombin that results in fibrin formation, leading to a hypercoagulable 
state. Abbreviations: TFMVs are tissue factor (TF) associated with microvesicles 
(MVs); NETS are Neutrophil extracellular traps; VTE is Venous thromboembolism. 
Modified from Prandoni et al(2005)(Prandoni et al., 2005) 
 
 
• CANCER CELLS
-Production of procoagulant and TFMVs
-Direct blood clotting activation
-Expression of adhesion receptors
-Cytokines release
-Angiogenic factor release
-Activation of host endothelial cells, pro-adhesive platelet cells, 
procoagulant leucocytes e.g neutrophils that release NETS, 
monocytes that produce TF
-Fibrinolytic activities
• FIBRIN CLOT
Thrombin 
formation
• RISK OF VTE
Hypercoagulable 
state
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1.1.2.1  VTE risk in Cancer  
VTE was first recognised as linked to cancer by Trousseau over a hundred years ago 
(Trousseau, 1865; Piccioli et al., 1996). Recently, the risk of developing VTE has been 
identified as six to seven times increased in cancer patients when compared with 
non-cancer patients (Heit et al., 2000; Pabinger et al., 2013). VTE is the second most 
common cause of cancer deaths(Ambrus et al., 1975), and studies have consistently 
demonstrated VTE to be an early predictor of mortality in cancer patients (Chew et 
al., 2006; Paskauskas et al., 2008; Hisada & Mackman, 2017), with two-fold higher 
mortality in patients with PE (Naess et al., 2007). The highest risk of VTE occurrence 
in cancer has been determined in a large population-based cohort study to be within 
the first 3 months from the diagnosis of cancer(Blom et al., 2005). In addition, the 
occurrence of ‘silent’ sub-clinical VTE is possibly higher than the 15% clinically 
detectable VTE seen in cancer patients(Johnson et al., 1999), worsening the clinical 
outcome for cancer patients.   
 
The risk of VTE occurrence is multifactorial and can be generally classified into 3 main 
categories; cancer-specific (qualities of the malignancy), patient-specific (consisting 
of patient characteristics, haemostatic system and blood counts) and therapy-specific 
(Figure 1.2). Cancer itself is an independent risk factor for VTE(Heit et al., 2000). 
Conversely, the risk of diagnosing cancer after VTE is established is also high, 
especially in the first 6 months to 1 year following a thrombotic incident (Sorensen et 
al., 1998). Although controversial, this opinion suggests that VTE could either be an 
indication of occult cancer many years in the making through rigorous screening, or 
that cancer and VTE may at the very least, share common risk factors(Prandoni & 
Samama, 2008). However, the efficacy of extensive screening strategies in routine 
practice has been called into question by a multicentre randomized controlled study 
due to findings of no clinical benefit in cancer patients (Carrier et al., 2015). In the 
study, there were no associations between the use of comprehensive or aggressive 
methods to screen for VTE with serious adverse events or impact on survival, 
although this trial was limited in its design with inherent outcome bias.  
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Other risk factors for VTE are patient-specific and include a wide array such as older 
age, obesity, dehydration, surgery, trauma, prolonged hospital stays, immobility, use 
of contraceptive pills or post-menopausal treatments(Franco & Reitsma, 2001). 
Other common risk factors include tumour mass effect, lymph node occlusion and 
there are also some patient conditions that have substantial VTE risk such as 
paroxysmal nocturnal haemoglobinuria, antiphospholipid antibody syndrome and 
myeloproliferative disorders(Franco & Reitsma, 2001). Myeloproliferative disorders 
(MPD) in particular are a collective group of haematologic disorders that involve 
cellular overproduction in the bone marrow and peripheral blood, in which vascular 
thrombotic events are one of the earliest manifestations in about 25-30% of 
diagnosed patients(Hachulla et al., 2000; De Stefano et al., 2008). These patient 
conditions may or may not be associated with genetic factors such as F5Leiden and 
F2 mutations, deficiencies of antithrombin III, protein C and S, which is likely to 
compound the risk(Anderson et al., 1992; Rosendaal, 1997; Kujovich, 2011). For 
example in heterozygous carriers of the F5 Leiden mutation, the regular use of 
contraceptive pills carries an higher multiplied VTE risk (an odds ratio (OR) = 15·6) 
when compared with risk carried by use of the pills alone (OR = 4) or presence of F5 
Leiden mutation alone in the general populace (OR = 6)(Wu et al., 2005). 
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Figure 1.2 Risk factors for cancer VTE development.  
Risk factors include tumour characteristics, patient characteristics, variations in the 
haemostatic system, type of treatment administered, concentrations of blood cells. 
Modified from Lyman et al, 2013(Lyman et al., 2007).  
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1.1.2.2  Chemotherapy and the risk of VTE 
Anti-cancer therapy also poses an additional high risk of VTE. These include 
chemotherapy as adjuvant or neo-adjuvant, hormonal medications, antiangiogenic 
agents, combination treatment regimens and surgery have a pro-thrombotic 
effect(Falanga & Marchetti, 2012). While the actual incidence is unknown in patients 
receiving chemotherapy, VTE risk can be as high as 11% or more annually, making 
chemotherapy a major independent risk factor by itself (Otten et al., 2004). For 
example, VTE incidence of about 18% have been associated with Non-small cell lung 
cancer treated with Cisplatin-based chemotherapy in a prospective study of major 
vascular events (Numico et al., 2005). Furthermore, the risk of VTE can be quadrupled 
in cancer patients on chemotherapy as opposed to those with cancer alone(Heit et 
al., 2000). The incidence of chemotherapy-associated VTE may also be 
underestimated, due to other confounding factors that may increase the risk in 
cancer patients such as the use of indwelling intravenous catheters, surgery, 
dehydration, immobilisation and prolonged hospital stay(Otten et al., 2004). An 
increased VTE risk is also frequently associated with chemotherapy regimens 
administered in certain cancers with naturally high VTE incidences, such as pancreatic 
cancer and high-grade glioma, which are known for high incidence rates of up to 
28%(Mandalà et al., 2007; Simanek et al., 2007) while an elevated risk from 
3%(Khorana et al., 2006)  to 9%(Mandala et al., 2010) due to chemotherapy has been 
observed in those cancers with low VTE incidence such as breast cancer.   
 
As incidence of VTE varies by cancer type, site, dose and type of medications 
administered (Haddad & Greeno, 2006), chemotherapy-induced hypercoagulability 
in relation to specific drug combinations in treatments is a significant complication 
and can be a difficult study to undertake, due to the intricate pathogenic mechanisms 
that are likely involved. One study assessed this and reported that the use of 
Thalidomide as a monotherapy, carries a 5% lesser VTE risk when compared to its use 
in combinations for MM treatment (Singhal et al., 1999). Phase 1 clinical studies 
conducted by the Southern Europe New Drugs Organisation (SENDO) from 2000 to 
2010 described significantly elevated VTE occurrence amongst advanced cancer 
patients that were administered various cytotoxic combination regimens(Mandala et 
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al., 2012). In another phase 1 clinical trial, cisplatin and gemcitabine combinations 
with anti-angiogenic agents (Semaxanib SU5416) resulted in severe thrombogenic 
complications in patients with solid tumours, where 9 serious thromboembolic 
events were evoked in 8 out of 19 patients(Kuenen et al., 2002). In addition, a meta-
analysis of 15 randomized controlled clinical trials demonstrated that there was an 
increased VTE incidence of 12% during treatment with standard chemotherapy 
combinations in several advanced solid tumours, further lending support to a 
significant VTE association with chemotherapy(Scappaticci et al., 2007).   
 
Although the mechanisms for this chemotherapy-related thrombotic phenomenon 
are poorly defined in literature, nevertheless there are various possible mechanisms 
that have been postulated; some involving direct endothelial damage in combination 
with tumour-specific products such as pro-coagulant proteinase(Falanga et al., 2013), 
and subsequent activation of the haemostatic cascade through monocytes or platelet 
induction(Walsh et al., 1992; Togna et al., 2000; Haddad & Greeno, 2006). For 
instance, Doxorubicin (DOX), an anthracycline agent, is used in many cancers such as 
MM, and it can directly induce platelet activation (Figure 1.3) and consequent 
thrombus formation through consistently increased cell membrane 
phosphatidylserine (PS) lipid exposure and PS-bearing microvesicle (MV) generation 
(Kim et al., 2011). Others less direct methods include stimulating the release of 
procoagulant MVs(Date et al., 2013), other prothrombotic proteins and inflammatory 
cytokines such as proangiogenic vascular endothelial growth factor (VEGF), and 
exerting an inhibitory effect on anti-thrombotic regulators such as protein C, S and 
antithrombin III as illustrated in figure 1.3. An example is the significant reduction of 
functional protein C levels in colorectal cancer patients on Fluorouracil (a pyrimidine 
analogue) infusion, which abated following treatment cessation(Feffer et al., 1989).  
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Figure 1.3 Chemotherapy and VTE.  
Chemotherapy can induce varied thrombogenic effects through several mechanisms 
such as direct endothelial toxicity, platelet activation and aggregation, monocytic TF 
expression, decreased thrombin regulators such as antithrombin III (AT III), protein C 
and S, altered fibrinolytic activities, increase TF activity from endothelial cell 
apoptosis, tumour cell secretion of prothrombotic cytokines such as PAI-1, IL-1β, TNF-
α, and increased vascular endothelial TF expression levels. Adapted from Haddad and 
Greeno, 2006(Haddad & Greeno, 2006). 
 
Chemotherapy regimens often act at the molecular level, by involving DNA and 
mitochondrial damage, which induces apoptosis in cells(Caley & Jones, 2012). They 
interfere with cell division and stimulate widespread cell death. There are also 
membrane alterations caused by DNA/RNA intercalating drugs such as Cisplatin and 
Adriamycin, which potentiate coagulation (Ahmad et al., 1995). Increased TF activity 
as shown in figure 1.3 is also a marked phenomenon in cancer-related thrombosis, 
and a significant role has been suggested in association with MVs(Lechner & 
Weltermann, 2008). Other effects of chemotherapy include increased endothelial 
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and monocytic TF expression, stimulation of endothelial cell apoptosis resulting in 
more PS exposure, and alterations in coagulation and fibrinolytic molecules to 
support prothrombotic tendencies (Figure 1.3). However, there are still several gaps 
in knowledge of the specific coagulation processes that constitute prothrombotic 
mechanisms in cancer patients, that require filling to achieve better understanding 
of the VTE complications that result from chemotherapy use. 
 
 
1.1.2.3  VTE prognosis and anti-thrombotic interventions 
VTE occurrence in cancer patients indicates poor prognosis and early 
mortality(Khorana, 2010). In a population-based study of 3135 patients diagnosed 
with cancer, 1-year survival was only 12% in patients that experience it (Sorensen et 
al., 2000; Haddad & Greeno, 2006). This significant association with short-term 
prognosis is also reflected in a prospective observational cohort of 4458 adult cancer 
patients, which Kuderer et al evaluated between 2002 to 2006 in 115 U.S 
sites(Kuderer et al., 2008). In this study, VTE developed in 93 (2.1%) patients at a 
median of 38 days, while 137 died during observation at median follow-up of 75 days, 
and it was calculated in a multivariate analysis that VTE incidence was a significant 
independent predictor of early mortality all round (HR=6.98, 95%CI: 2.83–17.21; 
P<.0001). Due to the associated high morbidity and mortality, it is important to 
develop strategies that can prevent VTE and reduce the incidence in cancer patients. 
VTE thromboprophylaxis is safe and feasible, as has been shown by various studies 
that have reported considerable benefits of use of thromboprophylaxis with 
concurrent chemotherapy. For example, in the FRAGEM and CONKO-004 clinical 
trials, the incidence rates of VTE were significantly reduced in advanced pancreatic 
cancer with simultaneous use of Low molecular weight heparin (LMWH) and 
chemotherapy; from 23% in patients with no anticoagulation to 3% in patients with 
Dalteparin in FRAGEM and 15% in patients with no anticoagulation to 5% in patients 
with Enoxaparin in CONKO-004 trials(Riess et al., 2010; Maraveyas et al., 2012).  
 
VTE is mostly preventable, and widespread antithrombotic therapies based on 
heparin and Vitamin K analogues are recommended in clinical use by the National 
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Comprehensive Cancer Network (NCCN)(Khorana, 2007), American Society of Clinical 
Oncology (ASCO)(Lyman et al., 2007), and European Society for Medical Oncology 
(ESMO)(Mandala et al., 2011) and are effective. In addition, a multinational cross-
sectional study across 32 countries showed that 51.8% of hospitalized patients aged 
40-72 in 358 hospitals had a VTE risk from both surgical and medical units, and a low 
number received appropriate prophylaxis, which further signifies the importance of 
hospital-wide uptake of therapeutic recommendations worldwide (Cohen et al., 
2008). In England, the National Institute for Health and Care Excellence (NICE) 
therefore produced a set of guidelines, targeted at reducing inconsistent use and 
under usage of thromboprophylaxis for cancer patients in hospitals in the 
country(NICE, 2010). Clinical practice guidelines for the prevention of VTE 
recommend that hospitalized cancer patients, cancer patients undergoing surgery, as 
well as MM patients on chemotherapy should receive routine VTE prophylaxis(Lyman 
et al., 2007; Mandala et al., 2011; Farge et al., 2013). In practice, such routine anti-
thrombotics recommended for hospitalized cancer patients are continued till disease 
control is achieved. To achieve this end, risk assessments have been regularly 
performed for all hospitalized patients since 2007, and the possibility of developing 
more sensitive risk assessment tools and biomarkers with better precision is 
desirable. One example is a predictive risk model developed by Khorana et al, which 
identifies cancer patients with high individual risk of thrombosis based on basic 
clinical and laboratory variables which can determine cancer patients with 
approximately 7% short-term risk of symptomatic thromboembolism (Khorana et al., 
2008b). Thromboprophylaxis regimens with LMWH such as Dalteparin (Fragmin TM) 
which target pro-coagulant agents thrombin and Factor Xa(FXa), are currently 
indicated before and up to several weeks after surgery and in chemotherapy 
combinations in clinical management(Khorana, 2007). However, the clinical burden 
is still overwhelming in cancer patients, for instance, studies show that even while on 
oral anticoagulants; the incidence of recurrent thromboembolism is still twice as 
probable in patients with cancer (Levitan et al., 1999; Bona et al., 2000). Furthermore, 
these recurrent cases have even poorer survival rates, can be resistant to further oral 
anticoagulation and are more likely to need prolonged hospitalization(Caine et al., 
2002). The emergence of new direct oral anticoagulants such as Apixaban have 
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provided a useful oral alternative to LMWH, due to issues that exist with non-
compliance from patients averse to LMWH given by injections and prohibitive cost of 
long-term use in some metastatic cancers(Noble et al., 2015; Smrke & Gross, 2017). 
However, as oral anticoagulation efficacy is not fully established in clinical practice, 
careful consideration over any advantage needs to be fully assessed per patient to 
ensure actual clinical benefit (Carrier et al., 2014). In addition, more targeted, 
personalized and safer therapies need to be designed and developed to improve 
prognosis, particularly as these cancer patients may also have greater risks of 
bleeding than non-cancer patients.  
 
1.2  Coagulation cascade 
 
The coagulation cascade is a sequence of clotting factors in the haemostatic system, 
which progress in a stepwise fashion to produce coagulation in the blood. Two groups 
(Macfarlane in the U.K and Davie & Ratnoff in the U.S.A) first proposed this waterfall 
process in 1964, and described the concerted interaction of blood components that 
are mostly serine proteases involved in two main pathways; an intrinsic and an 
extrinsic-TF driven (Davie & Ratnoff, 1964; Macfarlane, 1964). More recently, a 
different view emerged which suggested that the development of clotting can be 
influenced by the cell surfaces the factors interact with, and that such clotting 
processes are determined by the properties of the lipid-containing cell surfaces which 
regulate it (Hoffman & Monroe, 2001). Consequently, the cascade theory has now 
largely been superseded by a proposed model where the clotting pathways is not 
separated distinctly into two but have overlapping and interdependent components. 
In this model, cells with similar phospholipid layers such as phosphatidylserine (PS) 
may have different roles in coagulation process which depends on the constituent of 
their surface receptors(Hoffman & Monroe, 2001).  By highlighting the importance of 
specialized roles of surface receptors for coagulation proteins, this model is more 
adaptable and addresses some inadequacies of the preceding system. It reflects 
better the intricate mechanisms that may be found in vivo, and may aid 
understanding of clotting irregularities in haemostatic disorders(Hoffman & Monroe, 
2001). 
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1.2.1  Phases of coagulation 
 
There are 3-4 phases of coagulation in the haemostatic process, which are illustrated 
in table 1.1 and figure 1.4 as: 
 
§ Initiation 
§ Amplification 
§ Propagation 
§ Termination or Inhibition 
 
Table 1.1 The 4 phases of cell-based model of coagulation  
Modified from Hoffman and Monroe, 2001 (Hoffman & Monroe, 2001) 
Initiation Amplification Propagation Termination 
Vascular 
endothelium 
and circulating 
blood cells are 
disturbed; 
there is 
interaction 
between TF and 
plasma-derived 
factor VII  
Thrombin 
activation of 
aggregated 
platelets, 
cofactors V and 
VII, and factor XI 
on the platelet 
surface 
Large amounts 
of thrombin 
production 
which leads to 
formation of a 
stable plug at 
the site of 
insult and 
subsequent 
cessation of 
blood loss 
Restriction of 
the coagulation 
process to 
prevent 
thrombotic 
occlusion of 
vessels 
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Figure 1.4 The Coagulation cascade.  
Illustration of the clotting cascade based on cell surfaces comprising of the phases of 
coagulation -initiation, amplification and propagation from Ferreira et al, 2010 
(Ferreira et al., 2010), originally adapted from Vine, 2009 (Vine, 2009). Abbreviation: 
FT is Tissue Factor, FvW is Von Willebrand factor. 
 
 
Initiation: 
 
There are two main methods of initiation of the clotting cascade; and TF is a key 
player in both(Hoffman & Monroe, 2001). There is a well-known process where TF in 
the cell membrane, once exposed to plasma (as explained below) is complexed with 
factor VII (FVII) and proteases, and this complex attracts and serves as a homing 
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beacon to the site of endothelial injury(Hoffman & Monroe, 2001). This localization 
allows platelets to aggregate and leads to further production of other cytokines that 
further attracts other secondary members of the clotting system, such as monocytes 
and neutrophils. Platelets are also stimulated to produce thrombin whose activity 
leads to fibrin production and clot formation. In the second more recent proposed 
explanation, TF-containing MVs carry circulating TF in the bloodstream (produced 
due to stimulating conditions in vivo) and these TF vehicles find and bind free 
platelets (that do not normally carry TF intrinsically) or platelets of an evolving 
thrombus plug(Conde et al., 2005). These MVs may be produced from an initial vessel 
wall insult or elsewhere in the body and from different types of cells, which may 
explain blood clot formation in a location different to the site of initial injury. This 
model lends itself well to cancer VTE development, and may also serve to explain 
how cancer MVs bearing TF may lead to indiscriminate thrombosis(Conde et al., 
2005). 
 
In the haemostatic system, TF is released from cells found in the sub-endothelium 
when they come into contact with the intraluminal contents within the blood. Once 
released, TF attaches to activated factor VII found in circulation in the plasma and 
forms a complex that binds to protease-activated receptors (PARs). This complex 
initiates the extrinsic pathway by cleaving factor X (FX) to an activated form FXa, 
which binds to FVa (prothrombinase) and subsequently coverts prothrombin to 
thrombin in the common pathway (Figure 1.4). In the intrinsic system, the TF-FVII 
tenase also activates Factor IX (FIX)(Davie & Ratnoff, 1964). This can be rapidly 
inactivated by Tissue Factor Pathway Inhibitor (TFPI) or by antithrombin III if it leaves 
the cell surface. If not, FIXa can combine with factor Va (FVa) in turn, which can then 
lead to initial thrombin production from prothrombin (Monroe et al., 1996). For the 
intrinsic pathway, Factor XII is converted to XIIa on contact with negatively charged 
surfaces (subendothelial collagen) and converts FXI to FXIa which in turn converts 
factor IX to IXa, which then converts factor X to Xa to enter the common pathway. 
These actions result in the production of thrombin in small amounts and leads to the 
amplification step. However, this amount of thrombin is insufficient to form a full 
clot, and enough quantities are only generated in subsequent steps. 
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Amplification: 
 
When the endothelial breach allows sequestered TF to be exposed to intraluminal 
contents, the thrombin subsequently produced has three main functions. First, 
thrombin on TF-bearing cells in small volumes causes more platelets to adhere to the 
ECM matrix (Diaz-Ricart et al., 2000), by cleaving through use of its protease activated 
receptors (PAR), especially PAR2 located on endothelial surfaces. There is further 
platelet activation as well as cleaving of other factors V, VIII and XI into active 
components(Monroe et al., 1996). Once platelets are activated their α-granules are 
degranulated emptying the FV contained within in a partially activated 
form(Monkovic & Tracy, 1990). Secondly, this form is now fully activated by thrombin 
or FXa, which through its non-PAR receptors such as GPIb/IX, any thrombin that is left 
remains active enough to activate other coagulation factors that are found on the 
platelet surface.  For instance, FVIII is usually produced as a complex with von 
Willebrand factor (vWF) bound to platelets surface, and then immediately cleaved by 
thrombin to release vWF (Hultin, 1985). Amplification sets the stage ahead for the 
assembly of a more complex structure in propagation where large-scale thrombin 
generation commences. 
 
Propagation: 
 
At this stage, thrombin necessary for clot formation is produced, once the 
coagulation factors are activated in the amplification stages, the tenase and 
prothrombinase complexes are arranged on platelet surfaces(Hoffman & Monroe, 
2001). The remaining coagulation factors such as FIX(Ahmad et al., 1995), X(Cirino et 
al., 1997), XI(Greengard et al., 1986) in their activated forms bind to the platelet 
surfaces through high affinity receptors. These play different interlinked roles 
mediating the coagulation process. For example, FIX-Xa complexes can activate FX on 
platelet surfaces. FXa-Va are then formed into complexes which are necessary for 
extensive thrombin generation(Hoffman & Monroe, 2001). This thrombin ‘burst’ 
causes fibrinogen conversion to fibrin. Fibrin is necessary to provide a structural 
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scaffold for clot formation and so soluble fibrin is converted by thrombin to cross-
linked fibrin which forms the haemostatic clot(Rickles et al., 2003). This clot stabilizes 
the platelet plug, leading to formation of a thrombus. 
 
In tumours, overexpression of fibrin has been noted along with increased levels of 
fibrinogen growth factor, and this may be important in tumour invasion (Sahni et al., 
2008). Fibrin production may also impair host defences by coating the tumour cell 
with a protective layer, to enable it to evade detection by phagocytes and avoid 
identification by impedance of natural killer cells (Palumbo et al., 2005). High levels 
of fibrinogen may also indicate poor prognosis in some malignancies such as 
endometrial(Seebacher et al., 2010), ovarian(Polterauer et al., 2009), renal(Tian et 
al., 2017) and colorectal cancer(Tang et al., 2010; Sun et al., 2014). 
 
Termination or Inhibiton: 
 
This is a haemostatic step to prevent blood vessels from unnecessary and 
indiscriminate occlusion. Here, sustained TF-induced coagulation by the TF-FVII 
catalytic complex is regulated in a negative feedback loop mediated by a multivalent, 
Kunitz-type plasma proteinase inhibitor protease called Tissue factor pathway 
inhibitor (TFPI) (Broze, 1995a). TFPI production is triggered when the TF-FVII complex 
cleaves FX to form FXa. TFPI either indirectly inhibits by forming a aggregated 
complex with the TF-FVII-FXa or directly by binding to FXa whereby the Xa-TFPI 
complex inhibits TF-FVII (Broze, 1995b). Furthermore, thrombin can bind to 
thrombomodulin, an anti-thrombotic protein, and the complex formed activates anti-
inflammatory protein C(aPC) localized on endothelial surfaces (Stearns-Kurosawa et 
al., 1996). APC binds to Protein S and helps to cleave complexes of FVa-FVIIIa, 
preventing further indiscriminate clotting factor activations(Hoffman & Monroe, 
2001). Thrombin itself can be inactivated by antithrombin III, also found on 
endothelium, which rapidly inhibits FIXa and FXa activities in the clotting 
pathways(Hoffman & Monroe, 2001). 
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1.3  Role of haemostatic factors in cancer thrombosis 
 
Under normal homeostasis, the coagulation network (consisting of the intrinsic and 
extrinsic arms) works harmoniously through the four main steps to merge into a 
common pathway to generate thrombin, which in turn induces conversion of 
fibrinogen to fibrin and eventually construction of a blood clot. In malignant disease, 
cancer cells may exert a direct prothrombotic effect by stimulating the constitutive 
expression of TF (in association with coagulation factor VII) on tumour cell surface or 
endothelial stroma and thus have constant hypercoagulable ability(Contrino et al., 
1996). Therefore, a few studies have suggested the possibility that in various 
conditions, different cancers may activate or exhibit different coagulation cascade 
factors and components. Baagatin et al, for instance reviewed the findings in breast 
cancer perioperatively, and reported changes in the coagulation factors system such 
as increased platelets and platelet aggregation, prolonged PT and APTT, fibrinogen, 
D-dimer, VWF, PAI-1, and decreased AT, PS, PC and plasminogen(Bagatin et al., 2013).  
A clinical study by Boersma et al examined 168 patients with malignancy and central 
venous catheters (CVC) and reported that those who developed thrombosis had 
higher FVIII (203 ±62% versus 166± 59%; p=0.023) immediately following CVC 
insertion(Boersma et al., 2016). This increasing trend was also supported by Kovacs 
et al, who identified an increasing trend of FVIII (1.71%, IQR 1.13-2.91 to 1.94%, IQR 
1.33-3.06) over 2 months of administration of thalidomide-prednisolone treatment 
combination in myeloma patients, although there were no significant differences in 
those who developed VTE (1.38% 95% CI 1.27-1.49) and those who did not (1.68% 
95% CI 1.52-1.85) in this study (Kovacs et al., 2015). Also, another study assessed FVII 
and reported a decrease in median levels (89.1%, IQR 69.7-106.0) in patients with 
haematological malignancy compared to healthy controls (92.7%, IQR 82.8-106.5), 
although this was not associated with increased VTE risk(Negaard et al., 2008). There 
are also additional reports of laboratory findings of other coagulation factors 
frequently increased in several malignancies such as FV, IX, XI which may represent 
independent risk factors for thrombosis (Dogan et al., 2006; Battistelli et al., 2008; 
Yigit et al., 2008).  Although these findings of different elevated coagulation factors 
in various malignant conditions such as MM(Auwerda et al., 2007), 
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colorectal(Battistelli et al., 2008) and breast cancer(Yigit et al., 2008), further 
supports the role of coagulation in cancer thrombosis, the possibility that there might 
be distinct cancer-specific coagulation pathways for different malignancies is yet to 
be extensively researched. PC for instance is known to be exhibit a TF-dependent 
pathway of coagulation unlike MM which expresses little or no TF and may likely 
utilize other as yet unclear pathways in haemostasis.  
 
The interdependency of both arms of the clotting cascade also has an impact on 
regulating haemostasis, for instance when TF-FVII complex from the extrinsic system 
can also cross-over and activate FIX and FX(Osterud & Rapaport, 1977). As a highly 
interconnected system, the inhibition of a part of the coagulation system is likely to 
only cause partial impairment of the system (Al-Horani & Desai, 2014). Moreso, 
various heterogenous sub-pathways or side arms might theoretically develop in 
certain biological conditions when specific components of arms are either more 
active or inactive than others. Transcriptionally, it has recently been suggested that 
in different tumours, there may exist alternative pathways of coagulation system 
regulation formed by oncogenic protein and miRNA coding genes, and that this 
property may be amenable to specialized biologically-based approaches to 
personalized anticoagulation (D'Asti & Rak, 2016). In addition, clotting systems in 
biological models may differ considerably in cancers of various aetiology (such as in 
solid and non-solid cancer types) and contribute to specific tumour qualities such as 
early invasion, metastasis and angiogenesis. For example, high levels of pre-operative 
fibrinogen (374.5 vs. 332 mg/dl, p=0.002) in renal cell carcinoma as compared to 
healthy controls have been identified as associated with significant increase in 
tumour size (p=0.004), histologic grade (p<0.001) and metastasis (p<0.001) (Erdem 
et al., 2014). 
 
In order to study this theory of the role of various coagulation factors in cancer 
thrombosis, it would be necessary to characterize the factors that contribute in 
different extents to pro-thrombosis in various cancer models, and the haemostatic 
endpoints involved. One of such central endpoints involves thrombin, as one of the 
key processes in cancer metastasis usually involves TF-initiating thrombin production, 
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and then local fibrin deposition followed by platelet recruitment through PAR-
activated signalling processes for clot formation (Camerer et al., 2004).  
 
1.4  Thrombin 
 
1.4.1  Thrombin structure 
 
Thrombin, also known as factor IIa, is one of the functionally important serine 
proteases involved in coagulation(Davie & Kulman, 2006). It is produced as a 
zymogen precursor, prothrombin, from the liver and secreted into the bloodstream. 
The liver contains specific Vitamin K carboxylase enzymes that catalyses the Vitamin-
K dependent post-ribosomal conversion of up to 12 glutamic acid residues in the N-
terminus of prothrombin precursors to gamma-carboxyglutamyl acid (Gla) residues, 
which prevents the thrombin protease to bind to phospholipid layers of cell 
membranes indiscriminately(Suttie, 1980). At sites of vascular damage, prothrombin 
is converted by proteolytic cleavage into active thrombin by coagulation factors (FXa-
FVa prothrombinase complex) downstream of the clotting cascade. These remove 
the Gla domain; such that thrombin can then attach to platelets in the initiation phase 
of coagulation, activate other factors FV, FVIII, FXI, FXIII in the amplification phase, 
and coverts fibrinogen to fibrin at its active catalytic site through catalytic cleavage 
of the Arginine-Glycine bond, during propagation as shown in figure 1.5 (Monroe et 
al., 1996; Hoffman & Monroe, 2001).  
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Figure 1.5 Functional role of thrombin.  
Thrombin structure showing the fibrin-binding exosite 1 and the active or catalytic 
site. Cleavage takes place between Arginine (Arg) and the adjacent Glycine (Gly) 
peptide bond in the active site, leading to fibrinogen conversion to fibrin. S1 and S2 
are the pockets for Arg and Val, respectively, and DP is the pocket for Phe. 
Abbreviations: Ala, alanine; Arg, arginine; Asp, aspartic acid; Glu, glutamic acid; Gly, 
glycine; Leu, leucine; Phe, phenylalanine; Pro, proline; Ser, serine; Val, valine. 
Adapted from Coppens et al, 2012(Coppens et al., 2012). 
 
Thrombin is a critical link between vascular disruption, coagulation and platelet 
activation. Its function is mediated through a family of proteases called the PAR 
family(Coughlin, 1999), which are G-protein coupled signalling receptors also 
implicated in tumour growth and whose specific inhibition inhibits this 
growth(Coughlin, 2000). The family consists of PAR1, PAR3, and PAR4 which are 
specifically activated by thrombin, and also FXa-activated PAR1 and PAR2(Versteeg 
et al., 2004). PAR1 and PAR3 contain thrombin-interacting sites on their amino-
terminal (N-terminal) and carboxy-terminal (C-terminal) extracellular domains 
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(exodomains or exosites). PAR1 is the prototype of the family, and thrombin 
signalling occurs when the N-terminus is cleaved by thrombin at a specific site to 
reveal a new N-terminus that can then bind other downstream intramembrane 
signalling molecules (Rasmussen et al., 1991; Vu et al., 1991). The thrombin-specific 
cleavage site is on a peptide chain of the PAR1 N-terminal exodomain, between 
residues Arginine 41 and Serine 42(Hugel et al., 1999). This site is responsible for 
fibrinogen conversion to fibrin by cleavage of the glycine-arginine bond (Figure 6B). 
The pleiotropic effects of PAR1 activation occur through coupling to various G-protein 
families such as G12/13, Gq, and Gi (Figure 1.6). Likewise, PAR3 has also been derived 
by knockout mice gene studies and is known to mediate thrombin-triggered 
phosphoinositide hydrolysis in various human tissues (Ishihara et al., 1997).  
 
Thrombin activity can be modulated in several ways, including through regulators of 
TG such as the platelet-expressed glycoprotein GPIba (Jain et al., 2007) or endothelial 
thrombomodulin(Horowitz et al., 2011). These processes determine the success of 
coagulation and may be linked to tumour development and spread, and potentially 
aid pathways of the metastatic process. For instance, Shaker et al, have identified an 
association between thrombin pathway activation through measurements of pre-
operative D-Dimer levels in plasma with the presence of lymph node metastases in 
early breast cancer patients(Shaker et al., 2017), although D-dimers here may only 
serve as biomarkers and this study is still ongoing. 
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Figure 1.6 Thrombin-activated PAR1 signalling effects. 
The intracellular signalling network and phenotypic effects of thrombin-activated PAR-1 signalling. Members of the G-protein families activate PAR1 
signalling which leads to: Rho-mediated changes in platelet cytoskeleton, phospholipase Cβ triggering of phosphoinositide hydrolysis, calcium 
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mobilization, and protein kinase C activation, facilitation of platelet aggregation through calcium-regulated kinases and phosphatases, MAP kinases, 
and inhibition of adenylyl cyclase. Modified from Angiolillo et al (Angiolillo et al., 2010). 
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1.4.2  Thrombin importance in VTE 
 
There are several reports in literature that suggests that VTE development may be 
associated with a change in TG. D-Dimers and fibrinogen, and to a lesser extent 
thrmonin-antithrmobin complex, prothrombin fragments F1 +2, protein C and S and 
MVs, as components of the coagulation process have been extensively studied to 
demonstrate some degree of efficacy in identifying patients with high risk of 
VTE(Samuelson Bannow & Konkle, 2018). For instance, several studies have identified 
elevated D-dimers markers in association with VTE events; one is a large clinical study 
of a subset of 111 patients with haematologic malignancies such as MM from Vienna 
Cancer and Thrombosis Study (CATS) where elevated D-Dimers of >1.4mg/L in the 
75th percentile was found positively associated with increased VTE risk of HR 1.8, IQR 
1.0-3.2(Ay et al., 2009). Using clotting factor levels in the blood, TG has also shown 
similar promise to potentially predict risk of developing thrombosis in statistical 
simulation models(Brummel-Ziedins et al., 2005). Furthermore, TG measured by 
functional assays may also be used to predict thromboembolic events, as suggested 
by a cohort study of 1033 patients with various cancers where a cumulative 
comparison found that patients with elevated peak thrombin had a higher 
(11%>4%)significant likelihood of developing VTE in the first 6 months of diagnosis 
than in people with lower peak thrombin (Ay et al., 2011). In two prospective 
population-based cohorts, elevated basal peak thrombin generation was associated 
with subsequent risk of VTE (Lutsey et al., 2009).  In a recent study, VTE has been 
linked to significantly higher levels of urine and plasma prothrombin fragment 1 + 2, 
D-dimer, lag time, time to peak, and endogenous thrombin potential(Wexels et al., 
2017). However, these results although promising, are still in development and are 
not entirely consistent yet, probably due to the need for standardization of the 
methods of TG measurement.  
 
Clinically, it may be more useful to assess the prothrombotic state in cancer patients 
through TG, as it is a method that comprehensively evaluates thrombin production 
stages such as initiation, amplification, propagation and inhibition (Figure 1.8) and 
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also provides a quantitative assessment of the amount of thrombin formed(van Veen 
et al., 2008). Furthermore, TG measurement provides an attractive method to gain 
insight into the complex interactions of the various factors that determine 
coagulation capacity and acquire composite knowledge of how it influences the 
hypercoagulable predisposition of distinct cancer types. 
 
1.4.3  Thrombin measurement 
 
Several methods exist for assessing procoagulant activity, including tests for primary 
and secondary haemostatic function (Table 1.2) such as prothrombin time(PT)-based 
clotting assays, tests for fibrin formation to degradation products and D-Dimer 
assays, and also newer approaches such as thromboelastography (TEG) and whole 
blood rotational thromboelastometry (ROTEM)(Herring & McMichael, 2012). These 
methods have different endpoints and varying degrees of successes, acceptance and 
utility over time. Of note is that the popular clotting based assays (based on 
calculating the prothrombin time, the partial thromboplastin time or the activated 
clot time) have recognized limitations. For example, clot formation occurs after 
generation of approximately 10nM thrombin-antithrombin, which coincides with the 
start of the propagation phase of the coagulation cascade, and any thrombin 
produced afterwards is not detected by these standard clot-based assays(Brummel-
Ziedins et al., 2005). Chromogenic assays are the main methods of measuring 
thrombin generation kinetics (Peetz, 2016) with the calibrated automated 
thrombography (CAT) being a fluorogenic enhancement that may make the leap from 
bench-side to routine clinical practice. 
 
Table 1.2 Tests of Coagulation function.  
Types of functional tests to assess haemostasis. Modified from Heiserman, 2015 
(Heiserman, 2015) 
Coagulation function Test 
Vascular function Bleeding time, tourniquet test 
(capillary fragility, cuff test) 
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Platelet function Bleeding time, clot retraction, 
platelet count 
Clotting ability Prothrombin time, activated 
partial thromboplastin time, 
thrombin time 
Fibrinolytic function Clot retraction, fibrinolysin assay, 
D-dimer assay 
 
 
The CAT assay is a global assay that can be used to evaluate and quantify the 
haemostatic qualities of a biological substrate(Hemker et al., 2006). By giving a 
dynamic picture of TG through the measurement of the amount of thrombin cleaved 
from a fluorogenic substrate in real time as shown in Figure 1.7A, CAT may become a 
useful tool in cancer related clinical scenarios. Although it has been in existence in 
various forms since the 1950’s, it was optimized by Hemker et al (Hemker et al., 2003) 
into a dynamic modern version that measures five main parameters in TG as it occurs 
during the phases of coagulation. These parameters eventually displayed as a 
thrombogram curve are the Lag time, Endogenous thrombin potential (ETP), Peak 
thrombin produced (Peak), time-to-peak (ttPeak or TTP), and Velocity index 
(Vel.Index).  According to Hemker et al, the Lag time in minutes refers to time 
thrombin formation commences, and it corresponds to the initiation and 
amplification stages of the coagulation cascade as illustrated in figure 1.7B (Hemker 
et al., 2003). The ETP is the area under the thrombogram measured in nanomolar 
multiplied by minutes while the Peak is the maximum nanomolar thrombin produced 
in the time of the assay during the propagation phase of the cascade. TTP is the 
duration it takes to reach maximum thrombin production in minutes. There are two 
other lesser parameters that can be reported; the Vel.Index which is the slope 
between the lag time and TTP (measured in nanomolar per minute) and the Start tail 
in minutes which is the time TG comes to an end (or the termination of the inhibition 
phase), although this value is less absolute as it can be difficult to determine when 
TG definitely ends(Hemker et al., 2003). With this number of endpoints, the CAT assay 
gives a more dynamic clotting assessment and could play a role in clinical practice to 
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assess clotting irregularities and abnormalities in patients with cancer related clotting 
disorders. However, more studies are needed to understand and address official 
optimization and standardization issues for the assay technique. 
 
A) 
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B) 
 
Figure 1.7 Measurement of thrombin generation in the CAT assay  
A.) Basic process of the CAT assay B.) TG curve during the 4 phases of coagulation. 
Adapted from Centers for Medicare &Medicaid Services (CMS), Elsevier Health, 
(http://www.journals.elsevierhealth.com/cms/attachment/2009083251/203112949
1/gr13). Accessed November 17, 2017 
 
 
1.5  Tissue Factor (TF) 
 
1.5.1  TF structure 
TF (also known as factor III or formerly, thromboplastin) is a 47 kDa membrane-bound 
protein, that can be found in most cells of the body especially those surrounding 
blood vessels and is constitutively expressed in normal haemostasis(Bach, 1988; 
Mackman, 2009). It is a glycoprotein receptor (referred to as the cluster of 
differentiation CD 142) comprised of a single chain of 295 amino acids. In 1987, 
Morrissey et al synthesized human TF from cDNA copies as a molecular weight 
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precursor of 29,593 with a leader sequence of 32 amino acids, while the mature 
protein is a single polypeptide chain composed of 263 amino acid residues in total 
(Morrissey et al., 1987; Spicer et al., 1987; Morrissey et al., 1988a; Morrissey et al., 
1988b). Hybridization techniques have localized TF gene to chromosome 1(Carson et 
al., 1985). It has 3 main domains which has specific purposes- an hydrophilic 
extracellular consisting of 219 residues, a C-terminal intracellular region of 21 
residues and an hydrophobic transmembrane that contains 23 residues(Spicer et al., 
1987). The extracellular domain contains three N-linked carbohydrate chains; one of 
which is an N-terminal residue that in turn consists of two fibronectin domains. These 
fibronectin domains have the ability to bind to FVII and VIIa (a serine protease 
glycoprotein)(Banner et al., 1996), and thereby exponentially increase the catalytic 
efficiency of TF:FVII complex(Huang et al., 2006), which triggers the coagulation 
cascade(Rapaport & Rao, 1995).  
 
TF is a key initiator of the extrinsic coagulation pathways in the body and also 
contributes significantly to other pathways of coagulation(Steffel et al., 2006; Aird, 
2012). Clotting mechanisms involving the endothelium may be heavily dependent on 
TF as well as phospholipids such as phosphatidylserine (PS) carried on cellular 
membranes (Furie & Furie, 2005; Steffel et al., 2006). TF occurs in the body in mostly 
three forms; the intracellular TF, the TF attached to the cell surface and the soluble 
form. Surface TF is normally encrypted. Decryption is known to change TF into a 
coagulant TF capable of inducing signalling pathways and several mechanisms have 
been proposed to cause this phenomenon. Some authors have suggested different 
mechanisms including PS external exposure to create an ideal negatively charged 
surface(Wolberg et al., 1999; Kirszberg et al., 2009), oxidation of the cysteine 
residues on TF structure(Ahamed et al., 2006), regulation by cell membrane itself 
through lipid rafts localization(Sevinsky et al., 1996; Awasthi et al., 2007), and 
monomerization as opposed to TF disulphide isomerization (dimerization) (Bach & 
Moldow, 1997). Notwithstanding the veracity of these postulated mechanisms, none 
of them have been widely agreed on as the main cause of TF decryption. However, 
Ettelaie et al have found that the dimerization of TF protein in vivo, elicited a 
sustained response and direct activation of various intracellular signalling pathways 
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such as p42/44 MAPK and JNK-SAPK, due to a possible feedback mechanism from 
phosphorylation of the transmembrane cytoplasmic domain of TF(Ettelaie et al., 
2007). 
 
Soluble and surface TF are also present as isoforms which may be spliced, and which 
have implications for tumour progression and coagulant function. The normally 
spliced full-length TF (fTF) and the alternatively spliced isoforms (asTF) can be found 
in different states in the body. Initially identified by Bogdanov in 2003, this spliced 
variant asTF is encoded by 5 exons unlike the fTF of 6 exons transcript(Bogdanov et 
al., 2003). asTF in various cancers cell lines have been linked to thrombus 
development as it has been identified in high quantities inside clots collected from 
humans, and also its ability to co-localize with platelet aggregates(Bogdanov et al., 
2003). These findings have allowed suggestions that asTF may be involved in 
thrombus development and have specific porocagulant functions(Kocaturk & 
Versteeg, 2012). However further studies in vivo are necessary to understand its 
implicit clinical roles as compared to fTF in heamostasis, angiogenesis and disease 
pathogenesis. 
 
1.5.2  TF-FVII complex 
 
Like other Vitamin-K dependent factors, FVII is a single polypeptide chain - also 
known as stable factor or preconvertin- that consists of 406 amino acids including ten 
which are Gla residues(Hagen et al., 1986). Conversion to active FVIIa is accomplished 
by cleavage of an arginine-isoleucine bond which gives a 2 chains- a light chain 
containing the Gla region and a heavy chain that contains the active site(Hagen et al., 
1986). Inactivation also occurs through a slower cleavage of the arginine-glycine 
bond(Radcliffe & Nemerson, 1976). 
 
Normally, the endothelium performs the role of physically separating the two main 
initiators of coagulation apart; TF expressing cells located in the subendothelium 
from the circulation thereby keeping TF from activation of blood borne zymogen FVII 
and VIIa. However, in endothelial disruptions or conditions that promote 
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overexpression of TF, this balance may be thwarted resulting in excessive, 
indiscriminate or inappropriate coagulation. Damage to the endothelial lining causes 
TF-producing cells to be in contact and bind with the FVII in the blood circulation 
(Figure 1.9). As explained above, in the extrinsic coagulation pathway FVII is 
subsequently converted to FVIIa, then the TF-FVIIa complex that is formed activates 
FX by proteolytic cleavage (Figure 1.8). Thrombin is produced as a result, further 
amplified by the involvement of the intrinsic pathway, and leads to deposition of 
fibrin and platelet activation (Versteeg et al., 2001). 
 
 
Figure 1.8 A break in the endothelial lining wall exposes extravascular TF to the 
bloodstream.  
A) Intact vessel lumen surrounded by 1-endothelium and 2-subendothelium B) 
Vessel damage C) TF-VII complex formation leading to thrombin formation and 
ultimately fibrin deposition. Adapted from Telomerase and Cancer: Metastasis, 
Epigenetic mechanisms, Teratogenesis (Part 7), (https://cf.ppt-
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online.org/files/slide/p/PqmJhDTBGpQsSvHnui3O70UIzjLy9Mfb4N1Rl5/slide-54). 
Accessed November 18, 2017 
 
 
1.5.3  TF-FVII: signalling and upregulation 
 
TF-FVII proteolytic activity seems  to occur in two ways; through PAR2-dependent 
signalling, although this level of PAR2 activation seems to occur at higher TF 
concentrations and  also by PAR1 and PAR2 activation mediated by FXa at lower 
concentrations(Riewald & Ruf, 2001). TF-FVII complex leads to transient cystolic 
calcium fluxes creating intracellular gradients and initiating the classical 
phospholipase C (PLC)/calcium pathway and phosphoinositide hydrolysis(Camerer et 
al., 2000). This activity highlights TF acts as a direct receptor for signalling through its 
cytoplasmic tail (Cunningham et al., 1999). Once TF is attached to FVII, it is coupled 
to a PAR receptor and this TF-FVII-PAR2 complex induce proangiogenic activities and 
inflammatory cytokines and growth factors (Ruf et al., 2011). It is now established 
that TF-FVII mediates gene modification and protein production through the 
activation of mitogen-activated protein kinases (MAPK) that are well known for gene 
transcription and translation from protein phosphorylation. There are six major 
genetic isoforms of MAPK including p42/p44 MAP kinase, p38 MAP kinase and stress-
activated c-Jun N-terminal kinase, all with different roles in stress, inflammation and 
signalling (Hommes et al., 2003; Dhillon et al., 2007). Of these, malignant 
transformation are frequently associated with the Ras and B-raf isoforms(Dhillon et 
al., 2007). These isoforms induce transcription of growth factors such as vascular 
endothelial growth factor (VEGF), and encoding cytokines such as interleukin (IL)-1β, 
IL-8, macrophage inflammatory protein 2-alpha (MIP2α), and leukaemia inhibitory 
factor (LIF), and genes regulating cell organization and motility in metastasis 
(Camerer et al., 2000; Pendurthi et al., 2000). Nuclear factor-κappa B (NFkB) is 
another transcription molecule that is involved in downstream TF 
signalling(Mackman, 1995), as shown by the reduction in NFkB activity possibly 
through nuclear translocation that was associated with TF mRNA downregulation, in 
the presence of LWMH(Ettelaie et al., 2011).  
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TF via PAR-2 intracellular signalling also has a role outside coagulation in tumour 
growth, angiogenesis and embryogenesis. In cancer development, TF-FVII-PAR2 
complex have been associated with recruitment of growth factors, chemokines and 
inflammatory cytokines to the tumour microenvironment, which are  implicated in 
its expansion and metastasis(Ruf et al., 2011). This advancement is also known to be 
suppressed in the inhibition of the TF complex, which emphasizes its integral role in 
tumorigenesis. In vitro, studies of PAR-2 deficient breast cancer cells have described 
TF-PAR2 signalling as inducing the release of the chemokine CXCL1, which is a 
implicated in aggressive tumour phenotypes(Schaffner et al., 2010). In clinical cancer 
specimens of relapsed patients, TF and PAR2 activities have been found to be 
upregulated with a marked phosphorylation of TF cytoplasmic domains(Rydén et al., 
2010). In glioblastoma cells, pronounced TF-PAR2 expression was observed and 
further antibody-inhibition experiments resulted in significantly reduced cell 
proliferation and spread (Gessler et al., 2010).  In addition, upregulation in TF-
complex activity may result in other pathologic conditions of clinical importance. For 
example, aberrant TF was recently identified as overexpressed in ectopic endometrial 
tissues in patients suffering from endometriosis(Krikun et al., 2008). This may 
highlight the non-haemostatic roles of TF in disease, with known associations with 
inflammatory cytokines such as IL-1B (Krikun et al., 2008; Krikun, 2012) and 
embryogenesis (Carmeliet et al., 1996).  
 
1.5.4  TF involvement in Cancer VTE 
 
Since 1865, cancer has been associated with thrombosis since Armand Trousseau 
studies described a link between them (Boccaccio & Comoglio, 2009). Most solid 
cancer types such as PC are known to express TF(Kasthuri et al., 2009; Welsh et al., 
2012), while others including haematological cancers such as MM generally have 
absent or low levels as shown by Ceserman-Maus et al in a study where 55 human 
myeloma lines expressed no TF, unlike 90% of solid tumour lines(Cesarman-Maus et 
al., 2012b). Some PC may have high TF expression that could indicate poor prognosis 
as a result of overall tumour aggressiveness(Kakkar et al., 1995). For instance, high 
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TF expression which accounted for 44.2% (n=50) of a total of 113 Pancreatic ductal 
adenocarcinoma (PDAC) patients analysed, correlated with tumour extension (p= 
0.0043), lymph node metastasis (p= 0.0043), advanced stage (p= 0.0002), and high 
tumor grade (p= 0.0164)(Nitori et al., 2005). In these solid malignancies such as 
melanoma, TF expression levels may be up to 1000-fold compared to non-metastatic 
cells which suggests a key role in cancer dissemination and prothrombosis(Mueller 
et al., 1992). 
 
TF involvement favours a hypercoagulable state. Giesen et al, was the first to suggest 
that TF in the blood stream can lead to thrombus formation ex vivo(Giesen et al., 
1999). It is now well known that tumours with highest TF expression also exhibit the 
highest symptomatic VTE occurrences, and this expression increases with tumour 
progression (White et al., 2007). Traditionally, elevated thrombotic risk is seen 
associated with TF in solid tumours; however, this has also been noted at similar 
elevated incidences in haematological cancers. In PC, for example high TF-expression 
has been found associated with over 25% of clinical VTE incidences by Khorana et al, 
2007(Khorana et al., 2007a). A study of newly diagnosed MM before and after 
treatment who developed VTE have also shown increased TF expression (15.1fM) 
compared to those that did not (11.4fM; p<0.001), although this TF was associated 
with MVs (Auwerda et al., 2011). Cancer cells may directly activate the coagulation 
system themselves, notably by promoting TF expression (the primary initiator of the 
coagulation cascade) on the cell surface of tumour and stromal cells that can release 
circulating TF (Callander et al., 1992; Contrino et al., 1996; Shoji et al., 1998). Also, 
the potential secretion by malignant tissues of proteolytic cancer procoagulant (CP) 
a 68 kDa vitamin K-dependent neoplastic cysteine proteinase enzyme which activates 
FX (Falanga & Gordon, 1985), and stimulates platelet activation in a fashion similar to 
thrombin, may have further hypercoagulable effect. 
 
TF involvement is observed widely in inflammation and angiogenesis. In angiogenic 
tumour-associated endothelium for instance, increased TF expression has been 
observed, while elevated TF antigen production levels have been correlated with 
VEGF expression (Nakasaki et al., 2002; Khorana et al., 2007a). Elevated TF activity 
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can lead to high vascular density, enhanced angiogenesis and metastatic progression 
in a variety of human tumours including PC, breast and colorectal cancer (Contrino et 
al., 1996; Nakasaki et al., 2002; Khorana et al., 2007a; Echrish et al., 2014). Metastatic 
potentiation from TF-dependent activation of coagulation, may occur though PAR-2 
signalling (Kocaturk & Versteeg, 2012). Furthermore, as a procoagulant protein, TF 
elevation in association with MVs is found in several cancers, where an important 
role may be in inducing thrombosis through the coagulation pathway. 
 
Notably, TFMVs levels have been elevated in treatment of leukaemia cells with the 
anthracyclines DOX and Daunorubicin(Boles et al., 2012) while Maraveyas et al. 
reported high TF antigen levels in PC patients under treatment with Gemcitabine 
(GEM)(Maraveyas et al., 2010). Interestingly, despite high levels of reported VTE 
incidences, TF expression are observed to be absent in some MM cell lines and MM 
patient samples from treatment groups(Cesarman-Maus et al., 2012b). VTE 
development in MM may therefore involve TF-independent mechanisms. These 
findings indicate a likely possibility that there may be different factors underlying 
chemotherapy-associated VTE in MM and PC, despite similarly elevated VTE risks. 
 
1.6  Microvesicles (MVs) 
 
1.6.1  MV Origins 
 
MVs are small vesicular cell fragments enclosed by a phospholipid bilayer shed from 
activated and non-activated cells, which are involved in cellular interactions with the 
environment (Simak & Gelderman, 2006; Puddu et al., 2010). Also called 
microparticles(MPs), MVs were first reported in literature in relation to promotion of 
blood coagulation and were described as ‘precipitable factors’ in ultra-centrifuged 
plasma by Chargaff and West in 1946(Chargaff & West, 1946), and later as particulate 
‘dust’ formed from activated platelets in the clotting cascade by Wolf(Wolf, 1967). 
The term MVs is sometimes used as a general term to include other membrane-
encapsulated particles and cell products such as exosomes, apoptotic bodies, 
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ectosomes, phospholipid vesicles. Moreover, all these terms are used 
interchangeably now as composition differences that include size, morphology, 
protein content and buoyant density seem insufficient for a clear distinction and 
rigorous terminology is yet to be established (Bobrie et al., 2011). 
 
1.6.2  MV structure and function 
 
MVs generally vary in size from 30nm to 1µm, with the largest around 3µm (Conde-
Vancells et al., 2008; Rak, 2010; van der Pol et al., 2012; van der Pol et al., 2013). They 
have heterogeneous compositions and may consist of anionic phospholipids, 
cytoplasmic inclusions, and bioactive proteins and coagulation factors. They are also 
known to carry genetic substance such as RNA peptides, microRNA, mRNA, and DNA 
between various cells without direct cell-to-cell contact(Barteneva et al., 2013) and 
through these transfer, have been involved in events of physiological importance 
such as apoptosis, inflammation, angiogenesis, and haemostasis(Morel et al., 2005; 
Aharon et al., 2008). Molecularly, they have specialized roles that help in intercellular 
signalling, cell-to-cell communication and so can be involved in disease spread, sepsis 
dissemination, immune surveillance and cancer metastasis.  
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Figure 1.9 Illustration of tumour MVs and their surface proteins. 
Abbreviations: TF is Tissue Factor, FVIIa is activated coagulation Factor VII, PS is 
Phosphatidylserine, MUC-1 is Mucin-1, CD is Cluster of Differentiation. Modified 
from Geddings and Mackman, 2013(Geddings & Mackman, 2013). 
 
The structure of the MVs is a phospholipid bi-layer, anucleated and surrounding 
cytoplasmic constituents (Figure 1.9). The outer layer consists of  negatively charged 
lipids including phospahatidylserine (PS) (Lechner & Weltermann, 2008) which are 
imbedded with distinct antigens (Figure 1.9). These antigens may reflect the source 
of origin of the MVs(Tilley et al., 2008) and can serve as mode of identifying and 
targeting the MVs, for example endothelial derived MVs are known to carry CD31 or 
CD146 antigen(Jimenez et al., 2003). However, it is entirely possible for cellular 
antigens from a specific cell type to be released and attach to MVs from a different 
source, or even that MVs released from a specific cell type, carrying a specific antigen, 
may attach to another cell type, with the aim of inducing production of MVs with 
‘foreign’ embedded antigen. In this way, MVs from different parts of the body can 
mediate interactions such as metastasis and senescence (Lehmann et al., 2008). MVs 
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from similar or different sources might also fuse into bigger structures and share 
genetic material or biological parameters (Gyorgy et al., 2011a). This process may 
further compromise detection by obfuscating the primary antigen composition and 
cause difficulties in immunophenotypical identification. 
 
The characterization of MVs has revealed specialized functions due to cell-type 
specific proteins from isolates of different biological samples (Conde-Vancells et al., 
2008). The production of MVs is dependent on their cellular source, type of stimulus 
or stress, and pathologic state of parent cell (Freyssinet, 2003; Guervilly et al., 2011; 
Nomura & Shimizu, 2015). Previous studies have implicated MVs of different sources 
with the transfer and sharing of oncogenic material such as epidermal growth factor 
receptor factor VIII (EGRFvIII) in gliomas(Al-Nedawi et al., 2008), as vectors of genetic 
information (Al Dieri et al., 2002), rapid proliferation and cellular differentiation and 
even inducing apoptotic and procoagulant effects (Aharon et al., 2008; Wang et al., 
2012). MVs shed from some tumours such as breast cancer, also contain matrix 
metalloproteinases and proteases that help to break down the endothelial cell matrix 
(ECM) and facilitate tumour invasion (Dolo et al., 1998). Moreover, in cancer 
coagulopathy, oncogenic pathways may be stimulated to produce MVs incorporated 
with surface TF antigen(Rak, 2010). 
 
1.6.3  MV intracellular formation, release, acquisition and signalling 
mechanisms 
 
The molecular pathways involved in vesicular formation seems to be poorly 
understood. MVs formation has been proposed to occur from 3 ways; through 
generation as extracellular blebbing or reverse budding and subsequent fission from 
cell membrane surfaces (Zwaal & Schroit, 1997), as whole exosomes extruded 
through intracellular endocystic development also known as multivesicular 
endosomal fusion with plasma membrane(Harding et al., 1984), through apoptosis as 
part of the breakdown products of the parent cell itself(Distler et al., 2005) figure 
1.10). 
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Figure 1.10 Uptake and release of small and large MVs from parent cell to 
neighbouring or distant cells.  
Abbreviations: ILV is intraluminal vesicle; MVB is multivesicular body and SNAREs are 
soluble N-ethylmaleimide-sensitive factor attachment protein receptor (SNARE) 
system, which are involved in the transport and fusion of MVBs with the plasma 
membrane (MV release). Adapted from Choi et al, 2017(Choi et al., 2017). 
 
Because MVs are involved in different biological processes such as coagulation, 
various signalling pathways in the cellular microenvironment influence genetic 
regulation of vesiculation. In tumour development, oncogenes such as KRAS, tumour 
suppressor p53 are known to induce MV formation. In prostate cancer, MV formation 
is due to overexpression the Akt pathway activation and EGFR stimulation (Di Vizio et 
al., 2009; Rak, 2010). Also, Arf-6, an intracellular GTbinding protein of the ARF family, 
is known to promote MV shedding in various cancers such as breast cancer, gliomas 
and melanomas, leading to tumour cell invasion(Muralidharan-Chari et al., 2009). 
66 
 
This GTPase protein activates phospholipase D to stimulate recruitment of the 
extracellular signal-regulated kinase (ERK) to the plasma membrane(Muralidharan-
Chari et al., 2009). Subsequently, ERK phosphorylates myosin light-chain kinase 
(MLCK) activating it, for MV cellular release. Conversely, upon inhibition of Arf-6 
activation by expression of a dominant-negative Arf-6 mutant, or siRNA depletion, 
PKC-mediated phosphorylation of MLC occurs, which in turn blocks MV 
shedding(Muralidharan-Chari et al., 2009). The resultant effects of these MV-
dedicated pathways  in the parent cell includes outcomes such as calcium fluxes, 
cortical actin reorganization, altered lipid metabolism, which leads to vesicle 
formation(Piccin et al., 2007). Furthermore, it has been suggested that not only do 
oncogenes direct vesiculation, interestingly enough; they also form part of the 
material transferred by MVs(Al-Nedawi et al., 2008). These finding implies that MVs 
may function as instruments of lateral transfer between cells. 
 
MV release: 
Once vesiculation is initiated, assembly and extrusion out of the cell follows (Figure 
1.10). In order to do this, lipid rafts have been postulated to be involved in MV 
membrane blebbing; cholesterol-rich lipid rafts are found in area of cytoplasm where 
MVs arise, which are also areas where factors such as TF and P-selectin glycoprotein 
1 (PSGL) converge, leading to the possibility that MVs arise from such areas(Del 
Conde et al., 2005). Various theories have been proposed to explain how the MVs 
bleb from the parent membranes. One theory suggests that blebbing and release is 
similar to the amoeboid movement of cell motility (Paluch et al., 2006; Gadea et al., 
2008), where vesicular blebs arise from zones of actomyosin contractions near the 
cortical cytoskeleton of the plasma membrane (El-Sibai et al., 2008; Di Vizio et al., 
2009). At these front zones, swiftly forming membrane protrusions can easily arise 
from the hydrostatic pressure force generated by actin cross-linked proteins such as 
filamin and myosin which controls bleb retraction(Charras et al., 2008). Another 
theory implicates soluble N-ethylmaleimide-sensitive factor attachment protein 
receptor (SNARE) system, in MV release through the transport and fusion of 
multivesicular bodies (MVBs) which are large bodies containing several intraluminal 
vesicles (ILV) with the plasma membrane (Figure 1.10)(Choi et al., 2017). In cancerous 
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cells the GTPase/ROCK signalling system, known to be regulators of cell shape, 
mediates bleb-associated motility (El-Sibai et al., 2008) although this process in 
further malignant progression is less understood.  
 
MVs release may be physiological or pathological. In physiologic conditions it is 
known that the release follows a circadian rhythm (Madden et al., 2008), and levels 
are higher in females and affected by the menstrual cycle(Toth et al., 2007). In 
healthy individuals, MVs majority come from platelets and endothelium, which 
accounts for about 43.8% and 38.5% respectively of its sources (Berckmans et al., 
2001; Shah et al., 2008), whereas this composition changes in pathologic conditions. 
In these conditions, MVs formed accumulate at the site of injury to contribute to 
thrombus formation, facilitated by attachment to the ECM through PGSL and integrin 
receptors found on activated platelets and endothelium, in addition to P-selectin on 
monocytes, leucocytes and cancer cell-derived MVs, (Falati et al., 2003; Vandendries 
et al., 2007; Thomas et al., 2009). These MVs may also carry TF and its accumulation 
may initiate thrombin generation and eventually thrombus formation. 
  
MV uptake: 
Collier et al, have reported a mechanism of MV acquisition that may result in 
increased procoagulant potential of the endothelium, through the uptake and 
recycling of MVs (specifically TFMVs), and PS cell membrane exposure (Collier et al., 
2013). This mechanism is an internal cellular process that occurs either by engulfment 
of TFMVs with subsequent intracellular degradation, TF membrane incorporation and 
later re-exposure by MV blebbing on the endothelial cell surface (Aharon et al., 2008; 
Collier et al., 2013) or by initiation of an intrinsic endothelial TF production due to 
stimuli from external MVs. The isolation of endothelial MVs in certain cancers such 
as MM have also been documented(Hall et al., 2016), and MVs produced from other 
sources such as monocytes have been shown to be ingested by endothelial cells to 
induce increased TF activity and a procoagulant nature(Aharon et al., 2008). 
 
To aid uptake, some tumour MVs are known to express TF and more recently MuC-1 
as a tumour marker (Dvorak et al., 1981; Tesselaar et al., 2007) as illustrated in figure 
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1.9. In the thrombus, uptake is also facilitated by the PGSL on the MVs surface, which 
interacts with the P-selectin on the surface of activated platelets and endothelial 
cells(Falati et al., 2003). In fact, elevated P-selectin expression has been identified in 
the endothelial vasculature of several malignancies such as lung and breast cancer, 
and are involved in cancer metastasis and mediating prothrombotic 
progression(Shamay et al., 2016). Targeting of the corresponding ligand (PGSL) on 
these cancer MVs may therefore confer a therapeutic advantage in order to prevent 
acceleration of thrombus formation(Thomas et al., 2009).  
 
TFMVs: 
A recent focus has been on cancer MVs associated with TF or TFMVs, which are 
known to be elevated in some cancers and may have a role in VTE and in some of the 
processes that promote metastasis (Table 1.3). Davilla et al for example showed that 
about 50% of MVs generated from breast and PC, expressed TF and generated 
procoagulant activity when injected into animal models, an effect removed upon 
addition of anti-TF antibody (Davila et al., 2008). This suggests that MVs can serve as 
soluble sources of TF and may mediate coagulation processes such as conversion of 
coagulation factor VII to VIIa which is essential for the extrinsic pathway. 
Furthermore, the majority of TF circulating in the blood are carried or are associated 
with MVs (Tilley et al., 2008), which suggests that MV detection may represent an 
important research tool, especially in cancer thrombosis. 
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Table 1.3 The clinical studies of TFMVs in cancer VTE. 
Modified from Geddings and Mackman, 2013(Geddings & Mackman, 2013) 
Disease Method of 
measurement 
Patient 
numbers 
Conclusion Reference 
Pancreatic and Breast 
Cancer and VTE 
TFMV activity 
assay 
40 TFMV activity is increased in metastatic 
breast cancer and PC patients 
Tesselaar et al, 2007(Tesselaar 
et al., 2007) 
Pancreatic cancer and 
VTE 
TFMV activity 
assay 
10 Increased TFMV activity precedes VTE 
in PC patients  
Khorana et al, 2008(Khorana 
et al., 2008a) 
Various cancers: bone, 
lung, colorectal, 
oesophageal and VTE 
TFMV activity 
assay 
100 Cancer patients with VTE have higher 
levels of TFMV activity than those 
without VTE  
Tesselaar et al, 2009(Tesselaar 
et al., 2009) 
Various cancers: 
bladder, prostate, 
lymphoma, renal, testis 
Functional 
chromogenic 
assay 
66 Cancer patients with VTE have higher 
levels of TFMV activity than those 
without VTE  
Manly et al, 2010(Manly et al., 
2010) 
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Pancreatic cancer and 
VTE 
Flow 
cytometry 
60 Cancer patients with VTE show higher 
TFMV levels 
Campello et al, 2011(Campello 
et al., 2011) 
Myeloma and VTE TFMV activity 
assay 
122 TFMV activity is increased in MM 
patients and decreased after 
chemotherapy  
Auwerda et al, 2011(Auwerda 
et al., 2011) 
Pancreatic cancer and 
VTE  
TFMV activity 
assay 
348 TFMV activity is associated with 
mortality in PC patients  
Thaler et al, 2012(Thaler et al., 
2012) 
Glioblastoma and VTE Flow 
cytometry 
61 TFMV levels are elevated in 
Glioblastoma multiforme before and 
during treatment 
Sartori et al, 2013(Sartori et 
al., 2013) 
Pancreatic cancer TFMV activity 
assay 
52 Higher levels of circulating TFMV or TF-
related activity found correlated with 
increased angiogenesis 
Echrish et al, 2014(Echrish et 
al., 2014) 
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Figure 1.11 TFMVs contribute to cancer VTE.  
Tumour-derived microvesicles (TMVs) may produce TFMVs for direct or indirect 
enhancement of VTE, through binding and activation of endothelium to activate and 
release adhesion molecules such as selectins, VCAM-1 (Vascular cell adhesion protein 
1), binding and activation of platelets, activation of neutrophils to secrete neutrophil 
extracellular traps (NETs), binding of monocytes to induce more TF. Adapted from 
Hisada et al, 2015(Hisada et al., 2015). 
 
Tumour cells in vivo and in vitro can release membrane TFMVs (Figure 1.11) and are 
known to be significantly raised in cancer compared with non-cancer patients (Davila 
et al., 2008; Auwerda et al., 2011; Campello et al., 2011). In some clinical studies, 
elevated levels of TFMVs derived from tumour have been associated with VTE in 
several cancers such as PC (Zwicker et al., 2009; Geddings & Mackman, 2013). They 
have also been associated with an aggressive metastatic process where interaction 
with endothelium is a key element for VTE initiation and propagation, and for the 
invasion of a cancer cell into stroma. TFMVs have been shown to support coagulation 
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in clotting and thrombin generation tests in vitro (Bastida et al., 1984; Davila et al., 
2008) and promote the metastatic process through angiogenesis, cancer cell survival, 
immune suppression, and invasion (Zahra et al., 2011). For all these processes, the 
ability to interact with the endothelium is a key element. However, more details from 
future studies are needed about their interactions with the vascular endothelium, or 
the procoagulant changes seen because of this interaction.  
 
Accurate TFMVs measurement is a point of challenge in MV studies(Tatsumi et al., 
2014). There are two main methods to measure TFMVs; one through its functional 
activity in a given substrate and the other by measurement of its TF expression 
(Geddings & Mackman, 2013). Various tests exist to assay both endpoints; 
quantitative levels of TFMVs can be measured by flow cytometry and TF antigen by 
Enzyme-linked immunosorbent assays (ELISA) while TFMV activity can be measured 
by functional assays such as Zymuphen MP-activity kits, clotting-based tests, 
chromogenic assays, and thrombin or fibrin generation assays. Inhibitory assays of TF 
activity are also useful.  
 
It is notable that even in the same patient sample; both main methods of TFMV 
measurement do not always correlate with themselves. In a prospective study of 
pancreatic patients, TF activity was assessed by a fibrin generation test that 
correlated with VTE development in cancer, but however not to the TFMV expression 
measured by flow cytometry test (van Doormaal et al., 2012).  In another study, 
although there was a correlation of TFMV with cancer thrombosis risk, there was no 
correlation with a TF activity assay in the same phase II randomized controlled trial 
(Zwicker et al., 2013; Tatsumi et al., 2014). Furthermore, the variability in substrates 
used for measurement creates another level of difficulty for comparison across 
studies. Although plasma and serum are often used, the type of processing of this 
substrate may affect the results. For instance, a study found up to 80% lower levels 
of TFMVs in Platelet free plasma (PFP) than in Platelet-poor-plasma (PPP), probably 
due to the additional centrifugation steps involved in obtaining PFP, which removes 
more of the MVs(Lechner & Weltermann, 2008). Therefore, to improve 
standardization and reduce analytical variables, the Scientific Collaborative 
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Workshop of the International Society of Thrombosis and Haemostasis (ISTH), have 
recommended specific consensus protocols in isolation and measurement of MVs 
such as collection of blood samples in citrate containing tubes, specific centrifugation 
steps for sample processing, storage and flow cytometry bead detection 
steps(Gyorgy et al., 2011b). 
 
1.7  Endothelium and TFMVs in Cancer VTE 
 
The endothelium lines the lumen of blood vessels and is a vascular structure that 
plays a vital role in initiation of coagulation, amongst other functions in the body 
including angiogenesis, cell growth and adhesion, fibrinolysis, tissue remodelling. It 
also regulates immune responses (Figure 1.12) through anti-inflammatory mediators 
and vascular homeostasis (blood pressure) by controlling the smooth muscle tone of 
blood vessels through secretion of various vasomotor mediators. Normally, the 
endothelium provides a haemostatic balance between procoagulant and 
anticoagulant mechanisms, through active prevention of clot formation. It performs 
this function by production of anticoagulants Tissue Factor Pathway Inhibitor (TFPI), 
thrombomodulin, endothelial protein C receptor (EPCR), release of platelet inhibitors 
(including nitric oxide and prostacyclin), and inhibition of cellular attachments 
necessary for clotting(Watson, 2009; Esmon & Esmon, 2011) (Watson, 2009, Esmon 
and Esmon, 2011). In bleeding conditions, the endothelium performs a 
prothrombotic function by releasing TF into the extravascular space to initiate 
pathways consisting of several coagulation factors that lead to fibrin plug formation 
to halt bleeding. In hypercoagulable states, this regulatory balance is disrupted, and 
studies have indicated that the endothelium underlying vascular structures may be 
altered (Chirinos et al., 2005), as described previously in section 1.2.1. According to 
Date et al, it is possible that prothrombotic states in cancer may result from 
homeostatic imbalance in the endothelium with specific interactions of TFMVs or the 
acquisition of deficiencies of other coagulation factors(Date et al., 2017). A 
transformed procoagulant endothelium may not be clinically apparent at first but 
may eventually result in VTE manifestations such as deep venous thrombosis, which 
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have been established as a cause of high clinical morbidity and mortality in cancer 
patients (Blom et al., 2005; Blom et al., 2006). 
 
 
Figure 1.12 Main functions of the vascular endothelium.  
The critical functions of the endothelium include regulation of vascular homeostasis, 
modulating blood coagulation and fluidity, and regulation of immune responses. 
Adapted from Speciale et al, 2014(Speciale et al., 2014). 
 
The endothelium is important in regulating thrombin production. Specifically, it has 
been found that endothelial cells that over-express EPCR or are exposed to activated 
protein C (aPC in Figure 1.13) aid in limiting tumour invasion and metastasis. This 
aPC/EPCR pathway causes the reduction of the amount of endothelial produced 
adhesion molecules necessary for tumour growth and transmigration (Bezuhly et al., 
2009). Endogenous aPC produced by endothelial cells has a protective function, 
through use of monoclonal antibodies against aPC such as MPC1609 and MAPC1591, 
which blocks its signalling and further anticoagulant activity (Van Sluis et al., 2009). 
On the other hand, metastasis is promoted by blocking or reduction of the production 
of endogenous protein C which alters the endothelial cell barrier function through 
sphingosine-1-phosphate receptor-1 (S(1)P(1))activation(Van Sluis et al., 2009). In all, 
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these anti-coagulant properties of the endothelium occur by affecting the levels of 
thrombin produced and have a major impact in tumour growth and metastasis 
success. 
 
 
Figure 1.13 Endothelial regulation of thrombin production in the coagulation 
cascade.  
Once coagulation is stimulated, Tissue factor (TF) interacts with factor VII which 
generates activated factor VII (FVIIa). The TF-FVIIa complex then conversts factor X 
to factor Xa whose interaction with Va results in prothrombin conversion to 
thrombin, and fibrinogen conversion to fibrin. There are three key regulators of this 
process- Protein C is activated to aPC through its interaction with cell-surface 
thrombomodulin, to inhibit factors Va and VIIIa activities. Antithrombin inhibits the 
activation of multiple factors such as factor X and thrombin. Tissue factor pathway 
inhibitor (TFPI) interferes directly with the TF-FVIIa complex. Adapted from Ouellette 
and Hazelzet, 2016(Ouellette & Hazelzet, 2016). 
 
Numerous studies have detailed the importance of TF and TFMVs in driving 
coagulation pathways in the tumour endothelium over time. Such studies have 
demonstrated several correlations of high TF expression and activity levels with 
76 
 
angiogenesis, increased vascular density that may further enhance metastasis in 
several tumours (Contrino et al., 1996; Nakasaki et al., 2002; Khorana et al., 2007a). 
More recently, Echrish et al 2014, corroborated links between tumour TF, circulating 
TFMV and increased endothelial VEGF expression with microvessel density and 
invasion in pancreaticobiliary adenocarcinoma patient samples (Echrish et al., 2014). 
A previous study in our laboratory group has also identified endothelial MVs as being 
elevated in MM PPP(Hall et al., 2016). However, more work is necessary to detail TF-
derived MV induction of the endothelium into procoagulant states in a cancer 
microenvironment, and how such mechanism differs in solid tumours and non-solid 
ones, some of which are now known to have similarly high rates of VTE incidence. In 
summary, further investigations into the contributions of the endothelium to 
hypercoagulability are necessary in the hope that this may shed further clarity on 
underlying procoagulant pathways.  
 
1.8  Multiple Myeloma (MM) 
 
1.8.1  Description and Pathology 
 
Multiple myeloma is one of the well-known haematological cancers as it constitutes 
about 12% to 15% of hematologic malignancies (Greenlee et al., 2000). It is a 
malignancy that forms in a type of white blood cell called plasma cells. These plasma 
cells arise from post-germinal B cells of the immune system, as they are the primary 
component of humoral immunity and secrete immunoglobulins (Ig) composed of 
either kappa or lamda light chains attached to two heavy chains. MM is thus a plasma 
cell disorder that occurs due to monoclonal proliferation of these Igs deposited into 
the different parts of the body, crowding out healthy cells and leading to organ 
dysfunction, and ultimately death if left untreated. There are various 
immunoglobulins chains, which may be involved and they include IgG, IgA, IgM, IgD, 
and IgE, based on their composition of light chains attached to heavy chains(Cook & 
Macdonald, 2007). These paraprotein light chains or M-proteins are over-secreted in 
the bone marrow by plasma cells in the form of immunoglobulin (Ig) fragments to 
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form various extramedullary tissues deposits. In the kidneys these light chain 
deposits damage the renal tubules leading to nephropathy (Kyle et al., 2002), or are 
secreted into the blood leading to over-viscosity or excreted into urine as Bence Jones 
proteins. Various conditions exacerbate paraprotein precipitations such as infection, 
use of chemotherapy, radiation, dehydration (Haubitz & Peest, 2006).  
 
1.8.2  Epidemiology 
 
Worldwide, MM is the accounts for 0.9%-2% of all cancer deaths(Zweegman et al., 
2014) and is the second most common of all haematological malignancies in the  
developed countries(Jemal et al., 2010). Global incidence varies substantially, 
although overall it is estimated that about 86,000 incident cases occur annually, 
accounting for about 0.8% of all new cancer diagnoses, while around 63,000 reported 
deaths each year(Becker, 2011). In the UK, Myeloma is the 18th most common 
cancer, accounting for around 2% of all new cases in 2014 (Cancer Research UK; 
Myeloma Incidence Statistics 2014) with a male:female ratio of around 1.3:1. Like 
most adult cancers, median age of presentation is over 70 years old (Palumbo et al., 
2011a). Although survival is improving and has quadrupled in the past 40 years, there 
is still an age-discrepancy in survival trends with approximately three quarters of MM 
cases in England aged 15-49 survive their disease for five years or more, compared 
with a quarter of people 80 and above (2009-2013) (Cancer Research UK; Myeloma 
Incidence Statistics 2014). This may be due to higher occurrence of organ dysfunction 
and drug toxic effects, although the role of better hospital access and referral streams 
in the young may be the cause of this observation (Turesson et al., 2010; Zweegman 
et al., 2014). 
 
1.8.3  Risk factors 
 
Monoclonal gammopathy of undetermined significance (MGUS) is a benign earlier 
form, which is now recognized to precede most MM diagnosis (Landgren et al., 2009). 
While the aetiology of MM is poorly understood and remains elusive, the underlying 
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pathology of MM is assumed to be due to a cytogenetic malfunction from numerical 
or chromosomal rearrangements of transcription genes and translation to over 
production of paraproteins(Tricot, 2002). Primary translocation of Ig heavy chain 
(IgH) locus at 14q32 have been identified in over 40% of all MM(Bergsagel & Kuehl, 
2003), although at least 25% have no identifiable IgH rearrangements. The main IgH 
translocations include 11q13 (cyclin D1), 6p21 (cyclin D3), 4p16 (FGFR3 and MMSET), 
and 16q23 (c-maf), with increased incidence in higher stages i.e 50% in MGUS, 60-
65% in intramedullary MM, 70-80% in extramedullary MM, and >90% in MM cell 
lines(Bergsagel & Kuehl, 2001). There have also been reports of secondary 
rearrangements in later disease stages such as oncogene MYC at locus 8q24, the loss 
or deletion of chromosome 13, deletions and/or amplifications of chromosome 1 et 
cetera (Bergsagel & Kuehl, 2001; Sawyer, 2011). 
 
1.8.4  Staging 
 
Diagnosis of MM is usually made by identification of a monoclonal or phenotypically 
aberrant plasma cell by several methods such as immunohistochemistry or flow 
cytometry on bone marrow sections (Rawstron et al., 2008). The Durie-salmon 
classification(Durie & Salmon, 1975) was often used before 1975 but has largely been 
superseded by the International Staging System (ISS) developed by the International 
Myeloma Working Group (IMWG) which classifies patients into three risk categories 
(Table 1.4). The ISS has been proved to be more sensitive in predicting prognosis and 
guiding treatment as it is based on correlation of the patient clinical features to 
predict the exact tumour burden from A) extent of bone lesions B) haemoglobin level 
C) serum calcium level and D) M-component levels in serum and urine(Greipp et al., 
2005). 
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Table 1.4 International Staging System (ISS) for Multiple myeloma.  
Modified from Greipp et al, 2005(Greipp et al., 2005) 
Stage Criteria Median survival in 
months (months) 
I Serum ß2 microglobulin <3·5 
mg/l (296 nmol/l) and serum 
albumin ≥3·5 g/dl (35 g/l or 
532 μmol/l) 
62 
II Neither I or III* 45 
III Serum ß2 microglobulin ≥5·5 
mg/l (465 nmol/l) 
29 
 
1.8.5  Clinical presentation and Treatment 
 
MM often presents with bone diseases with symptoms such as frequent back pain, 
bone fractures and may involve focal or diffuse osteolytic lesions and spinal cord 
compression. The low blood cell counts in MM patients specifically of red blood cells 
which can lead to anaemia, and low white cell counts can predispose these patients 
to frequent infections from immunodeficiency while low platelets can result in easy 
bruising (Mehta & Singhal, 2003). In addition, signs of hypercalcemia and nervous 
system involvement such as muscle weakness and numbness are all commonly found 
in MM presentations(Coleman, 1997). Hyperviscosity due to paraproteins profusion 
can also lead to symptoms of stroke, dizziness, and confusion. 
 
As complete cure is rare, MM treatment aims include disease control, quality of life 
enhancement, and prolong survival. Factors that generally affect treatment 
outcomes include advanced age, cancer burden, level of end-organ damage and the 
cytogenetic abnormalities present. Chemotherapy is the mainstay of treatment. Due 
to potential stem cell toxicities and sublethal tumour damage and risk of 
myelodysplasia, Mephalan-only medications have mostly been superseded by 
combinations with newer agents such as imunomodulatory (IMiD) drugs, which have 
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significant clinical improvements(Kumar et al., 2008). Autologous stem cell 
transplantation in combination with high dose Mephalan is also associated with high 
risk of AML(Mailankody et al., 2011) and toxicity and is only now  used for eligible 
patients based on age, performance status, and comorbidities(Rajkumar, 2011).  
 
Recently, IMiD-based regimens are commonly regarded as standards in MM 
management due to improved clinical outcomes(Rajkumar, 2011). First line regimens 
include 3 types of agents; an alkylating agent (Melphalan or Cyclophosphamide), a 
corticosteroid (such as prednisolone or dexamethasone (DEX), and an IMiD agent 
(such as Thalidomide (Thal)(Singhal et al., 1999), Lenalidomide (LEN)(Richardson et 
al., 2002) or Bortezomib (BOR)(Richardson et al., 2003). More recently, newer agents 
such as Pomolidomide (Pom) and carfilzomib are being investigated in trials for 
routine clinical use and all these regimens aim to drive patients into a refractory stage 
(Rajkumar, 2011). There are three stages of MM therapy commonly seen in most 
patients-induction, remission and relapse; with most patients ultimately relapsing at 
5-year survival rates of 25% and 10-year survival of <10%(Blade et al., 1998). In the 
UK, the standard induction therapy for young people aged 60 or less who are 
relatively healthy is CTD (Cyclophosphamide, Thalidomide, Dexamethasone) or RCD 
(Lenalidomide, Cyclophosphamide, Dexamethasone) while those for patients above 
60 or those with worsened states is an attenuated dose of CTDa, or MPT (Melphalan, 
Prednisolone, Thalidomide)(Bird et al., 2011).  
 
1.9  Thrombosis in MM 
 
MM is a haematological cancer well known for its thrombotic propensity, through 
the creation of a microenvironment with elevated levels of inflammatory and 
procoagulant cytokines some of which, such as IL-6 can initiate coagulation pathways 
and fibrinogen production (Amrani, 1990; Tricot, 2002).  Other explanations 
proposed for this prothrombotic state include the acquired resistance to activated 
protein C receptor (APCR), which may allow indiscriminate prolonged clotting and 
whose abnormal presence has been suggested as the most frequent transitory 
baseline coagulation abnormality found in MM (Elice et al., 2006), and M-parapotein-
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induced hyperviscosity impairment of fibrin biosynthesis and subsequent 
degradation (Gabriel et al., 1983; Robert et al., 1993; Carr et al., 1996).  
 
Without treatment, the risk of VTE in MM is high. MM has been associated with 
increased risk for over four decades(Catovsky et al., 1970). In a large population-
based study of 4 million military veterans in the US, of the 6192 patients identified 
with MM, 2.4% developed DVT(Kristinsson et al., 2008). These MM patients were also 
known to develop a 9.2-fold increase in DVT risk in comparison to other patients in 
the study, with the highest risk observed in the first-year post-diagnosis. In another 
population study in Sweden which included 18,627 MM patients and 70,991 matched 
controls, the risk of VTE was found to be 7.5-fold after 1 year of follow-up(Kristinsson 
et al., 2010). However, the use of chemotherapy is also associated with increased 
thrombosis, which thereby worsens the risk, with the highest level of thrombotic-
related events seen in the first 6 months of treatment of newly diagnosed MM 
patients (Palumbo et al., 2006). Chemotherapy can cause VTE through several ways 
such as release of procoagulant molecules cancer cells, TF initiation, and damage to 
the endothelium, and different combinations carry variable VTE risks. In fact, several 
chemotherapy agents; single or combined have been associated with increased VTE. 
For instance MPT regimen in elderly patients showed an incidence of 17% versus 2% 
when Melphalan is used with Prednisolone only (Palumbo et al., 2006), while Thal 
with DEX showed 17% versus DEX only of 3%(Rajkumar et al., 2006). The newer IMiD 
drugs such as Lenalidomide (LEN) and Pomolidomide also carry substantial risk; for 
example, LEN used with DEX has an elevated risk of 11-14% before use of anti-
thrombotics in refractory or relapsed MM (Weber et al., 2007). Another study 
reported a high rate of VTE incidence in newly diagnosed MM when DEX was used in 
combination with LEN versus when DEX was administered alone; 75% (9 out of 12) of 
the LEN/DEX arm experienced thromboembolic events such as ischaemic stroke, 
while no events were reported in the control arm of DEX alone(Zonder et al., 2006). 
This incidence reduced significantly to 15% upon administration of a prophylactic 
dose of 325mg Aspirin as thromboprophylaxis, which supports the effectiveness of 
routine thromboprophylaxis in MM patients as recommended by ASCO, ESMO, 
IMWG(Lyman et al., 2007; Palumbo et al., 2008; Mandala et al., 2011). 
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Various thromboprophylaxis agents have been used in MM clinical management, and 
include Aspirin, LMWH and warfarin. Several studies have concluded that these are 
all likely to be similarly effective in supportive management except in elderly patients 
where warfarin showed less efficacy when compared to LMWH(Palumbo et al., 
2011b). Routine guidelines by the agencies above recommend a risk-stratified 
approach to thromboprophylaxis in IMiD-treated patients. For instance, in MM 
patients receiving Thal or LEN combination regimens, Aspirin (75 – 325mg) may be 
administered in low risk patients (without any risk factors)(Snowden et al., 2011). 
However MM Patients receiving Thal or LEN combinations that are high risk (with 2 
or more MM-related risk factors such as hyperviscosity or high disease burden and 1 
or more individual factors such as obesity or previous VTE) should receive high dose 
LMWH or dose adjusted warfarin(Snowden et al., 2011). 
 
1.10  Pancreatic Cancer (PC) 
 
1.10.1  Description and Pathology 
 
The pancreas is a large endocrine and exocrine organ located at the upper part of the 
posterior wall of the abdomen. It is a retroperioneal organ covered in front by the 
stomach and the duodenum to the right side(Longnecker, 2014). It has three parts 
consisting of the head, body and tail, which can be further, subdivided into five 
regions- the head, neck, body, tail and ucinate process (Figure 1.14). Histologically, it 
consists of two main types of tissues, an endocrine component formed by the islets 
of Langerhans cells and an exocrine component of secretory acinar cells that 
produces digestive enzymes (Figure 1.15) such as lipase, amylase, carboxypeptidase, 
trypsin and chymotrypsin(Longnecker, 2014). All these hormones and enzymes 
mostly regulate food intake, breakdown and absorption in the body. They drain 
through the main pancreatic duct of Wirsung and sometimes through the minor 
papillae into the duodenum at the papilla of Vater(Bockman, 1993).  
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Figure 1.14 The different regions of the pancreas.  
The pancreas has three main parts the head body and tail which can be divided into 
the five regions above. Adapted from: The pancreas, Educational healthcare 
resources, (http://teachmeanatomy.info/abdomen/viscera/pancreas/). Accessed 
August 3, 2017) 
 
Embedded deep inside the acinar exocrine portion of pancreatic tissue, the islet of 
Langerhans consists of four types of cells that produce different endocrine products 
(Figure 1.16): alpha cells produce glucagon, beta cells comprises 65-80% of islet cells 
secrete insulin, delta cells produce somatostatin, and enterochromaffin cells secretes 
pancreatic polypeptide and digestive polypeptide hormones(Klimstra & Longnecker, 
1994). These endocrine hormones; Insulin and glucagon specifically regulate glucose 
secretion and uptake in the cells and are vital for glucose metabolism(Aronoff et al., 
2004).   
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Tumours of the pancreas are mostly exocrine, based on a histopathological 
examination over 15 years(Morohoshi et al., 1983). About 95% arise from the 
pancreatic duct, are called pancreatic ductal adenocarcinoma (PDAC) and can grow 
anywhere along the length of the pancreas though most commonly found in the 
head(Lillemoe, 1995). Other types are acinar cell carcinoma, solid pseudopapillary 
neoplasm, cystadenomas and pancreatoblastomas (Hruban et al., 2007). The 
endocrine section gives rise to neuroendocrine tumours that arise from the islets; a 
small percentage 10-30% which may be functionally producing hormones or 
not(Lillemoe, 1995). The functional ones include insulinomas, gastrinomas, 
glucagonomas, VIPomas, somastinomas. 
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Figure 1.15 The histological tissues of the pancreas.  
A) Anatomy of the pancreas in relation to surrounding structures B) Endocrine cells 
embedded amidst exocrine acinar cells. Adapted from Sartin, 2016(Sartin, 2016).  
 
1.10.2  Epidemiology 
 
Pancreatic cancer is one of the world’s deadliest cancer, with most patient death 
occurring within 1 year of diagnosis as observed of 36,800 deaths out of 43,140 new 
cases diagnosed in both sexes in 2010(Jemal et al., 2003; Jemal et al., 2010). It has 
the lowest survival by stage of any other solid tumour (Jemal et al., 2009); a 10-year 
prospective study reported very low survival rates amongst 196 patients with proven 
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adenocarcinoma; where only 27 patients survived beyond 1 year and only 1 non-
resected patient survived beyond 5 years(Gudjonsson, 1987). A comprehensive 
review of 37,000 hospital cases of PC has also shown overall survival of only 0.41%, 
with only 156 surviving patients after 5 years(Gudjonsson, 1987) and this survival 
rates and statistics have not improved much since then. This high mortality is mainly 
because of the propensity to early metastasize and spread (Pandol et al., 2009), (109 
patients of the 10-year study above in fact had metastasis to the peritoneal nodes 
(64%) and secondly to the liver(27.4%)) with even the smallest primary lesions often 
show perineural and lympho-vascular invasion (Hezel et al., 2006). More recently, the 
5-year survival rates have improved but differs country to country, based on 
management approaches such as early surgical removal, stage, absence of lymph 
node metastasis. Worldwide, survival is generally around 5%; in England for instance, 
from 2001-2006 the rate was 3%, compared with 6% in the USA for a similar study 
period of 1999-2005(Jemal et al., 2010).  
 
Still regarded as largely incurable, it is the fifth most common cause of cancer death 
in the UK (Cancer Research UK; Pancreatic Cancer Mortality Statistics 2014) and 
Europe  (Ferlay et al., 2007). In the U.S, PC is the fourth leading cause of cancer death 
(Jemal et al., 2008) and second most common gastrointestinal malignancy (American 
Cancer Society, Cancer Facts and Figure 2010). It is strongly related to age; in the 
period of 2012-2014 for example almost half (47%) of cases diagnosed on average 
each year were in people aged 75 and over in the UK (Cancer Research UK; Pancreatic 
Cancer Mortality Statistics 2014). Sex distribution is approximately equal. There were 
8,817 pancreatic cancer deaths in the UK in 2014: 4,426 (50%) in males and 4,391 
(50%) in females, giving a male:female ratio of around 1:1(Cancer Research UK; 
Pancreatic Cancer Mortality Statistics 2014). 
 
1.10.3  Risk factors 
 
Smoking (Blackford et al., 2009; Lynch et al., 2009), environmental tobacco 
exposure(Vrieling et al., 2010), alcohol intake(Genkinger et al., 2009), high 
consumption of fatty meals and low vegetables, fruits and Vitamin C (Lynch et al., 
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2009; Thiebaut et al., 2009; Vrieling et al., 2010), obesity(Philip et al., 2013)  and 
exposure to chemicals such as beta-naphthylamine and benzidine(Mancuso & el-
Attar, 1967) and trace elements such as lead, nickel and selenium(Amaral et al., 2012) 
have been established as risk factors to developing PC. There has also been marked 
risk associated with chronic pancreatitis (Lowenfels et al., 1993; Malka et al., 2002) 
as well as diabetes mellitus, specifically new onset (Rosa et al., 1989; Everhart & 
Wright, 1995; Gupta et al., 2006). At 10% incidence, a familial risk is also considerable 
based on inheritance of specific familial gene clusters (Schenk et al., 2001; Petersen 
& Hruban, 2003; Ferlay et al., 2007; Wang et al., 2007). 
 
The tumour arises due to accumulations of genetic mutations leading to activations 
of oncogenes such as the KRAS oncogene, and inactivation of various tumour-
suppressor genes. For example, the first known mutations involve activating KRAS 
point mutations at codon 12 (from GGT to GAT or GTT, and more rarely CGT). This 
mutation results in glycine substitution with aspartate, valine, or arginine. Although 
these mutations may occur sporadically in normal pancreas tissue, they are detected 
in higher quantities from up to 30% of early neoplasms in to a higher frequency up to 
almost 100% in advanced PDAC (Klimstra & Longnecker, 1994; Rozenblum et al., 
1997). Other germline mutations occur such as in INK4A and BRCA2 genes, which are 
associated with several variants of PC as shown in Table 1.5. Consistent with a central 
developmental function, growth factors also play an important part in PC growth (Li 
et al., 2004; Deer et al., 2010). 
 
Table 1.5 Pancreatic tumours and common associated genetic alterations.  
Adapted from Hezel et al(Hezel et al., 2006). 
Pancreatic neoplasm Histological 
features 
Common genetic 
alterations 
Ductal adenocarcinoma Ductal 
morphology; 
desmoplasia 
KRAS, p16INK4a, TP53, 
SMAD4 
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Variants of ductal 
adenocarcinoma: 
  
a) Medullary carcinoma Poorly 
differentiated; 
intratumoral 
lymphocytes 
hMLH1, hMSH2 
b) Colloid (mucinous 
noncystic) carcinoma 
Mucin pools MUC2 overexpression 
Acinar cell carcinoma Zymogen 
granules 
APC/_-catenin 
Pancreatoblastoma Squamoid nests, 
multilineage 
differentiation 
APC/_-catenin 
Solid pseudopapillary 
neoplasm 
“Pseudo” 
papillae, solid and 
cystic areas, 
hyaline globules 
APC/_-catenin, CD10 
expression 
Serous cystadenoma Multilocular 
cysts; glycogen-
rich epithelium 
VHL 
Pancreatic endocrine 
tumours 
Hormone 
production 
MEN1 
 
 
1.10.4  Staging  
 
PC can be comprised of three main types of tissues; papillary 39% of tumours, tubular 
59% and mixed 5% (Terada et al., 1998; Tanase et al., 2006). Based on histological 
examination, these tumours are graded into well, moderately and poorly 
differentiated(Morohoshi et al., 1983) which is reflected in the standard 
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Tumour/Node/Metastasis (TNM) classification and staging proposed by Rindi et al for 
foregut tumours(Rindi et al., 2006): 
 
T- Tumour:  
T0: Tumour in situ / dysplasia (0.5 cm). T1:Tumour invades lamina properia or 
subserosa and the size is less than 1 cm. T2:Tumour more than 1 cm in diameter and 
invades muscularis properia or subserosa. T3:Tumour penetrates serosa. T4:Tumour 
invades the adjacent structure.  
N-Regional lymph node:  
N0: No involvement of regional lymph nodes. N1: Involvement of regional lymph 
nodes.  
M-distant metastasis:  
M0: No distant metastasis M1: There is distant metastasis. 
 
Staging:  
Stage I = T1 N0 M0  
Stage IIa=T2 N0 M0 Stage IIb =T3 N0 M0  
Stage IIIa=T4 N0 M0 Stage IIIb = any T N1 M0  
Stage IV = any T any N M1 
 
1.10.5  Clinical presentation and Treatment 
 
Usually symptomless in the early stages and are often non-specific until advanced 
stages. Abdominal symptoms such as recurrent discomfort, loss of appetite, nausea 
and vomiting, change in bowel habits such as diarrhoea, steatorrhea, and 
constipation may also be present(Lillemoe, 1995). Late presentation signs such as 
jaundice often signals head involvement and inoperability(Lillemoe, 1995). Surgery is 
usually advocated in early stages of PC and includes pancreaticoduodenectomy when 
the head of the pancreas is involved, distal pancreactectomy with splenectomy for 
those involving the body or tail,(Castillo et al., 1995) while Whipple’s procedure 
removes the head, the duodenum, part of the stomach and bile duct, the gallbladder 
are all removed to limit extension(Whipple et al., 1935). 
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Chemotherapy is often used as adjunct post-surgery and as palliative in non-
resectable patients(Lillemoe, 1995). Gemcitabine (GEM) combinations such as with 
LMWH (such as Dalteparin) has mostly replaced 5-FU based therapies (such as 
FOLFORINOX-oxaliplatin, irinotecan, fluorouracil, and leucovorin) due to its relatively 
better safety profile and efficacy, although overall outlook for survival is still 
poor(Heinemann et al., 2008). In some few centres, FOLFORINOX is still used as first 
line-treatment for advanced PC due to slightly better survival advantage, longer time 
before quality of life deterioration compared to GEM(Conroy et al., 2011). 
 
The clinical experience of targeting growth factor receptors such as anti-EGFR agent, 
both TKIs and monoclonal antibody [mAb]) [cetuximab (Erbitux), anti-VEGF 
bevacizumab, and other antiangiogenic agents axitinib in PC has limited success, of 
little or no therapeutic merit(Goel & Sun, 2015). These therapies, for example GEM 
plus bevacizumab when compared to GEM with placebo may also lead to increase 
toxicities and no overall survival for advanced disease (Kindler et al., 2010). There 
remains a valid concern that from a clinical perspective, these agents also drive 
thrombosis lead to excess thrombotic events and therefore undermine any potential 
benefit obtained from use of anti-cancer therapies (Maraveyas & Johnson, 2009; 
Echrish et al., 2011). To date however, there is little treatment benefit in the use of 
growth factor targeted receptors in PC management. 
 
1.11  Thrombosis in PC 
 
PC has one of the highest VTE rates amongst malignancies worldwide, with incidences 
that reach up to 57% in patients(Khorana & Fine, 2004). In PC, an intrinsic 
procoagulable state exists as a complex interaction of prothrombotic and 
proangiogenic protein expressions. This thrombotic state further aids tumour 
development and expansion and accounts for poor prognosis in PC(Mandalà et al., 
2007). It is surmised from several histologic studies that the tumour stroma is 
surrounded extensively by fibrin and the tumour is known to produce high amounts 
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of prothrombin, coagulation factors, angiogenic factors and fibrinogen, all leading to 
an excessive propensity to clot formation (Wojtukiewicz et al., 2001). 
 
PC is widely known to have high-grade TF antigen expression (Nitori et al., 2005; 
Khorana et al., 2007a). This high TF expression levels have been significantly 
correlated with increased VTE risk as high as 26.3% (p= 0.04) (Khorana et al., 2007a), 
and worse treatment prognosis overall (Nitori et al., 2005). In fact, as 77% of poorly 
differentiated PC have a markedly elevated TF expression compared to 20% of the 
less-progressed well-differentiated ones, a strong linear correlation is linked between 
TF expression and poor histologic grade of PC(Kakkar et al., 1995), which may account 
for its low survival rates(Khorana & Fine, 2004). In addition, while numerous cancers 
can be said to express high TFMV levels, PC in particular also has one of the highest 
TFMV activity (Tesselaar et al., 2007; Tilley et al., 2008). Furthermore, high amounts 
of functional thrombin receptors such as PAR-1 can be found on PC cells, signifying 
an additional link in thrombin-enhanced tumour progression (Rudroff et al., 2001).  
 
Thromboprophylaxis in PC clinical management is not used routinely as the natural 
evolution of VTE in aggressive advancement of PC is poorly characterized. Although 
VTE in PC may result in increased complications and worse survival outcomes, the 
actual impact of use of anti-thrombotics on survival remain uncertain. While some 
studies have analysed the risk of VTE associated with PC and the consequences on 
treatment and survival, most suggest that VTE development may signify a more 
aggressive cancer biologically and consequentially worse prognosis, while other 
studies find that there is little or no effect on overall survival. For instance, Shaib et 
al reviewed 201 patients with PC and reported VTE in 58 patients (28.9%) but found 
no survival difference between PC patients with VTE and those without VTE(Shaib et 
al., 2010). Few studies have also associated any clinical benefit with use of 
prophylactic anticoagulants; for example in a cohort of 90 patients; 72 of which had 
PC (49 with metastatic disease (54.4%), 24 developed VTE (26.7%)), Mitry et al 
retrospectively surmised that the risk of VTE was significantly reduced (HR: 0.03 [95 
CI: 0.003-0.27]) with administration of thromboprophylaxis, but conversely increased 
in those with metastatic disease (HR: 4.4 [95CI: 1.1-17.9]) (Mitry et al., 2007). 
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However, in the same study there was also no difference in overall survival in patients 
with VTE (6.6 months) and those without (6.1 months). 
 
 
1.12  Aims 
 
Understanding the intricate mechanisms underpinning cancer thrombosis may 
ultimately lead to assembly of biomarkers that may predict VTE patterns in cancer 
patients at risk or in the general population. This is because VTE may sometimes be 
the first symptom of occult cancer in otherwise healthy people, and reliable markers 
and methods of identifying them are necessary in cancer management. 
Personalizable anti-coagulation may be an achievable end goal obtained by use of 
various measurable predictive markers of VTE risk in cancer management. Current 
research indicates possible clinical benefits to integrating an individual unique 
thrombotic phenotype produced by comprehensive methods into their VTE risk 
determination. A deeper understanding of the mechanisms of endothelial 
involvement in thrombotic events may also potentially aid in developing better 
therapeutic solutions in cancer management. 
 
The overall aim of this thesis is to investigate the hypothesis that the study of 
thrombin generation, TF expression and TFMV activity can differentiate between the 
coagulation processes in two cancer types of diverse pathogenesis that are outwardly 
(clinically) similar in their high VTE incidences. From previous projects in our 
laboratory that showed that endothelial MVs are elevated in MM during 
chemotherapy treatment, and the finding that TFMV’s levels are raised in PC patients, 
we have theorized that first, the endothelium may be involved in procoagulant 
activities during cancer development. Another theory is that as TFMV’s levels are 
raised in PC patients, they may be correlated to the process by which thrombin is 
generated in such cancers. Thus, the initial aim was to examine the interaction of 
TFMVs that are produced from cancer cell lines with endothelial cells leading to a 
prothrombotic cross-talk that can be evidenced in various assays for measuring 
procoagulant activities including TG. 
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It is also known that solid cancers such as PC which is an adenocarcinoma have high 
levels of TF expression and thus may produce thrombin in a TF-dependent pattern, 
and this may differ from haematological cancers such as MM which is a plasma cell 
disorder that have little or no TF expression. Therefore, the hypothesis here was that 
the CAT assay may be used for measurement of TG in both PC and MM cell lines to 
allow an extensive definition of the patterns of TG which may be associated with the 
levels of TF produced. Furthermore, there might be differential contributions of the 
various factors of the coagulation cascade to these TG, from which surfaced the 
hypothesis that plasma deficient of one or more coagulation factors may affect the 
characteristics of thrombin produced in these malignancies. 
 
In addition, it is also theorized that these patterns of TG may also be seen in patients’ 
plasma obtained from both MM and PC patients, which may allow future use as a 
biomarker in identification of VTE risk in these patients. 
 
1.12.1  Objectives 
 
§ To investigate how cancer TFMVs can interact with endothelial cells in vitro 
and confer procoagulant activity (PCA) as determined by flow cytometry and 
clotting assay 
 
§ To measure the thrombin generation (TG) parameters of endothelial cells that 
acquire PCA with a CAT fluorogenic assay 
 
§ To determine the TG characteristics of solid tumour and haematological 
cancer cell lines by CAT assay and highlight any significant differences in TG 
kinetics in various coagulation factor plasma conditions  
 
§ To evaluate the TF antigen surface expression of the cancer cell lines with flow 
cytometry and correlate with their TG properties 
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§ To determine the TG properties of cancer MVs derived from these cancer cell 
lines through high centrifugation 
 
§ To assess the TG properties of MM and PC patient plasma samples as 
representatives of solid and haematological cancers, before, during and after 
treatment 
 
§ To measure the circulating TF antigen levels in MM and PC patient serum with 
quantitative ELISA. 
 
§ To correlate the TG results of these cancer patients with the circulating TF 
levels. 
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Chapter:2  Materials and Methods 
 
 
2.1  Cell culture 
 
All cells were cultured in their recommended media, grown in sterile culture flasks 
(Sarstedt, Leicestershire, UK), and incubated in a humidified incubator at 37°C under 
an atmosphere of 5% CO2. All cell culture experiments were carried out in a Class II 
Biological safety hood that had sterile laminar air flow to provide sterile working 
conditions, which was cleaned with Trigene disinfectant (VWR International, 
Leicestershire, UK) and 70% v/v ethanol (Sigma-Aldrich, Poole, UK), before and after 
carrying out protocols. The CO2 incubator and water bath for prewarming culture 
materials to 370C were also regularly cleaned with Virkon disinfectant (Scientific 
Laboratory Supplies Limited, UK) and 70% ethanol. All other equipment such as 
universal bottles, pipette tips boxes, were disinfected with 70% ethanol before 
placing in the biosafety hood in order to avoid culture contamination. All growth 
media were stored at 40C, and prewarmed in a water bath for at least 30 minutes 
before use. In addition, all cells were routinely tested for mycoplasma contamination 
(MycoProbe Assay, R&D Systems, Abingdon, UK). 
 
 
2.2  Cell lines 
 
2.2.1  HUVECs 
 
Primary Human umbilical vein endothelial cells (HUVECs; PromoCell, Heidelberg, 
Germany) are isolated from umbilical cord veins (Jaffe et al., 1973) of pooled donors 
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(from up to four different umbilical cords). HUVECs were chosen due to their unique 
endothelial properties exhibited as an intermediate between those of large vessels 
and microvascular endothelium(Bicknell, 2004). HUVECs are readily available and 
have been used widely in published literature and in our laboratory especially for 
thrombosis-related studies. They were cultured in endothelial cell growth media 
(ECG; PromoCell), supplemented with FBS 0.05 v/v, Endothelial Cell Growth 
Supplement 0.004 v/v, Epidermal Growth Factor (recombinant human) 10 ng/ml, 
Heparin 90 μg/ml, Hydrocortisone 1 µg/ml (all from PromoCell). HUVECs were seeded 
at 1 x 106/ml cells in a 25cm2 tissue culture flask and left to adhere overnight at 370C 
in a 5% CO2 incubator. HUVECs were used at approximately 70% confluency and were 
utilised at passages 3-6 only. 
 
2.2.2  Cancer cell lines  
 
Solid tumour cells (pancreatic cancer (ASPC-1, CFPAC-1, PANC-1, MIA PaCa-2), SKOV-
3 ovarian cancer, UMSCC81B Head & Neck squamous cancer, PC9 lung cancer) and 
malignant haematological cell lines (Multiple myeloma (MM1.S, U266B, H929), JJN3 
plasma cell leukaemia, U937 histiocytic lymphoma) were cultured as described above 
in section 2.1. 
 
ASPC-1, UMSCC81B, PC9 and all haematological cell lines were cultured in Roswell 
Park Memorial Institute 1640 (RPMI) 1640 medium (PAA; Yeovil, Somerset, UK) 
supplemented with 10% (v/v) FBS. CFPAC-1 and MIA PaCa-2 cells were maintained in 
Iscove’s Modified Dulbecco’s Medium (ATCC; Teddington, UK), supplemented with 
10% FBS, 1% L-glutamine and for MIA PaCa-2 cells only, 2.5% (v/v) horse serum from 
Gibco® (Life Technologies Ltd, Paisley, UK). SKOV-3 was maintained in McCoy’s 5A 
medium (PAA) supplemented with 1% L-glutamine (PAA) and 15% (v/v) FBS. All media 
were supplemented with 1% penicillin/streptomycin, which is provided as 100 
units/ml penicillin, 100 μg/ml streptomycin (p/s) (Lonza, UK). 
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2.2.2.1  MM and other haematological cancer cells 
The haematological cancer cell lines used in this study were MM.1S, U266B, H929, 
JJN3, U937, and U937 and were purchased from ATCC, while H929, U266 and JJN3 
were a kind gift from Dr Guy Pratt (School of Cancer Sciences, University of 
Birmingham, UK). MM.1S was derived from peripheral blood of 42 year old female 
with immunoglobulin (Ig) A myeloma (Goldman-Leikin et al., 1989), U266B was 
derived from an IgE producing myeloma patient(Nilsson et al., 1970), H929 was 
derived from a patient with IgAk myeloma with malignant effusion(Gazdar et al., 
1986), JJN3 is a subclone of JJN1 which is a parental cell line derived from plasma cell 
leukaemia in a 57 year old woman (Jackson et al., 1989), U937 was from pleural 
effusion of a 37 year old male with generalized histiocytic lymphoma(Sundstrom & 
Nilsson, 1976). 
 
2.2.2.2  PC cells and other solid cancer cells  
All solid cell lines were purchased from the American Type Culture Collection (ATCC) 
except PANC-1, SKOV-3, PC9 European Collection of Authenticated Cell Cultures 
(ECACC) and UMSCC81B (kind gift from Dr Thomas Carey, University of Michigan). 
ASPC-1 is a human pancreatic adenocarcinoma cell line established from ascites of a 
62 year old female (Chen et al., 1982). CFPAC-1 is a metastatic ductal pancreatic 
adenocarinoma obtained from a 26-year-old male with cystic fibrosis and liver 
metastasis (Schoumacher et al., 1990). MIA PaCa-2 is derived from a 65-year-old man 
with pancreas adenocarcinoma of the body and tail with periaortic infiltration (Yunis 
et al., 1977). PANC-1 was obtained from adenocarcinoma in the head of the pancreas 
of a 56-year-old man with duodenal wall invasion(Lieber et al., 1975). Other solid 
cancer cell lines used include SKOV-3, derived from ascites of a 64 year old female 
with metastatic ovarian adenocarcinoma (Fogh et al., 1977). UMSCC81B is a Head 
and Neck Squamous Cell cancer from the University of Michigan Tonsillar squamous 
cancer cell line, and PC9 is a Non-small cell lung cancer line derived from well-
differentiated adenocarcinoma in human lung tissue. 
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2.2.1  Passaging 
 
Cells were grown to 70-90% confluency and sub cultured within this logarithmic 
phase, in order to maintain optimal density for continued growth. The growth 
medium was changed 2-3 times a week and cell viability was determined by trypan 
blue assay (section 2.3). Adherent cells with the exception of HUVECs were removed 
from culture flasks by scraping with a cell scraper (Sarstedt), while non-adherent cells 
were removed by pelleting with centrifugation at 320xg for 3 minutes. Once pelleted 
by centrifugation, for both adherent and non-adherent cells, the supernatant was 
discarded before resuspension of cell pellet in fresh growth media for transferral to 
a new flask for reseeding. HUVECs were removed by trypsinization, which entailed 
washing of cells in the culture flask with sterile phosphate buffered saline (PBS) twice, 
then addition of 3-5 ml of 0.05% trypsin ethylenediaminetetraacetic acid (Trypsin 
EDTA; PAA, Yeovil, UK) for 3-5 min at 37°C in the 5% CO2 incubator. Then excess 
culture media of 10ml was added to the flasks and left for 3-5 minutes to neutralize 
trypsin action, prior to removal of the cell suspension and washing twice by 
centrifugation at 320xg for 3 minutes, before reseeding in fresh growth media in new 
culture flasks. Except for Corning® tissue culture flasks (orange top; VWR, UK) used 
for HUVECs culture, all other culture plastics used in this study was purchased from 
Sarstedt, UK. 
 
2.2.2  Ethics statement 
 
The use of commercially available cell lines such as those used in this study have been 
approved at a School level within the University of Hull. 
 
2.2.3  Cryopreservation 
 
To ensure high viability after recovery from storage, a cell count by trypan blue assay 
was performed (section 2.3) and only cells with 90% viability were cryopreserved to 
ensure recovery after thawing. To freeze, cell suspensions obtained as described 
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above were centrifuged at 320xg for 3 minutes and resuspended at a high cell 
concentration (3-5 x 106 cells/ml) in freezing media made up of 90% v/v heat 
inactivated fetal bovine serum (FBS; BioSera, Ringmer, UK) and 10% dimethyl 
sulfoxide v/v (DMSO; Sigma-Aldrich, Poole, UK). DMSO is a cryoprotective agent used 
to prevent formation of ice crystals during freezing, and thus reduce ionic stress on 
the cells. Then the cells in freezing media suspension were aliquoted into 1 ml 
cryovials, before these vials were placed in cryo-freezing containers (“Mr. Frosty”, 
Nalgene®;Fisher Thermo Scientific,Roskilde, DK) filled with 100% isopropyl 
alcohol(Sigma-Aldrich; Poole, UK) and slowly frozen at a cooling rate of 
approximately 1°C per minute in a -80°C freezer. The frozen cryovials were 
transferred to a liquid nitrogen storage vessel after 24 – 48 hours.  
 
To recover frozen cells, the cryovials were placed in a 37°C water bath for rapid 
thawing over 1-2 minutes. The surface of thawed cryovials were sprayed with 70% 
v/v ethanol and transferred to the class II biosafety hood. Cells were transferred from 
the cryovials and suspended slowly in a 50 ml sterile universal tube at 1:10 volume of 
pre-warmed cell medium to cell suspension. Cells were then pelleted by 
centrifugation at 320xg for 3 minutes to remove the DMSO-containing freezing 
media. Thereafter, the supernatant was discarded and cell pellets were resuspended 
in appropriate medium before transfer to 25 cm2 tissue culture flasks for culturing 
and further assays. 
 
 
2.3  Cell count and viability assay 
 
To determine cell count, cell suspensions of adherent and non-adherent cells were 
removed by pipette from tissue culture flasks and pelleted by centrifugation at 320xg 
for 3 minutes, before resuspension in 1ml of PBS. 10µl of the cells suspended in PBS 
was placed into 500µl polypropylene tubes, and 10µl of 0.4% trypan blue (Sigma-
Aldrich, Poole, UK) was added. This was mixed to attain homogeneity by pipetting up 
and down gently a few times, before 10µl was withdrawn and applied to the counting 
chamber on the Hawksley haemocytometer (improved Neubauer of depth 0.1mm, 
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1/400mm2). The stained suspension of cells spread by capillary action into the area 
under the cover slip. Under a phase contrast microscope at 10x magnification, non-
viable cells were identified as those stained blue by the dye because of the permeable 
nature of their damaged cell membranes, while viable cells were identified as those 
with intact membranes with no colour penetration. The cells visualized in the middle 
large gridded square (1 mm2) of the haemocytometer were counted (the central blue 
square in figure 2.1), and the cell concentration and viability derived from the 
calculation formula below:  
 
Cell concentration= Total cell count in central blue square x dilution factor of 2 x 
counting chamber size of 104/ml 
 
% Cell viability= (cell count of viable clear cells with no colour penetration/ Total cell 
count in central blue square) x 100% 
 
Final volumes for corresponding experiments were achieved through adjustment of 
the cell concentrations (in cell/ml) calculated from the cell count by dilution to 
desired volumes. Cells with ≥70% viability was used for most experiments except 
those involving HUVECs where >90% was used. 
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Figure 2.1 Appearance of the haemocytometer gridlines (central blue gridded 
square is 1 mm2) used to count cells and estimate viability.  
 
2.4  MV preparation  
 
2.4.1  MV-rich media preparation: 
 
Confluent monolayers of adherent tumour cell lines and suspensions of non-
adherent cell lines were centrifuged at 320xg for 3 minutes, according to the method 
optimized for isolation of cell- free MV suspensions in our laboratory (Yates et al., 
2011). The supernatant was collected and further centrifuged at 1000xg for another 
5 minutes to remove cells and larger cellular debris, in order to obtain cell-free media 
containing tumour MVs, which was assessed for clotting activity with the modified 
prothrombin-based Clotting time (CT) assay below (section 2.5) and used for further 
experiments. 
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2.4.2  HUVECs culture in tumour-MV-rich media and platelet free plasma 
(PFP) 
 
Spent growth media was removed from the HUVECs in the 25cm2 culture flasks and 
discarded, then replaced with different concentration volumes (25, 50 and 100%) of 
the tumour MV-rich media, with the remaining volume made up with fresh ECG 
media. Incubation resumed for 24, 48 and 72 hours alongside control flasks of 
HUVECs cultured with addition of plain tumour culture media with no MVs. After 
incubation, the procoagulant activity (PCA) of HUVECs was then assessed with the CT 
assay (described in section 2.5) and the experiments were repeated four times. Based 
on the clotting results, HUVECs cultured in UMSCC81B MV-rich media was selected 
for further assessments below in Chapter 3. For all experiments, untreated controls 
of HUVECs cultured without media containing tumour MVs were used. 
 
Furthermore, to assess the effect of spent tumour growth media that was added to 
HUVECs, the HUVECs were cultured with either spent MV-rich media or fresh MV-
rich media as control. Spent MV-rich media is UMSCC81B MV-rich media removed 
from culture after 24 hours incubation, while fresh MV-rich has not been used in 
culture. Fresh MV-rich media was obtained from Vivaspin * 6 centrifugal 
concentrators with a Molecular weight cut-off (MWCO) of 10kDa (Sartorius Stedim 
Biotech AG, Göttinngen, Germany) which were used to concentrate MVs in cell-free 
supernatants. These are tubes that consist of high thoroughput polyethersulfone 
membranes used for optimal filtration of protein, antibodies, nanoparticles and MVs 
with >90% recovery rates. The ultrafiltration concentrator was filled with 6ml of 
tumour supernatant containing MVs and centrifuged twice at 4000xg for 30 minutes, 
then recovered with fresh tumour media. This was later used as fresh MV-rich media 
to replace the ECG media of HUVECs during the time course assays above, as a 
comparison to HUVECs cultured in spent tumour growth media. HUVECs were also 
incubated in the filtrate obtained. 
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For the CAT assay described below in section 2.8, the concentrated MVs at the 
bottom of the concentrating chamber was used without further recovery with fresh 
media. 
 
2.4.2.1  HUVECs culture in platelet free plasma (PFP) of cancer patients 
HUVECs (1x106/ml) were cultured as above and the spent media in tissue flasks 
replaced with 1 ml of patient platelet free plasma (PFP obtained from whole blood of 
cancer patients as described below in section 2.8.3). Incubation resumed for 24 hours 
along with control flasks of HUVECs cultured with addition of platelet-free normal 
control plasma (NormTrol; Helena Biosciences, Gateshead, UK). HUVECs were then 
harvested form the culture flasks, and the CT was assessed.  
 
2.5  Clotting time (CT) assessment  
 
2.5.1  Cells and cell-free supernatant CT assessment 
 
Cells were harvested from culture flasks by centrifugation twice at 320xg for 3 
minutes to remove spent media, as described above, and resuspended with 5ml PBS 
before cell counts as detailed in section 2.3. For neutralization experiments, cells (1 
x 105 cells/100 μl PBS) were incubated in the presence or absence of 5 μl (5 mg/ml) 
of polyclonal rabbit anti-human TF (American diagnostica, Stamford, USA) in 1.5 ml 
polypropylene tubes, for 30 min at 37°C to block cell surface TF expression. Then CT 
was assessed with a Thrombotrack SOLO steel ball coagulometer (Alere, Stockport, 
UK). This coagulometer measures the prothrombin time (PT) of the clot formed in a 
sample undergoing coagulation placed in a cuvette; where a steel ball in the centre 
of the sample rotates along the circumference as a result of the small magnetic field 
generated. The liquid sample consists of either 1x105 cells in 100 µl PBS suspension 
or cell-free media (100µl per cuvette) to which 100µl of normal plasma control 
(NormTrol; Helena Biosciences, Gateshead, UK) containing coagulation factors except 
TF, was added. The mixture was incubated for 2 minutes at 370C, before the start 
button on the coagulometer was pressed, which counts down for 3 seconds, after 
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which 100µl of 25mM CaCl2 was added to initiate the reaction. Once the timer was 
initiated, the clotting reaction measures the time taken for the ball to stop rotation 
due to fibrin clot formation. The results are mean ± standard deviation (SD) of 
measurements repeated on three separate occasions n=3.  
 
Samples, such as controls (PBS for cells and the respective media for cell-free 
supernatants) and NormTrol, that showed no clot in >999.9 seconds were deemed 
unable to support coagulation in the length of time of assay. 
 
2.5.2  Patient Platelet-free plasma CT assessment 
 
In both clinical studies, whole blood was collected from patients and healthy 
volunteer controls into sodium citrate anticoagulated tubes as described in section 
2.8.3. These were processed into platelet free plasma (PFP), 100µl of which was 
incubated for 2 minutes each at 370C where clotting was initiated by 100µl of CaCl2. 
Plasma samples that demonstrated no clot in >999.9 seconds were also deemed 
unable to support coagulation in this assay. 
 
2.6  Flow cytometry 
 
Flow cytometry is a widely used laser-based technology that is useful in multi-
parameter analysis of single cells and cell subpopulations. It consists of 3 main 
systems; the fluidic, optical and electronic systems. It can be used to analyse 
fluorescent labelled antibodies that attach to specific antigens, proteins, ligands or 
molecules found in substrates such as cells and MVs. It can also assess the intra- and 
extracellular expressions specific proteins of cells or substrates and define 
homogenous cell populations based on their sizes and granularity. To detect these 
properties, cells or particles in suspension are passed through the fluidic system of 
the flow chamber of the cytometer. The suspension is allowed to flow 
haemodynamically through the core of the sheath fluid in a small nozzle, such that a 
laser beam that is located perpendicularly outside the sheath fluid, can focus on each 
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cell (Figure 2.2). Light is scattered in different directions as the cells pass through in 
a single file at the interrogation point. The forward, side light scatter and fluorescence 
emission (FSC, SSC and FL) are captured by detectors placed in the front and sides of 
the sheath, and cells are distinguished based on these qualities. The FSC, SSC refer to 
the size and granularity of the cell or particles flowing through, while florescence 
(FL1, FL2, FL3 or FL4) is emitted when cells or particles are stained with specific 
antibodies, which are coupled to fluorochromes. These fluorochromes are excited by 
the laser light in the cytometer and to obtain precise detection, fluorescence emitted 
from the 3 parameters (FSC, SSC and FL) are passed through an optical system which 
consists of various filters and mirrors and sensors. The emissions they detect are 
amplified by photomultiplier tubes (PMTs), and eventually converted into voltage 
pulses, which are designated events of the electrical system. The measured voltage 
pulse area corresponds directly to the intensity of fluorescence for that event, and 
this electrical signal is converted from analog into digital inputs that is detected by 
the external computer connected to the cytometer. Data acquired can be further 
used to identify cell characteristics and populations, which can be further divided into 
different subpopulations by using gates and various plotting options such as dot 
plots, scattergrams and histograms. 
 
The flow cytometer used in this thesis was a Becton Dickinson FACS Calibur 
instrument (BD Biosciences, Oxford, UK), which was cleaned, serviced and calibrated 
on a regular basis by the BD Biosciences service team. Furthermore, data acquisition 
and preliminary analysis was done on an Apple Macintosh G5 computer, equipped 
with BD CellQuest Pro v.6.0 software (BD Biosciences). 
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Figure 2.2 Flow cytometry illustration.  
Cells or particles in suspension are passed through the cytometer in a single file 
hitting the laser beam at an interrogation point where light is dispersed into FSC and 
SSC. Fluorescence emission is also acquired from samples and all events are collected 
through lens and filters at similar wavelengths to corresponding detectors. The 
signals are further amplified and converted into an electrical current, which is 
detected as analysable data by the connected computer system. Adapted from: 
Castillo-Hair S.; FlowCal: Software for analysis and calibration of flow cytometer data, 
Benchling (https://benchling.com/pub/tabor-flowcal). Accessed October 1, 2017 
 
 
2.6.1  Flow cytometric evaluation of cell surface TF expression in HUVECs 
and Cancer cells 
 
For the detection of TF cell surface expression on HUVECs and cancer cells; 50µl of 
cells at 1x106/ml per tube was incubated in a 5ml polypropylene tube (Sarstedt, UK) 
with 5µg of fluorescein isothiocyanate (FITC)-conjugated mouse anti-human 
CD142/TF antibody (clone CLB/TF-5; Bio-Rad (formerly AbD Serotec), Kidlington, UK)) 
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or a concentration-matched FITC-conjugated mouse anti-human IgG1 isotype control 
(Bio-Rad, UK). This isotype control is used to control for changes in the level of non-
specific background signal caused by primary antibodies due to non-specific 
binding Fc receptors present on the cell surface. The mixture was left in the dark 
for 30 minutes incubation at room temperature, to allow the fluorochrome-labelled 
antibody to bind to the target epitopes present on the specific antigen on the cell or 
particle surface. Then the mixture was washed twice by centrifugation at 320xg for 3 
minutes with 5ml of PBS to remove any excess antigen, and then resuspended in 
300µl of PBS before flow cytometry. This method of antibody staining allows the 
selected antigens expressed on cell surface to be detected by the flow cytometer, 
where the level of fluorescent signal emitted is directly proportional to the number 
of fluorochrome molecules conjugated to the TF antibody on each cell. This allows 
direct estimation of the TF antigen levels expressed in the cell population.  
 
For each sample test tube, a minimum of 10,000 events was acquired on the 
cytometer. Data acquired represents the mean fluorescent intensity (MFI) of TF 
expression in relation to the MFI of cells stained with isotype control antibody, and 
the results recorded were presented as mean fluorescence ratio (CD142/TF 
antibody/negative control) according to the formula below: 
 
MFIR = MFI value of the TF positive sample / MFI value of the negative isotype 
control sample 
 
2.7  Confocal microscopy imaging 
 
2.7.1  CFSE-staining protocol 
 
For confocal microscopy, UMSCC81B cancer cells were stained with 5(6) - 
Carboxyfluorescein diacetate N-hydroxysuccinimidyl ester (CFSE; Abcam, Cambridge, 
UK ab113853) in order to obtain CFSE-stained MVs derived from UMSCC81B cells. 
CFSE is a cell permeable, non-fluorescent pro-dye that is cleaved by intracellular 
esterases in live cells to release a green fluorescent carboxyfluorescein molecule that 
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is membrane impermeable. UMSCC81B cells (1x106/ml) were centrifuged at 320xg 
for 3 minutes into a pellet before discarding the supernatant. The cell pellet was 
resuspended with 5ml PBS and then 10µM of reconstituted CFSE solution was added 
and mixed by gentle pipetting for uniform labelling, before incubation at 370C for 10 
minutes. Staining was then quenched with equal volume of 5 ml RPMI cell culture 
media. The cells were washed twice with 5ml PBS at 320xg for 3 minutes to remove 
unincorporated CFSE before seeding in 75cm2 culture flasks containing 15ml fresh 
media. After 24 hours, labelled MV-rich tumour media was harvested for addition to 
HUVECs in culture, by replacing the ECG media of HUVECs in 25cm2  tissue flasks, as 
described above in section 2.4.2. Cultures of UMSCC81B without CFSE-staining were 
used concurrently as controls.  
 
2.7.2  Confocal Laser scanning microscopy analysis of HUVECs incubated with 
tumour MVs 
 
The 1x106/ml of HUVECs cultured in CFSE-stained MV-rich media derived from 
UMSCC81B cells were labelled with 5µg CD142/TF: phycoerythin (PE) or isotype-
matched negative control:PE antibody for 30 minutes in the dark at room 
temperature. Then they were washed twice with PBS by centrifugation as described 
above and resuspended in PBS. They were then transferred into Lumox Dishes (35mm 
Ø x 12mm Adherent Surface; Starstedt Ltd) at 2x105 in 200 µl density, immediately 
after staining with PE-conjugated antibody. Confocal microscopy was performed 
using a Zeiss LSM710 Laser Scanning Confocal Microscope and images acquired using 
ZEN software version X (Zeiss Group, Oberkochen, Germany) to view HUVECs as 
compared to controls incubated with plain media without tumour MVs. 
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2.8  Thrombin generation (TG) by Calibrated Automated Thrombography 
(CAT) assay 
 
2.8.1  Thrombin generation in cells 
TG was assessed by the Hemker et al, 2003 method (Hemker et al., 2003) using a 
calibrated automated assay in real time. Here, 20µl of live cells at various cell 
concentrations were plated into Immunulon transparent round bottom 96-well 
microtiter plates (ThermoFisher Life Sciences, Loughbrough, UK) for the CAT assay. 
Then 20 µl of Thrombin activator/PPP-Reagent LOW (Diagnostica Stago, Theale, UK) 
which contained 1pM recombinant relipidated TF and 4µM phospholipids 
(phosphatidyl-serine, -choline, and -ethanolamine) standard preparations in HEPES-
buffered saline was used as positive control, while 20µl of PBS was the negative 
control. Afterwards, 80µl of platelet-free normal control plasma (NormTrol) or 
plasma deficient in coagulation factors VII and XII were added to the microplate wells. 
All plasmas were purchased as freeze-dried pooled immunodepleted human plasma 
(Helena Biosciences, Gateshead, UK) and each reconstituted according to 
manufacturer’s instructions in 1ml of distilled H20.  
 
Then the microplates were agitated and incubated to 370C for 10 minutes while TG 
was initiated by addition of 20µl of a FluCa Kit solution (Diagnostica Stago, Theale, 
UK) containing 0.1M CaCl2 and a fluorogenic substrate (Z-Gly-Gly-Arg-amino-methyl-
coumarin fluorophore). The fluorescence emission was measured by Fluoroscan 
Ascent® fluorometer (Thermolab systems OY, Helsinki, Finland) with 
excitation/emission wavelengths of 390nm/460nm. Measurement occurred up to 1 
hour after automatic mixing of contents of the wells at every 20 seconds, according 
to the Thrombogram guide (Giesen, 2012).  
 
Real time TG curves were calculated using Thrombinoscope™ software version 
3.0.0.29 (Thrombinoscope B.V., Maastricht, The Netherlands). Each condition 
contained 2 wells, one test well for cell induced TG, the other a calibration well as 
control for thrombin activity in test well (Figure 2.3A). 20µl of Thrombin Calibrator 
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α2-macroglobulin/thrombin complex (Thrombinoscope B.V., Maastricht, The 
Netherlands) was used in calibrator wells. Measurement in the calibration well helps 
correct for inner filter effects and substrate consumption(Castoldi & Rosing, 2011). 
Each experiment was carried out in triplicate, independently. Time to start of 
maximum TG or until one-sixth of the peak height is reached (Lag time), endogenous 
thrombin potential or area under the curve (ETP), Peak height of thrombin (Peak), 
time to peak (TTP or ttPeak) and velocity index (Vel.Index) of TG were amongst the 
parameters evaluated (Figure 1.8B). The variation that is found parallel experiments 
that are identical in one 96-well plate is 3–5%(Hemker et al., 2003).  
 
A) 
 
 
B) 
 
Figure 2.3 Thrombin generation curve in a CAT assay. 
A) Example of typical thrombogram readout from CAT assay experiments in this 
thesis. The green curve represents the fluorescence from the thrombin calibrator 
wells while the blue represents those from the sample test wells.  
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2.8.2  Thrombin generation in microvesicles 
 
MVs were concentrated from conditioned media of cancer cells in culture by removal 
of 6ml of supernatant which was added to a Vivaspin * 6 centrifugal concentrator and 
centrifuged twice at 4000 x g for 30 minutes, then recovered with 1ml of PBS (section 
2.4.2). Then, 20µl of MVs were plated into Immunulon transparent round bottom 96-
well microtiter plates (ThermoFisher Life Sciences, Loughbrough, UK) for the CAT 
assay as described above for live cells. 
 
2.8.3  Thrombin generation in patient platelet-free plasma 
To obtain platelet-free plasma using standard venepuncture techniques, venous 
blood samples were taken from the antecubital vein of the patients arm into blue 
3.8% tri-sodium citrated bottles for plasma. Fresh PFP was obtained by immediate 
centrifugation of the citrated blood collection tubes in serial steps; first at 180xg for 
10 minutes at room temperature (to prevent cold-induced platelet activation) to 
obtain platelet rich plasma (PRP) and then at 12,000xg for an additional 10 minutes 
to obtain plasma free of platelets (PFP). All PFP samples were used fresh in further 
analysis within 4 hours of blood collection or aliquoted and stored in an -800C freezer. 
 
For TG, frozen PFP of patients of Multiple myeloma, Pancreatic cancer and controls 
were defrosted at room temperature. Then they were gently pipetted up and down 
for <30 seconds to ensure adequate mixture. Afterwards, 20µl of PPP-Reagent LOW 
(Diagnostica Stago, UK) were plated into the transparent round bottom 96-well 
microtiter plates (ThermoFisher Life Sciences, UK) to serve as thrombin activator for 
the CAT assay. PFP (80µl) were then added to the plates, before warming up to 370C 
to commence the CAT assay as described above. 
 
2.9  Estimation of soluble TF in patient serum by ELISA 
 
Patient serum processed from whole blood (described in clinical methods Chapter 5) 
was evaluated for TF antigen concentrations using a commercially available ELISA kit 
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(Quantikine ELISA kit of Human coagulation Factor III/TF; R&D systems Bio-techne, 
Abingdon, UK). According to manufacturer’s instructions, all samples were thawed in 
room temperature and reagents were prepared fresh by dilution to recommended 
working concentrations before use. 
 
In this test, a monoclonal antibody specific for TF that is pre-coated onto a 
polystyrene microplate is used for a sandwich enzyme inmmunoassay. All serum 
samples were diluted 1:1 in Calibrator Diluent with 150μl sample + 150μl diluent. The 
wash buffer concentrate (25X of buffered surfactant with ProClin ® preservative) was 
diluted up to 500ml in distilled H20. Once prepared, 100μl of diluted serum or 
standard was added to each microplate well and any TF present was bound by the 
antibody immobilized into the microplate wells. Then, the plate was placed on a 
horizontal orbit shaker (Stuart Scientific, Essex, UK) and covered up with the provided 
plate sealers to incubate for up to 2 hours at room temperature to ensure antigen 
binding to antibody. The plate was then washed twice by filling each well with 400 μl 
wash buffer on a microplate autowasher (Asys Atlantis; Biochrom, Cambridge, UK) to 
remove any unbound substances. This was followed by addition of 100 μl of 
Horseradish Peroxidase (HRP)-linked polyclonal TF-specific antibody per well, 
incubated for 2 hours at room temperature. This plate was washed again twice as 
above and a substrate solution at 200 μl per well (made of mixture of 100 μl colour 
reagent A –stabilized hydrogen peroxide and 100 μl colour reagent B- stabilized 
tetramethylbenzidene chromogen) was added, that turned the colour in the wells 
blue in relation to amount of HRP-bound to TF antigen initially attached. This colour 
reaction is allowed to proceed for about 30 minutes and is halted by addition of 50 
μl of 1M sulfuric acid stop solution per well, to stop the action of HRP on the substrate 
solution and turning the wells yellow. The optical intensity of the yellow colour was 
immediately measured by a microplate reader (Biotek Synergy HT, Winooski, USA) at 
450nm wavelength. Each sample or standard measurement was performed in 
duplicates and the reported intra-assay precision within the assay was CV of 2.8% 
while the inter-assay precision between 40 assays was 5.5 %. 
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2.10  Statistics 
 
The results are expressed as mean ± standard deviation, except where indicated 
otherwise. Student t-tests and Analysis of variance (ANOVA with multiple 
comparisons) were used to determine statistically significant differences between 
groups. P values less than *0.05, **0.01, ***0.001 were considered significant. 
Pearson’s correlation coefficient (r) was used to describe correlations and the 
associated student t-tests was used for statistical significance. All statistical analysis 
was performed with GraphPad software, version 7 (GraphPad Software, Inc., 
California, USA) or SPSS computer software (version 20.0 (IBM Corp.). Clinical 
statistics were carried out by a professional statistician (Dr Eric Gardiner) as described 
in chapter 5. 
 
114 
 
Chapter:3  Cancer microvesicles induce Tissue 
Factor-related procoagulant activity in 
endothelial cells in vitro. 
 
Work from this chapter has been presented in the peer-reviewed publication:  
 
Adesanya MA, Maraveyas A, Madden LA. Cancer microvesicles induce tissue factor-
related procoagulant activity in endothelial cells in vitro. Blood Coagulation and 
Fibrinolysis. 2017 July;28(5):365-372. 
 
And in the conference presentations: 
 
Adesanya MA, Madden LA, Maraveyas A. Cancer microvesicles induces tissue factor-
related procoagulant activity in endothelial cells in vitro. National Cancer Research 
Institute (NCRI) conference; Liverpool (UK), Nov 2016 
 
Adesanya MA, Madden LA, Maraveyas A. Cancer microparticles induces tissue factor-
related procoagulant activity in endothelial cells in vitro. 10th American Association 
for Cancer Research - Japanese Cancer Association (AACR-JCA) Joint Conference on 
Breakthroughs in Cancer Research; Maui, (Hawaii, USA), Feb 2016. 
 
Adesanya MA, Maraveyas A, Madden LA. Procoagulant activity of tumour 
microparticles on the endothelium. International Society of Experimental 
Haematology (ISEH) 44th Annual Scientific Meeting; Kyoto (Japan), Sep 2015.  
 
Adesanya MA, Maraveyas A, Madden LA. Procoagulant activity of tumour 
microparticles on the endothelium. 4th Hull York Medical School (HYMS) 
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Postgraduate Research Conference; Hull, (UK), May 2015. *Prize awarded for Best 
Poster presentation. 
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3.1  Introduction 
 
Microvesicles (MVs) are the small particles shed from activated and non-activated 
cells that are involved in cellular interactions with its environment (Simak & 
Gelderman, 2006; Puddu et al., 2010). MVs have heterogeneous compositions and 
may consist of anionic phospholipids, cytoplasmic inclusions and bioactive proteins 
such as tissue factor (TF) (Morel et al., 2005; Aharon et al., 2008). The production of 
MVs is dependent on their cellular source, type of stimulus and disease state of 
parent cell(Freyssinet, 2003; Lacroix et al., 2010; Lacroix et al., 2013; Nomura & 
Shimizu, 2015) Previous studies have implicated MVs of different sources with the 
transfer and sharing of oncogenic material such as EGRFvIII in Gliomas(Al-Nedawi et 
al., 2008), as vectors of genetic information(Meziani et al., 2008) and even inducing 
apoptotic and procoagulant effects(Aharon et al., 2008; Wang et al., 2012); for 
example in cancer cells that are non-TF expressing(Shaker et al., 2016). MVs are 
sometimes used as a general term to include other membrane encapsulated particles 
secreted from a cell such as exosomes and microparticles(MP) (Ge et al., 2012). A 
recent focus has been on cancer MVs associated with TF, which are known to be 
elevated in some cancers and may have a role in VTE (Davila et al., 2008; Haubold et 
al., 2009) and in some of the processes that promote metastasis. However not much 
is known about their interactions with the vascular endothelium, although it can be 
hypothesized that such interactions may result in some procoagulant effects.  
 
The role of chemotherapy is also important and is to be considered in MV generation. 
In a pilot study in our laboratory, the number of circulating tumour cell-derived MV 
in MM patients were elevated 6–8weeks after chemotherapy suggesting that the 
tumour cells that undergo cellular changes such as apoptosis in the presence of 
cytotoxic agents release MVs. Previous studies in the literature have demonstrated 
that MV from various cellular origins may also induce endothelial dysfunction 
(Freyssinet, 2003) and our finding of elevated endothelial MVs following 
administration of IMiD-based chemotherapy in Multiple Myeloma (MM) lends 
support to these studies. This pilot study in our laboratory investigated MV origins in 
newly diagnosed and relapsed MM patients under treatment and revealed raised 
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levels of endothelial MV populations(Hall et al., 2016), which therefore suggests the 
hypothesis that the host’s response to chemotherapy treatment may also contribute 
to the increased thrombogenicity observed in MM patients. This is a markedly 
different procoagulant profile than in solid malignancies, and the involvement of 
known procoagulant TF and other intrinsic or extrinsic factors of the clotting cascade 
in various thrombotic events have yet to be determined in most cancers. Thus, this 
thesis study hypothesizes that TF and other coagulation factors (such as factor XII of 
the intrinsic and factor VII of the extrinsic clotting cascade) may influence the clotting 
and thrombin production profile of endothelial cells, and suggests further evaluation 
for the role of the endothelium and MVs during tumour interactions. 
 
TF is a 47 kDa membrane-bound protein that is a key initiator of the extrinsic 
coagulation pathways in the body and also contributes significantly to other 
pathways of coagulation(Steffel et al., 2006; Aird, 2012). Clotting mechanisms 
involving the endothelium may be heavily dependent on TF and other cellular 
phospholipids such as phosphatidylserine (PS) carried on MV membrane(Furie & 
Furie, 2005). Tumour cells in vivo can release membrane MVs carrying TF (TFMVs), 
and are known to be significantly raised in cancer compared to non-cancer patients 
(Auwerda et al., 2011; Campello et al., 2011). In some studies, elevated levels of 
TFMVs derived from tumour have been associated with VTE in several cancers such 
as pancreatic patients (Zwicker et al., 2009; Geddings & Mackman, 2013) and in other 
diseases such as Irritable bowel disease (Palkovits et al., 2013). They have also been 
associated with the metastatic process where interaction with endothelium is a key 
element for VTE initiation and propagation and also for the invasion of a cancer cell 
into stroma, therefore facilitating the theory that their involvement is an important 
step for endothelial thrombogenic initiation.  
 
Hypercoagulable states are linked to cancer (Trousseau, 1865; Lee, 2002). 
Thrombotic disorders are one of the early manifestations of cancer in some patients 
and are an important cause of cancer treatment compromise (Khorana et al., 2007c). 
The risk of developing VTE is 6-7 times increased in cancer patients when compared 
to non-cancer patients (Heit et al., 2000; Blom et al., 2005), and studies consistently 
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demonstrate VTE to be an early predictor of mortality(Chew et al., 2006). In 
prothrombotic states, studies have indicated that the endothelium lining blood 
vessels may be altered (Chirinos et al., 2005). Such changes have been found in vitro 
from treatment of endothelial cells with human blood products such as serum, which 
led to shorter coagulation time, marked intrinsic or extrinsic coagulation factor 
generation, and increased thrombin formation (Zhang et al., 2016). A transformed 
procoagulant endothelium may not be clinically apparent at first, but hypothetically 
may result in eventual VTE manifestations such as deep venous thrombosis (DVT), 
which have been established as a cause of high clinical morbidity and mortality in 
cancer patients (Blom et al., 2005; Blom et al., 2006). Thus, it is theorized that the 
assessment of the procoagulant activities of endothelial cells, after exposure to 
prothrombotic products of cancer cells such as TFMVs can reveal a phenotypic and 
functional transformation of such endothelial cells. TFMVs have been shown to 
support coagulation in clotting and thrombin generation tests in vitro (Bastida et al., 
1984; Davila et al., 2008) and promote the metastatic process through angiogenesis, 
cancer cell survival, immune suppression and invasion (Zahra et al., 2011). For all 
these processes, the ability to interact with the endothelium is a key element. A 
deeper understanding of the mechanisms of endothelial involvement in thrombotic 
events may potentially aid in developing better therapeutic solutions in cancer 
management.  
 
 
3.2  Aims 
 
The aim of this chapter is to investigate how these cancer MVs can interact with 
endothelial cells in vitro and potentially confer procoagulant activity (PCA) through: 
 
§ Estimation of prothrombin clotting times of endothelial cells  
§ Evaluation of TFMV expression on endothelial cells 
§ Measurement of thrombin generation of endothelial cells 
§ Assessment of thrombin generation of endothelial cells in Factor VII and XII-deficient 
plasma  
119 
 
 
Detailed methodology and materials used can be found in METHODS chapter 2. 
Briefly, four solid cancer cell lines; Head and Neck Squamous Epithelial cell line 
UMSCC81B, lung cancer PC9, and pancreatic cancer CFPAC-1 and ASPC-1 which 
express high levels of TF (Yates et al., 2011; Welsh et al., 2012) and primary HUVECs 
were cultured in their respective media. After incubation in MV-rich media or 
platelet-free plasma (PFP obtained from cancer patients as described in chapter 5), 
HUVECs were assessed for clotting ability (METHODS section 2.5), TF expression on 
the flow cytometer (METHODS section 2.6), and MV adherence on confocal 
microscopy (METHODS section 2.7) and thrombin generation on the calibrated 
automated thrombography (CAT) assay (METHODS section 2.8). Statistical analysis 
was performed on GraphPad software, version 7 on the results expressed as mean ± 
standard deviation. Student t-tests and Analysis of variance (ANOVA) were used to 
compare differences in groups while relationships between CT and TF surface 
expression were assessed with Pearson correlation coefficient on linear regression 
analysis. P values less than *0.05 were considered significant. 
 
3.3  Results 
 
3.3.1  Optimization: Procoagulant activity of cell-free media containing 
microvesicles, tumour cells and HUVECs 
 
A few experiments were carried out to optimize the methods used in this chapter. 
Briefly, cell-free media were obtained from tumour cell suspensions in PBS by double 
centrifugation; first at 320xg for 5 minutes and then at 1000xg for another 5 minutes, 
as described in METHODS section 2.4.2. A one-stage clotting assay (section 2.5) was 
used to assess the PCA of the 4 cancer cells. Cell-free media (100µl per cuvette) was 
mixed with 100µl of human Normal control (NormTrol) plasma for 2 min at 37°C on 
a Thrombotrack SOLO coagulometer. 100µl of 25 mM CaCl2 was added to the mixture 
to initiate a clotting reaction, and then the time it takes for a clot to form (was 
recorded in duplicate at three independent repeats. As the reconstituted NormTrol 
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plasma used does not clot without the addition of exogenous TF, all cell-free media 
obtained from cancer cell lines with detectable cell surface TF expression were found 
to support coagulation in these assays. (Figure 3.1 and 3.2A). These preliminary 
studies also showed that subsequent serial dilutions in PBS of the cell-free media 
which contained tumour MVs, supported coagulation in a concentration-dependent 
manner (Figure 3.1). 
 
 
Figure 3.1 Dose-response of cell-free media containing tumour MVs. 
The dose-response of CT with serial dilutions of cell-free media from four solid cancer 
cell lines: Head and Neck Squamous Epithelial cell line UMSCC81B, lung cancer PC9, 
and pancreatic cancer CFPAC-1 and ASPC-1 showed a concentration-dependent 
curve for each of the cell lines. CT was measured with a one-stage clotting assay. 
 
Further initial studies show that clotting ability was lost from filtrate obtained from 
concentration of tumour media containing MVs in Vivaspin concentrator of MWCO 
10 kDa, as described in METHODS section 2.4.2. HUVECs cultured in the filtrate also 
showed no clotting in the times measured suggesting that the majority of the clotting 
activity was in fact associated with MVs as the main proportion of MVs were 
presumably removed by the filtration step. There was also no clotting seen in HUVECs 
supernatant before and after incubation with tumour MV-rich media. Also, CFSE-
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staining as described in section 2.7.1 did not alter the PCA of MV-rich media produced 
from stained UMSCC81B (CT= 25.57+/- 2.8 seconds; p=0.67) compared to MV-rich 
media from UMSCC81B without stain (CT=27.43+/3.81 seconds).  
 
3.3.2  Procoagulant activity of HUVECs cultured in cell-free media containing 
UMSCC81B tumour microvesicles (MV-rich media) 
 
HUVECs incubated in UMSCC81B media containing MVs, showed the shortest PCA 
times measured on the CT assay (section 2.5) amongst the 4 cancer cell lines used to 
obtain MV-rich media (Figure 3.2A), and so was selected for further assays and 
analysis. HUVECs showed no significant difference in CTs cultured with either spent 
MV-rich tumour media or fresh MV-rich tumour media (p=0.97). Relative to controls 
(unexposed HUVECs), exposed HUVECs also exhibited PCA in a tumour media 
concentration-dependent but not time-dependent manner, with the shortest CT 
(48.59 +/-5.72 seconds) seen with 100% concentration of UMSCC81B media 
containing MVs (Figure 3.2B). There is a statistically significant overall difference 
(*p=0.0113) of the mean CTs (88.4+/-34.5 seconds) of HUVECs exposed to media 
derived from UMSCC81B, from the control HUVECs (234.2 +/- 53 seconds) that were 
cultured without UMSCC81B MV-rich media influence (Table 3.1, Figure 3.3). 
However, there was no significant difference overall between HUVECs CT in NormTrol 
and HUVECs CT in factor XII deficient plasma (p=0.0842).  
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B) 
 
Figure 3.2 Clotting times of HUVECs cultured in MVs-rich media of solid cancer cell 
lines (parent cells). 
A.) HUVECs cultured in UMSCC81B MV-rich media shows the shortest CTs of <50 
seconds amongst the 4 solid cancer cell lines media assessed over 24-72 hours and 
was selected for further assays. HUVECs control was cultured in tumour media 
without MVs. Data represents mean +/- S.D of n=4 or more B.) HUVECs harvested 
from 25%, 50% and 100% concentration of tumour media containing MVs and the 
corresponding controls of 25%, 50% and 100% media concentration without MVs. 
This shows the shortest CT at 100% MV media concentration at 48.59 +/- 5.72 
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seconds compared with control at 174 +/- 16.8 seconds (***p<0.001; ANOVA). Each 
value represents mean of 3 +/- S.D. Data significant at p < 0.05. 
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Table 3.1 Clotting times (CT) of HUVECs cultured in UMSCC81B MV-rich media over time. 
% Concentration of  
MV-rich tumour media 
used over 24-72 hour 
CT of HUVECs with 
NormTrol 
Plasma 
CT of Control HUVECs 
with NormTrol 
Plasma 
t-tests comparing 
HUVECs and Control HUVECs in NormTrol 
Plasma 
      0 - - - 
24 hour 
25% 113.2±1.4 293.6±47.1 *<0.05 
50% 110.8±19.1 328.6±51.8 **<0.01 
100% 54.9±12.5 282.1±13.2 ***<0.001 
48 hour 
25% 117.8±3.5 216.3±37.6 0.06 
50% 94.7±14.8 284±50.4 **<0.01 
100% 45.3±4.7 156.9±9.1 ***<0.001 
72 hour 
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25% 98.7±2.8 440.3±18.2 ***<0.001 
50% 124.5±39 182.9±25.3 0.2 
100% 41.0±0.3 171.2±1.9 ***<0.001 
HUVECs were cultured in 0, 25%, 50% and 100% concentrations of cell-free supernatants of UMSCC81B cells containing MVs for 24, 48, 72 hours and 
compared to untreated controls. Data represents mean +/- S.D of n≥3, significance at *p< 0.05, **p<0.01, ***p<0.001, Multiple t tests for comparison 
of results for HUVECs CT with Normal plasma (NormTrol). 
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A) 
 
 
Figure 3.3 Effect of tumour MVs on the CTs of HUVECs incubated in UMSCC81B MV-
rich media and control media without UMSCC81B MVs.  
Over 24-72 hours, the overall mean clotting time in HUVECs cultured in tumour media 
of 88.4+/-34.5 seconds and 234.2 +/- 53 seconds in controls, showed a significant 
difference (*p= 0.0113; t-test) between both groups with 62.3% increase in clotting 
ability upon addition of MVs to HUVECs media. Data represents mean +/- S.D of n=4 
 
3.3.3  Tissue Factor surface expression on HUVECs cultured in MV-rich 
tumour media 
 
Flow cytometry analysis showed a distinct subpopulation of HUVECs that had 
acquired TF expression (Figure 3.4). The percentage of this subpopulation was 
dependent upon the concentration of tumour media added (containing UMSCC81B 
MVs) to the HUVECs culture and not the duration of incubation. The range of TF-
positive HUVECs was determined to be 0, 4.2(+/-1.4), 12.5(+/-3.7) and 45.9(+/-18.7) 
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% for MV-positive media concentration of 0, 25, 50 and 100% (n=5) (M1 in Figure 
3.4). The percentage of TF-positive subpopulation (M1) increased by 4.2(+/-1.4)%, 
12.5(+/-3.7) %and 45.9(+/-18.7)% as the concentration of tumour media containing 
MVs used in HUVECs incubation increased from 25% to 100%. There was no 
difference seen by increasing the duration from 24 to 72 hours. 
 
24 hours  48 hours   72 hours 
 
Figure 3.4 Time course assay showing TF surface attachment to endothelial cells. 
HUVECs were incubated with cell-free media with or without tumour MVs at various 
concentrations from 25% to 100% at 24, 48, 72 hours. Cells were then washed and 
labelled with 5µg of CD142:FITC monoclonal antibody with mouse anti-human IgG1 
as isotype control. Mean Fluorescence intensity (MFI) for each time point was 
measured on a flow cytometer with the HUVECs incubated without tumour MVs as 
negative controls.n IgG1 isotype in HUVECs control,n IgG1 isotype in test HUVECs,n 
TF expression in HUVECs control,n TF expression in test HUVECs 
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Correlating the actual number of TF-positive HUVECs per CT assay (derived from the 
% expressing TF, at 100,000 cells per assay) to coagulation times obtained showed a 
logarithmic relationship (Figure 3.5A); a finding that exists for tumour cells that has 
been previously reported in our laboratory (Welsh et al., 2012). Here, a near linear 
relationship existed between CT and TF expression on a Log10/Log10 plot such that 
high TF expression tends to result in short CT times, r2 = 0.7 (Figure 3.5B). 
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B) 
 
Figure 3.5 The cell surface TF expression of HUVECs cultured in media containing 
MVs of UMSCC81B cells.  
Following 24-72 hour cell culture, HUVECs were assessed by flow cytometry and 
plotted against their average CT from a one-stage clotting assay. A) Inverse 
correlation of TF expression with CT such that as TF expression increases, CT 
decreases. B.) Near linear relationship of CT with TF expressed per 105 HUVECs 
number on Log10/Log10 transformed data using regression, r2=0.7.  
 
 
3.3.4  The effect of TF-blocking on HUVECs cultured in MV-rich tumour 
media 
 
To confirm the previous findings above that demonstrate a relationship between the 
TF and the CT of HUVECs cultured in MV-rich tumour media, the contribution of TF in 
the PCA of HUVECs was explored by the addition of anti-TF antibody to neutralize TF 
surface expression on HUVECs. Briefly, HUVECs cell suspensions (1 x 105 cells/100 μl 
PBS) were pre-treated with an anti-TF antibody (5 μg/ml) for 30 min at 37°C as 
detailed in METHODs section 2.5.1, and the CT time assessed in triplicate. This anti-
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TF blocking resulted in a decrease of the procoagulant effect significantly by 56% from 
214+/-5.2 to 424.23 +/-11.8 seconds, although it did not abolish CT completely in the 
times measured from the HUVECs cultured in 100% tumor media concentration 
(complete replacement of HUVECs ECG media with tumour MV-rich media) (Figure 
3.6).  
 
Figure 3.6 Effect of TF-inhibition on CT of HUVECs cultured in MV-rich tumour 
media over 24 hours. 
Inhibition of coagulation by incubation of TF-positive HUVECs with anti-TF 
competitive blocking agent reduced the procoagulant effect significantly by 56 
%(*p=0.0022; t-test).  Each value represents mean of 3 +/- S.D. Data significant at p 
< 0.05. 
 
3.3.5  Localization of TFMVs on HUVECs endothelial cell surface after 24 hour 
incubation in MV-rich tumour media 
 
CFSE- intracellular staining of UMSCC81B cells during cell culture was used to 
fluorescently label released MVs prior to incubation with HUVECs (as described in 
section 2.7.1). After incubation HUVECs acquired fluorescence corresponding to 
uptake of CFSE-labelled MV, which was confirmed by confocal microscopy. In figure 
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3.7, confocal microscopy showed UMSCC81B cells stained with CFSE, HUVECs 
expressing CFSE-labelled MVs derived from UMSCC81B media and control HUVECs. 
 
A) 
 
B) 
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C) 
 
Figure 3.7 Localization of TFMVs on HUVECs cell surface after 24 hour incubation 
in MV-positive media from cancer cells.  
A) UMSCC81B’s producing CFSE-labelled tumour MVs B.) HUVECs acquiring CFSE-
stained MVs C.) Control HUVECs cultured without MV presence. 
 
3.3.6  Cell-induced Thrombin generation (TG) in HUVECs cultured in MV-rich 
tumour media 
 
HUVECs harvested from MV-rich media (HUVECs TF) and fresh tumour media 
(HUVECs control) was assessed for thrombin generation (TG) in a Calibrated 
automated thrombography (CAT) assay (as described in METHODs section 2.8.1), at 
1 x 106/ml cell concentration per microplate well. As negative controls, HUVECs 
cultured in ECG media without any treatment (HUVECs plain) and platelet-free 
plasma (plasma only) was also assessed for TG. The TG in 3 plasma conditions was 
measured as described for the cancer cell lines in section 2.8.1 using NormTrol or 
plasma deficient in coagulation factors VII (FVII) and XII(FXII), to assess if 
procoagulant HUVECs are of the TF-FVII dependent coagulation type. Overall, ANOVA 
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tests with multiple comparisons showed significant differences between the means 
±S.D of the TG values obtained (Table 3.2, Figure 3.8). 
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Table 3.2 Thrombin generation in HUVECs cultured in MV-rich tumour media. 
 Platelet-free plasma Lag times (minutes) 
/p value vs NormTrol 
ETP (nM/minute)  
/p value vs NormTrol 
Peak thrombin (nM)  
/p value vs NormTrol 
TTP (minutes)  
/p value vs NormTrol 
HUVECs 
plain 
NormTrol 9.073±0.74 1568±11 137±1 14.56 ±0.6 
Factor XII-deficient 
Plasma 
8.63±4.16 
/0.96 
1320±41 
/0.34 
65±16 
/*0.04 
23.14±3.41 
/*0.011 
Factor VII-deficient 
Plasma 
18.79±0.62 
/***0.0001 
- 12±1 
/**0.0034 
60.7±4.11 
/***0.0001 
HUVECs 
Control 
NormTrol 6.47±1.13 1521±144 133±34 13.27±3.69 
Factor XII-deficient 
Plasma 
8.33±1 
/0.45 
1502±154 
/0.96 
85±35 
/*0.013 
20.52±2.96 
/***0.0001 
Factor VII-deficient 
Plasma 
15.31±2.93 
/***0.0001 
1299±11 
/0.59 
69±22 
/*0.013 
25.52±1.32 
/***0.0001 
HUVECs 
TF 
NormTrol 2.58±0.73 1547±139 177±16 6.15±0.56 
Factor XII-deficient 
Plasma 
3.67±1.27 
/0.63 
1663±132 
/0.15 
147±23 
/0.058 
7.028±1.11 
/0.8 
Factor VII-deficient 
Plasma 
9.42±4.68 
/***0.0002 
1562±53 
/1.1 
104±3 
/**0.0028 
22.05±1.54 
/***0.0001 
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plasma 
only 
NormTrol 21.14±2.35 1524±3 154±1 67.67±1.45 
Factor XII-deficient 
Plasma 
55.66±4.72 
/***0.0001 
- 26/**0.0029 60.67±1 
/0.097 
Factor VII-deficient 
Plasma 
62.67±1.16 
/***0.0001 
- 12/**0.0011 68.68±0.4 
/0.94 
HUVECs plain= HUVECs cultured with ECG media, HUVECs control=HUVECs cultured in fresh Roswell Park Media Institute (RPMI) tumour media, plasma 
only= plasma (NormTrol, Factor VII or Factor XII-deficient) were all used as controls for HUVECs TF (HUVECs harvested from culture in MV-rich media 
of TF-positive UMSCC81B). Values represent mean ± S.D of n=3.
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3.3.6.1  Lag times 
In NormTrol plasma, as shown in table 3.2, Lag times was shortest significantly 
(p=0.0001) in HUVECs TF at 2.58±0.73 minutes when compared to the controls 
(HUVECs plain and HUVECs control). Lag times of HUVECs plain (9.07±0.74 minutes) 
was 2.6 minutes longer than that of HUVECs control (6.47±1.13 minutes), and also 
over 60% longer than lag times of HUVECs TF of 2.58±0.73 minutes.  
 
However, the overall Lag times was prolonged in FVII-deficient plasma compared to 
NormTrol plasma (Table 3.2). For instance, Lag times of HUVECs TF in NormTrol of 
2.58±0.73 minutes increased significantly (p=0.0002) by 72.6% to 9.42±4.68 minutes 
in FVII-deficient plasma. Also, Lag times of HUVECs control increased by over 136% 
from 6.47±1.13minutes in NormTrol to 15.31±2.93 minutes (p=0.0001) in FVII-
deficient plasma. Results obtained from HUVECs in factor XII-deficient plasma were 
similar to those in NormTrol plasma (Figure 3.8A). 
 
3.3.6.2  Endogenous Thrombin Potential (ETP) 
In NormTrol plasma, no significant differences (p=0.9305) were observed in the ETP 
of the 3 types of HUVECs assessed (Table 3.2); HUVECs TF had ETP of 1547±139 
nM/minute while HUVECs control had 1521±144 and HUVECs plain had ETP of 
1568±11 nM/minute. 
 
Although there was no significance, HUVECs control in FVII-deficient plasma overall 
had slightly less thrombin generation potential (1299±11 nM/minute) than in 
NormTrol plasma (14.5%, 1521±144 nM/minute) and FXII-deficient plasma (13.5%, 
1502±154 nM/minute). In addition, HUVECs TF ETP slightly increased from 1547±139 
nM/minute in NormTrol plasma to 1663±132 in FXII-deficient plasma but also showed 
no statistical significance on further analysis. Both HUVECs plain in FVII-deficient 
plasma, as well as plasma deficient in both FVII and FXII (plasma only) were incapable 
of attaining any thrombin potential that was recordable on the assay (Figure 3.8B). 
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3.3.6.3  Peak thrombin 
In NormTrol plasma, peak thrombin of HUVECs TF (177±16nM) was significantly 
higher (p=0.03) than HUVECs plain of 137±1nM and HUVECs control of 133±34 (Table 
3.2). 
 
Peak thrombin produced by HUVECs TF and controls in FVII-deficient plasma was 
overall significantly less than in FXII-deficient and NormTrol plasma (Table 3.2, Figure 
3.8C). For instance, HUVECs TF produced average peak thrombin of 177±16nM in 
FXII-deficient plasma and 147±23nM in NormTrol, which was 41.6% and 29.3% 
respectively higher than the 104±3nM of thrombin produced in plasma devoid of FVII. 
HUVECs control also produced less thrombin (69±22 nM) in FVII-deficient plasma 
compared to the 85±35 and 133±34 nM generated respectively in FXII-deficient and 
NormTrol plasma. These values were significant (p=0.0028) by 2-way ANOVA testing. 
 
3.3.6.4  Times-to-peak (TTP) 
In NormTrol plasma, the TTP of HUVECs TF was the shortest significantly (p=0.0058) 
at 6.15±0.56 minutes when compared to the controls (Table 3.2). The TTP of HUVECs 
plain (14.56±0.6 minutes) was 1.29 minutes longer than that of HUVECs control 
(13.27±3.69 minutes), which was also 57.7% longer than TTP of HUVECs TF at 
6.15±0.56minutes 
 
These TTP values were similar to values obtained in Lag times, with those from 
HUVECs in FXII-deficient plasma closely similar to values generated in NormTrol and 
higher that those in FVII-deficient plasma. For instance, the TTP of HUVECs TF in FVII-
deficient plasma of 22.05±1.54 minutes was 72% significantly higher than that 
obtained in NormTrol at 6.15±0.56minutes (p=0.0001). Also, TTP of HUVECs plain was 
significantly and markedly prolonged to 60.7±4.11 minutes (p=0.0001) in FVII-
deficient plasma compared to NormTrol plasma (Table 3.2, Figure 3.8D). 
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C) 
 
D) 
 
Figure 3.8 Thrombin generation in HUVECs cultured in MV-rich tumour media.  
A) Lag times B) ETP C) Peak thrombin D) Time-to-peak. HUVECs plain was HUVECs 
cultured with Endothelial cell growth (ECG) media, HUVECs control was HUVECs 
cultured in Roswell Park Memorial Institute (RPMI) media, plasma only was NormTrol 
or coagulation factor-deficient plasma which were all used as controls for HUVECs TF 
(HUVECs harvested from culture in MV-rich media of TF-positive UMSCC81B). Values 
represent mean +/- S.D of n=3. 
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3.3.7  Procoagulant Activity of HUVECs after 24 hour incubation in MV-
positive patient plasma 
 
HUVECs were cultured for 24 hours in 1ml of defrosted platelet-free plasma (PFP) 
(METHODS section 2.4.2) derived from whole blood of Multiple myeloma (MM) and 
Pancreatic cancer (PC) patients before treatment (described in section 2.8.3). Prior 
to this, the mean CT of PFP of both MM and PC patients were determined (section 
2.5.2) as 438 seconds and 265 seconds respectively, before the CT and TF expression 
of HUVECs on flow cytometry were assessed. PFP from PC and MM patients before 
treatment had previously been determined to contain MVs in published data from 
our group (Echrish et al., 2014; Hall et al., 2016). HUVECs viability reduced from >95% 
to <74% after 24 hours of culture in PFP. Although there was a 14.4% slight reduction 
of CT between control HUVECs and test HUVECs cultured in PC PFP (from 320 seconds 
to 274 seconds), this difference was insignificant (p=0.091) and there was no 
quantifiable TF expression on flow cytometry, hence only n=2 repeats were 
performed. HUVECs cultured in MM PFP did not show any clot formation in 2 repeats, 
and so this experiment was discontinued. 
 
3.4  Discussion 
 
Although TFMVs have been associated with pathogenesis of thrombosis in studies 
(Tesselaar et al., 2007), there are controversies regarding the production, initiation 
and expression of TF in pathologic amounts on endothelium during the growth and 
expansion of a tumour, due to its complex physiology. A few studies have explored 
the role of TFMV induced coagulation activity of the endothelium under cancer 
progression (Maiolo et al., 2002; Collier et al., 2013). In this study, the changes in PCA 
and TF surface expression in HUVECs under the direct influence of tumour 
microvesicles, may mark the transfer of hypercoagulability and the acquisition of an 
endothelial phenotype which can initiate and sustain clotting. The distinct population 
of HUVECs that acquired TF via tumour MV were shown to then promote coagulation 
in a cell number dependent manner with a near logarithmic relationship 
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demonstrated (Figure. 3.5) as has been previously shown for tumour cell-mediated 
coagulation in our laboratory(Welsh et al., 2012), that was also dependent upon cell 
surface TF expression(Tesselaar et al., 2007). The TF expression detected on HUVECs, 
after incubation with tumour media was consistent within the 2nd and 3rd log decade 
of fluorescence (Figure 3.4) which may suggest that the tumour MVs released during 
culture are also consistent in TF expression.  
 
As removal of MVs in tumour media resulted in no PCA or surface TF expression, the 
results of this study suggest that such hypercoagulability transfer from cancer cells to 
endothelial cells may likely involve tumour MVs. A previous study reported the 
induction of procoagulant effect by monocytic-derived MVs in endothelial 
cells(Aharon et al., 2008). Co-cultures of HUVECs with HeLa and HL60 cells in a 4 hour 
incubation, have also previously been reported to support the presence of a clotting-
defined, two-way interaction between tumour cells and endothelial cells in a TF-
related manner(Maiolo et al., 2002).  This interaction may also vary depending on 
other features. For example, although TF is involved significantly in the PCA of 
HUVECs exposed to tumour MVs, the activity is not completely dependent on TF as 
anti-TF blocking did not completely abolish clotting (Figure 3.6). Therefore, other 
factors such as the presence of phospholipids (for example phosphatidylserine and 
phosphatidylcholine) and their receptors, may contribute to a lesser degree in 
HUVECs PCA. Moreover, there was no significant overall variation between HUVECs 
TG in NormTrol and Factor XII deficient plasma (p=0.0842), denoting that this clotting 
interaction may not be dependent on factor XII presence in intrinsic coagulation 
pathways. 
 
There may be two mechanisms behind the acquisition of TF by endothelial cells. The 
first is extracellular and is possible through the release of TF from MVs and 
subsequent attachment to the endothelial cell surface. The other is an internal 
process either by engulfment of TFMVs with subsequent intracellular degradation, TF 
membrane incorporation and later re-exposure by blebbing on the endothelial cell 
surface (Aharon et al., 2008; Collier et al., 2013) or by initiation of an intrinsic 
endothelial TF production due to stimuli from external MVs. An alternative is that 
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both might occur at the same time, or specific stimulus and conditions might dictate 
the prevalence of one mechanism rather than the other. HUVECs have been shown 
to internalize MVs in vitro through a process of phospholipid carrier via integrin αvβ3 
and lactadherin (Terrisse et al., 2010). The engulfment and recycling of MVs through 
the Rab family of golgi-endosomal transport network has also been shown with two 
different TF presence levels under a short 4 hour duration(Collier et al., 2013). 
Further downstream, the implication of TF-VIIa-protease-activated receptor-2 or 
PAR-2 signalling systems in thrombin generation (and activation of other trans-
membrane G-protein-coupled receptors) leads to transcription of more 
prothombotic genes, amplification of signal transduction cascades in the host cells 
and facilitates tumour establishment (Rickles et al., 2003; Ruf et al., 2011). Of note, 
is the possibility that PAR-1 can also trans-activate PAR2(O'Brien et al., 2000), which 
promotes additional thrombin generation response in the endothelium and  tumour 
environment(Shi et al., 2004). Also, TF has various variants and isoforms such as the 
systemically active flTF, and levels of encryption that may be produced under 
different oncogenic influences which may ultimately affect the PCA(Bogdanov et al., 
2003; Bach, 2006; Wang et al., 2012). 
 
Endothelial cells can differentiate into different cell classes or types depending on the 
kind of stimulation received from their microenvironment (Lacorre et al., 2004). In 
vivo this plasticity is usually seen only with high doses of activation agents such as 
interleukin-6, lipopolysaccharides, tumour necrosis factor alpha (Sprague & Khalil, 
2009; Adams et al., 2013). Furthermore, endothelium from different body areas 
reflect specific tissue demands and are heterogenic (Aird, 2012), adding another level 
of complexity to the stimulation processes of the endothelium. This may explain the 
non-uniform acquisition of TF observed in distinct HUVEC populations as the source 
is from pooled donors; however, the data was consistent across differing batches of 
HUVECs. In addition, although the data was inconclusive regarding differences seen 
in HUVECs cultured in actual patient plasma, this does not reflect in vivo situations, 
and may be due to temperature differences, or insufficient quantities of plasma used 
that may be unable to induce a significant procoagulant change in the endothelial 
cells. 
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Although activated cells may acquire procoagulant activity similar to their parent 
cells, not much is known about their actual ability to generate thrombin. Thrombin is 
an important constituent of the clotting cascade, with the ability to initiate clot 
formation. In this chapter, it is shown that HUVECs associated with tumour MVs can 
produce thrombin, in sufficient quantities greater than the controls (Table 3.2, Figure 
3.8). This thrombin generation also varies depending on the amount of coagulation 
factors, specifically factor VII present in the plasma. This result can be understood in 
view of the relationship of TF to factor VII, in the formation of a complex that initiates 
coagulation pathways. This relationship may also have important consequences in 
the method of recruitment of endothelial cells in prothrombotic conditions, such as 
cancer development. Lag times and TTP are also shown to be significant parameters 
amongst the TG parameters assessed, suggesting a further role in standardization of 
the TG assay. 
 
In conclusion, HUVECs acquired a procoagulant phenotype in the presence of 
increasing concentrations of tumour MVs expressing TF. This acquired procoagulant 
activity was shown to be dependent on the number of HUVECs that subsequently 
express TF. It was also demonstrated that the procoagulant state once initiated may 
have TF-independent drivers, can produce thrombin that is important in clot 
formation and dependent on factors of the coagulation system, and for the first time 
suggest that this may not be a 'systemic' effect, but subpopulations of endothelial 
cells have different susceptibilities that may contribute to the HUVEC-MVs 
interaction. 
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Chapter:4  Thrombin generation in live 
haematological and solid cancer cells and 
microvesicles determined by calibrated 
automated thrombography. 
 
Work from this chapter has been presented in the peer-reviewed publication:  
 
Adesanya MA, Maraveyas A, Madden LA. Differing mechanisms of thrombin 
generation in live haematological and solid cancer cells determined by calibrated 
automated thrombography. Blood Coagulation and Fibrinolysis.  2017 
December;28(8): 602–611. 
 
And in the conference presentations: 
 
Adesanya MA, Maraveyas A, Madden LA. Characterization of the thrombin 
generation potential of haematological and solid cancer microvesicles by calibrated 
automated thrombography. Haematology Society of Australia and New Zealand, the 
Australian & New Zealand Society of Blood Transfusion and the Australasian Society 
of Thrombosis and Haemostasis (HAA) Annual Scientific Meeting; Melbourne 
(Australia), November 2016. 
 
Adesanya MA, Madden LA, Maraveyas A. The influence of coagulation factors on 
thrombin generation in solid tumour and haematological cancer cells by calibrated 
automated thrombography. European Haematology Association (EHA) Scientific 
Conference on Bleeding Disorders; Barcelona (Spain), September 2016- *Oral 
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presentation of Published abstract in official supplement of Haematologica; August 
16, 2016 101(s2): 1-11. 
 
Adesanya MA, Maraveyas A, Madden LA. Characterization of the thrombin 
generation potential of Pancreatic cancer and Multiple myeloma by calibrated 
automated thrombography (CAT). 8th International Conference on Thrombosis and 
Hemostasis Issues in Cancer (ICTHIC); Bergamo-Milan (Italy), April, 2016-*Published 
abstract in Thrombosis Research: 140 (S1);S186. 
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4.1  Introduction 
 
Thrombin is a key enzyme in haemostasis; it is a serine protease that forms the end 
product of the common pathway. The coagulation pathway is composed of intrinsic 
factors (such as factor XII), and extrinsic factors such as tissue factor (TF) and factor 
VII complex that ultimately lead to thrombin generation (TG). Multiple myeloma 
(MM) and pancreatic cancer (PC) manifest a dysfunction of the haemostatic system 
that gives rise to a high incidence of thrombotic complications, particularly during 
systemic cancer treatment phase(Khorana et al., 2007b; Dumitrascu et al., 2010; 
Carrier et al., 2011). However, it is hypothesized that thrombosis may signify different 
haemostatic processes in both types of cancer. For example, it has been speculated 
that thrombosis in MM does not influence cancer behaviour and is mostly as a result 
of treatment, whereas in solid cancers such as PC, it is seen as a sign of aggressive 
tumour behaviour and poor prognosis indicator (Zangari et al., 2010; Cesarman-Maus 
et al., 2012a). Furthermore, molecular mechanisms involved in PC thrombosis 
development, such as TF expression, cyclo-oxygenase-2 (COX-2) and plasminogen 
activator inhibitor 1 (PAI-1) up-regulation, may ultimately not be important in MM-
associated thrombosis due to its intra-vascular nature (Boccaccio & Comoglio, 2009; 
Cesarman-Maus et al., 2012a). To date few studies have been reported on TG 
variances using cancer cells themselves. There is limited knowledge on the thrombin 
generation kinetics in cancer (such as the measurement of thrombin output in various 
substrates, characterizing and profiling of thrombin generation, the influence of 
external pathways) and clinical and preclinical (in vitro) data in this setting are 
currently sparse. Therefore, the work in this chapter was undertaken to define TG in 
solid and haematologic cancers such as PC and MM. 
 
Although several methods exist for assessing procoagulant activity, chromogenic 
assays are the cornerstone of measuring TG kinetics with the calibrated automated 
thrombography (CAT) developed as a fluorogenic optimization that may become a 
useful tool in cancer related clinical settings (Peetz, 2016). Technical optimization is 
ongoing to make it a point of care test. The assay gives a dynamic picture of TG by 
measurement of the amount of thrombin cleaved from a fluorogenic substrate in real 
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time. Hemker et al (Hemker et al., 2003) developed the modern version of the CAT 
assay that measures 5 main parameters in TG: Lag time, Endogenous thrombin 
potential (ETP), Peak thrombin produced (Peak), time to peak (ttPeak or TTP), and 
Velocity index (Vel.Index). With this number of endpoints, the CAT assay gives a more 
comprehensive clotting assessment and could play a role in clinical practice to assess 
haemostatic discrepancies in patients with cancer-related clotting disorders. 
However, there still exists official standardisation issues for the assay results, and 
more studies are needed to address them in detail. 
 
The traditional substrates for the CAT assay, as developed by Hemker et al, have been 
platelet poor and platelet-rich plasma. Few studies have documented the use of 
other substrates including whole blood(Ninivaggi et al., 2012; Tappenden et al., 
2016), tumour cells(Takamiya & Sakata, 2008), lysed cells(Marchetti et al., 2012). 
Although the components of the coagulation cascade are well characterised in 
haemostasis, there are limited experimental data directed at understanding their 
relative importance in the coagulopathy of solid versus non-solid malignancies. 
Various factors of the cascade have been implicated in tumour cell sensitivity to cell-
associated procoagulants, including factor XII (Hageman factor) which was found to 
be necessary for initiation of intrinsic coagulation in malignant haematopoeitic cells 
via procoagulant phosphspholipids (phosphatidylserine or PS) on charged 
surfaces(Kunzelmann et al., 2004). In addition, Marchetti et al investigated the 
residual capacity of cancer cells to generate thrombin, after TF-FVII inhibition, which 
revealed a possible TF-FVII independent pathway that may occur in these 
cells(Marchetti et al., 2012). Thus, it is hypothesized that factors VII and XII may have 
distinct roles in thrombus formation (Kuijpers et al., 2014) as members of the 
extrinsic and intrinsic pathways respectively, and understanding their contribution to 
the process of cancer-associated thrombosis could inform clinical approaches to 
treatment and prophylaxis.  
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4.1   Aims 
 
The aims of this chapter were to: 
§ compare the characteristics of the thrombin curves generated by human solid 
malignant cell lines (with an emphasis on Pancreatic cancer) versus the curves 
generated by haematological malignant cell lines (with an emphasis on Multiple 
myeloma cell lines) 
§  explore the role of the intrinsic and extrinsic pathways in both cell lines by 
investigating TG in an environment of factor VII and XII deficient human plasma  
§ assess Tissue factor (TF) expression in these cell lines, in order to gain an insight into 
its relationship with TG. 
 
Detailed methods for the experiments in this chapter are described in METHODS 
chapter 2. Briefly, seven solid tumour cells (pancreatic cancer ASPC-1, CFPAC-1, 
PANC-1, MIA PaCa-2, ovarian cancer SKOV-3, Head & Neck squamous cancer 
UMSCC81B and lung cancer PC9) and 5 malignant haematological cell lines (Multiple 
myeloma MM.1S, U266B, H929, plasma cell leukaemia JJN3 and histiocytic lymphoma 
U937) were cultured as described in METHODS section 2.1. The cells and their MVs 
released into cell-free media were assessed for TG on a calibrated automated assay 
in real time. Time to start of TG (Lag time), endogenous thrombin potential (ETP), 
Peak height of thrombin (Peak), time to peak (TTP or ttPeak) and velocity index 
(Vel.Index) of TG were evaluated. TF cell surface expressions were also measured 
with 5µg of anti-human CD142: FITC antibody by flow cytometry (METHODS section 
2.6) and the mean fluorescence ratio or MFR (CD142/negative control) for each 
sample was evaluated and repeated three times on different days. Furthermore, at 
decreasing cell concentrations (5x106 - 4x104 cells/ml), UMSCC81B suspended in PBS 
(100µl per cuvette) was assessed for prothrombin times as previously described in 
the clotting assay (METHODS section 2.5) (Welsh et al., 2012). Relationships between 
TG parameters (Lag time, ETP, Peak, TTP, Vel.Index) and TF cell surface expression 
was assessed with Pearson correlation coefficient on linear regression analysis. 
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4.2  Results 
 
4.2.1  Thrombin generation in solid tumour and haematological malignancy 
cell lines in platelet free plasma 
 
Initially, 12 different cell concentrations were used to identify the optimal 
concentration at which TG signal is detectable in both solid and haematological 
cancers by the CAT assay. TG was assessed as described in section 2.8 in decreasing 
cell concentrations from (5x106 - 4x104 cells/ml) and was observed to be 
concentration dependent in both main cancer types (Table 4.1). Although ETP (Figure 
4.1B) in both solid and haematological cells remained similar, there were linear 
decreases in Lag times (Figure 4.1A) and TTP (Figure 4.1D) such that as concentration 
decreases both increased in duration. The inverse was seen for peak thrombin (Figure 
4.1C) and Vel. Indices (Figure 4.1E). Lag times and TTP also correlated very strongly 
(r=0.98, Figure 4.2) amongst all the 5 TG parameters measured. Furthermore, 
haematological cells had overall smaller TG curves compared to the solid cancer cells. 
UMSCC81B, CFPAC-1 and AsPC-1 cell lines initiated TG quickest within 1.5±0.2 
minutes in NormTrol, followed by SKOV-3 1.6±0.2, PC9 at 1.8±0.1, PANC-1 4.9±1.1 
while MIA PaCa-2s are least at 7.6±1.4 minutes. Amongst the haematological cells, 
U937 was the quickest and required 9.8±1.6 minutes to initiate TG while MM.1S was 
the slowest, taking 16.2±2.8 minutes (Table 4.1). The intra assay coefficient of 
variation (C of V) of Lag times, ETP and the rest of the TG parameters were 4.78%, 
3.53% and < 5% respectively, while the inter assay C of V of all the TG parameters 
were < 10%. All cell lines did not hydrolyse the fluorogenic substrate when plasma 
was absent, and as a result, no reaction occurred in the assay in this condition and no 
TG was recorded. 
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Table 4.1 Thrombin generation parameters of 12 cancer cell lines and low 1pM TF standard preparation. 
 Platelet free 
plasma 
Lag time 
(minute) 
ETP  
(nM/minute) 
Peak thrombin 
(nM) 
TTP  
(minute) 
Vel. Index 
(nM/minute) 
SKOV-3 NormTrol 1.6±0.2 1299±63  182±14  4.6±0.2 61.6±6.6 
F XII-deficient 1.9±0.3 1730±79*  173±24  5.3±0.1 50.8±3.4 
FVII-deficient 11.8±5.4** 992±172*  65±23**  20.3±6.8*** 8.1±4.5*** 
PC9 NormTrol 1.8±0.1 1265±137  174±10  4.8±0.1 58±3.4 
F XII-deficient 1.5±0.1 1825±119*  233±62*  4.7±0.5 74.7±28.9 
FVII-deficient 9.2±0.1* 1610±132*  121±20*  15.2±4.2** 18.9±9.7*** 
UMSCC81B NormTrol 1.5±0.2 1331±203  207±23  4.4±1.1 81.5±26.9 
F XII-deficient 1.7±0.1 1473±142  220±10  4±0.1 94.4±11 
FVII-deficient 10±4.4** 1510±120  104±64***  16.8±8** 18.9±15.8*** 
CFPAC-1 NormTrol 1.5±0.2 1294±47  217±12  3.7±0.2 95±16.4 
F XII-deficient 1.6±0.2 1722±107*  244±19**  4.2±0.3 93.7±16.6 
FVII-deficient 10.8±4.3*** 1332±154  105±38***  17.6±6.1** 19±13.6*** 
ASPC-1 NormTrol 1.5±0.2 1264±79  162±12  4.8±0.8 50.8±13.4 
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F XII-deficient 1.5±0.2 1751±124*  181±19**  6.7±0.8 41.3±12.9 
FVII-deficient 16.8±6.5** 1066±495  60±19***  26±6.8*** 6.7±2.5*** 
MIA PaCa-2 NormTrol 7.6±1.4 1080±107  71.±14  15.1±1.4 9.7±2.7 
F XII-deficient 5.1±2.6 1306±312  99±9  15.9±0.8 23.6±41.9 
FVII-deficient 19.7±6.3*** 1261±304  84±32  28.1±6.8*** 13.5±11.3 
PANC-1 NormTrol 4.9±1.1 1166±96  92±27  12.6±2.2 14.4±6.2 
F XII-deficient 3.8±0.6 1474±331*  95 ±41*  13.5±2.7 11.5±7.4 
FVII-deficient 21.8±3.6*** 1104±96  87±27  30.2±3.2** 10.6±3.6 
H929 NormTrol 13.2±2.1 1122±71 90±23 19.7±2.8 14.6±5.9 
F XII-deficient 16.5±2.9 1001±305. 49±16 28.5±4.2* 4.2±1.8 
FVII-deficient 21.3±4.7** 1319±385 77+36 30.3±6.4** 9.6±6.4 
JJN3 NormTrol 15.4±1.6 1084±108 67±8 23.1±1.7 8.7±1.1 
F XII-deficient 15.3±3.4 825±151 38±5 30.3±6.4* 2.5±0.4 
FVII-deficient 23.6±0.9** 797±155 44±13 34.0±0.8** 4.3±1.3 
U266B NormTrol 15.2±1.3 1086±108 71±12 22.7±1.6 9.6±2 
F XII-deficient 19.3±3.4 682±39** 35±9 34.0±4.0*** 2.4±0.4 
FVII-deficient 23.7±3.1** 861±20 47±12 34.8±4.7*** 4.4±1.6 
U937 NormTrol 9.8±1.6 999±115 60±20 17.8±1.1 7.6±1.7 
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F XII-deficient 7.6±1.4 670±12 32±3 26.6±5.2* 1.8±0.3 
FVII-deficient 28.0±7*** 968±244 46±5 39.2±6.4*** 4.2±0.5 
MM.1s NormTrol 16.2±2.8 986±102 65±12 21.7±4.4 9.5±2.8 
F XII-deficient 20.4±9.0 665±95 34±7 35.8±9*** 2.3±0.8 
FVII-deficient 29.4±2.4*** 702±10 37±6 40.7±2.7*** 3.2±0.5 
TF standard NormTrol 2.6±0.1 1399±175 254±6 5.4±0.1 93.5±3.7 
F XII-deficient 2.1±0.1 2011±164*** 328±8** 5.0±0 111.6±0.6 
FVII-deficient 14.3±1.8*** 1722±70* 219±24 18.5±2*** 53.6±11.3*** 
Cells were collected and washed in PBS at concentration of 0.63 x 106/ml to induce TG in 3 different platelet-free plasma (NormTrol, Factor XII-
deficient and Factor VII-deficient). TG parameters include Lag time, ETP, Peak, TTP and Velocity Index. Results are mean of n=4 ± S.D performed 
in duplicates. P values from two-way ANOVA multiple comparisons with NormTrol as baseline compared with Factor VII-deficient plasma and 
Factor XII-deficient plasma. Significance is at *p< 0.05, **p<0.01, ***p<0.001.  
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E) 
 
Figure 4.1 Thrombin generation with increasing cell numbers.  
A) Lag times B) ETP C) Peak thrombin D) Times-to-peak E) Velocity Index. TG was 
induced by 8 different concentrations of 12 cancer cell lines (from 100,000 to 937 
cells/20µl) in platelet-free plasma with low 1 pM TF standard preparations as 
controls. Results are mean of n=3 performed in triplicates (intra assay C of V of Lag 
times, ETP and the rest of the TG parameters were 4.78%, 3.53% and < 5% 
respectively, inter assay C of V of the TG parameters were < 10%). The 5 TG 
parameters measured by calibrated automated thrombography (CAT) assay are Lag 
times, Endogenous thrombin potential (ETP), Peak thrombin (Peak), Times-to-peak 
(TTP or ttPeak), Velocity index (Vel.Index). 
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Figure 4.2. Correlation of Lag times and TTP from solid tumour and haematological 
malignancy cell lines in platelet free plasma 
 
4.2.2  Clotting times and Thrombin generation 
 
To compare the TG parameters with another test of procoagulant activity, 
UMSCC81B cell lines at decreasing concentrations were selected for a prothrombin 
assay performed with a coagulometer as described in section 2.5. When compared 
with TG parameters, CT for UMSCC81Bs had the highest correlation with the 
thrombin Peak (r=-0.99, p= 0.0007) figure 4.3C, followed by times-to-peak in figure 
4.3D (r=0.92, p=0.0006) and lag times in figure 4.3A (r=0.9, p=0.0001). It also 
correlated less strongly with ETP in figure 4.3B (r=0.68, p=0.003). 
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C) 
 
 
D) 
 
Figure 4.3 Clotting times (CT) versus Thrombin generation (TG).  
A) Lag times:CT B) ETP:CT C) Peak:CT D) Times-to-peak:CT. TG parameters from the 
CAT assay were compared with clotting times from the one-step Thrombotrak Solo 
coagulometer. UMSCC81B cancer cell lines were used at decreasing concentrations 
(5, 2.5, 1.25, 0.63, 0.3, 0.15, 0.08, 0.04 x 10*6/ml) for both assays. CT for UMSCC81Bs 
had the highest correlation with the thrombin Peak (Pearson coefficient r=-0.99, p= 
0.0007), followed by times-to-peak, lag times and ETP. 
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4.2.3  Influence of coagulation factors on thrombin generation in solid 
tumour and haematological malignancy cell lines 
 
TG parameters measured in NormTrol and coagulation factor VII-deficient plasma 
indicated significant differences (Table 4.1, Figure 4.4), but TG parameters in 
NormTrol and factor XII-deficient plasma were not significant, especially in solid 
tumour cell lines. For instance, ASPC-1 had a 1.5±0.2 minute Lag time in NormTrol 
and under factor XII-deficiency, the duration of which was prolonged significantly by 
91% (p=0.0001) to 16.8±6.5 minutes with factor VII absence in plasma. Interestingly, 
there was a smaller change (less prolongation) in haematological cells, such that 
absence of factor VII in platelet-free plasma prolonged Lag times but to a much lesser 
extent than was observed in solid tumour cells (Figure 4.4A). For example, Myeloma 
U266B showed a lag time of 15.2±1.3 minutes in NormTrol plasma which increased 
significantly or lengthened (p=0.0014) by 36% to 23.7±3.1 minutes in factor VII-
deficient plasma, but only increased to 19.3±3.4 minutes (p=0.158) in factor XII-
deficient plasma. 
 
In all cell lines, Lag times (Figure 4.4A) and TTP (Figure 4.4B) were the TG parameters 
that showed the highest number of significant changes under the conditions 
described, followed by Peak thrombin produced, Vel. index, and ETP (Table 4.1). TTP, 
for example (Figure 4.4B) showed that haematological cells have a different profile 
to solid tumour cells as there were significant differences observed in TG in both 
factor VII and XII-deficient plasma when compared to NormTrol plasma, unlike in 
solid tumour cells where most differences were only seen in factor VII-deficient 
plasma compared to NormTrol. U937 for example had a TTP of 17.8±1.1 minutes in 
NormTrol plasma which became significantly prolonged by 33 %(p=0.019) to 26.6±5.2 
minutes in factor VII-deficient plasma, and by a much larger extent of 55% (p=0.0001) 
to 39.2±6.4 minutes in factor-XII deficient plasma 
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B) 
 
Figure 4.4 Influence of coagulation factors on thrombin generation in cell lines.  
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A) Lag times B) Time-to-peak TG in solid cancer cell lines such as PC was compared 
with haematological (such as MM) cell lines in vivo on the CAT assay, each at constant 
cell number of 0.63 x 106/ml. Results are mean of n=4 ± S.D performed in duplicates. 
*P values are from two-way ANOVA multiple comparisons with NormTrol as baseline 
compared with Factor VII-deficient plasma and Factor XII-deficient plasma. 
Significance is at *p< 0.05, **p<0.01, ***p<0.001 
 
Thrombin generation curves were produced by the CAT assay for the 12 cancer cell 
lines in 3 types of platelet-free plasma; NormTrol (Figure 4.5A), Factor XII-deficient 
plasma (Figure 4.5B) and Factor VII-deficient (Figure 4.5C). Under coagulation factor 
VII-deficient plasma conditions, TG in the majority of cell lines and control was 
affected, with significant delay in initiation, volume and times to reach peak, and TG 
was not completed in all the MM cells in 60 minutes. For instance, CFPAC-1 thrombin 
production reduced from 220 to 120 nM in factor VII-deficiency, a 45% reduction, 
while TG remained near 225nM in factor XII-deficiency. Conversely, for 
haematological cells only U937 retained the ability to complete its TG curve in 60 
minutes when factor XII was absent in plasma, at a reduced volume and velocity 
(from 17.8±1.1 to 39.2±6.4 nM/min) while the others such as U266B did not complete 
TG in the duration of experiment. 
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C) 
 
Figure 4.5 Thrombin generation curves of solid and haematological malignant cell 
lines.  
The graphs show the differences in TG in 3 types of platelet-free plasma: A) NormTrol 
B) Factor XII-deficient and C) Factor VII-deficient; induced by 12 cancer cell lines with 
low 1pM TF as control. Pancreatic CFPAC-1 and Multiple myeloma U266B are 
highlighted here as examples to compare the differences in TG. 
 
4.2.4  Influence of coagulation factors on thrombin generation in 
microvesicles released by cells from solid and haematological malignant 
lines 
 
In NormTrol and coagulation factor VII-deficient plasma, TG in MVs produced by solid 
cancer and haematological cell lines (detailed in section 2.8.2) followed similar 
patterns as their parent sources (Table 4.2; Figure 4.6). Overall Lag times were shorter 
in MVs of solid tumours in NormTrol plasma compared to haematological ones. 
Furthermore, apart from U937 MVs, none of the MVs from the hematologic lines was 
capable of generating enough thrombin in the 3 types of platelet-free plasma used 
(NormTrol, Factor VII-deficient and Factor XII-deficient) in the time allotted per assay 
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of 60 minutes. Similarly to the parent cell lines, TG in FXII-deficient plasma was alike 
to TG in NormTrol, while the TG parameters measured in FVII-deficient plasma were 
significantly reduced. 
 
Generally, Lag times were not affected by the absence of FXII except in MIA PaCa-2 
MVs where it was reduced by approximately 50% from 8.77± 3.28 to 4.52± 2.06 
minutes, although this change was not of any significance ultimately (p=0.12; two-
way Anova). UMSCC81B MVs Lag times occurred too fast to be recorded by the assay, 
which can only measure activity every 10-20 seconds (discussed in METHODS section 
2.8).
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Table 4.2 Thrombin generation parameters in Microvesicles from 5 cancer cell lines and low 1pM TF standard preparation. 
 Platelet free 
plasma 
Lag time 
(minute)  
/P value 
ETP 
(nM/minute) 
/P value 
Peak thrombin 
(nM)  
/P value 
TTP  
(minute) 
/P value 
Vel. Index 
(nM/minute) 
/P value 
UMSCC81B 
MV 
NormTrol - - - - - 
F XII-
deficient 
1.54±0.17 
/0.72 
1535±227 
/***0.0001 
220±89 
/***0.0001 
4.24±0.45 
/0.46 
90.21±57.6 
/***0.0005 
FVII-
deficient 
7.62±7.91 
/**0.0031 
1031±235 
/***0.0002 
99±62 
/*0.024 
13.89±10.9 
/***0.0007 
21.32±18.7 
/0.49 
ASPC-1 
MV 
NormTrol 2.42±0.43 880±149 105±46 6.73±1.68 28.46±20.12 
F XII-
deficient 
2.56±0.67 
/0.99 
1105.69±221.64 
/0.18 
112±48 
/0.92 
7.404±2 
/0.96 
26.25±19.68 
/0.98 
FVII-
deficient 
19.92±2.21 
/***0.0001 
126.2±37.05 
/***0.0003 
17±16 
/**0.0068 
32.97±6.81 
/***0.0001 
1.46±1.58 
/0.16 
PANC-1 
MV 
NormTrol 6.48±1.15 840.58±54.93 74±19 12.7±2 12.88±4.93 
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F XII-
deficient 
6.28±1.38 
/0.99 
1018.56±133.28 
/0.41 
83±24 
/0.88 
13.7±2.76 
/0.93 
12.03±5.54 
/0.99 
FVII-
deficient 
22.78±2.6 
/***0.0001 
769.94±344.02 
/0.87 
27±6 
/0.093 
34.22±4.8 
/***0.0001 
2.505±0.89 
/0.63 
MIA PaCa-2 
MV 
NormTrol 8.77±3.28 558.61±53.53 39±8.61 15.86±2.95 5.5±1.34 
F XII-
deficient 
4.53±2.06 
/0.12 
651.59±9.1/ 
0.89 
35.3±11.71 
/0.99 
21.62±7.78 
/0.23 
2.25±1.47 
/0.97 
FVII-
deficient 
16.44±1.68 
/***0.0029 
541.75±239.13 
/0.99 
24.47±9.95 
/0.75 
29.43±2.14 
/***0.0002 
2.14±0.93 
/0.96 
U937 
MV 
NormTrol 6.62±2.051 859.46±139.14 95.49±4.4 13.38±4.01 12.87±10.93 
F XII-
deficient 
4.36±4.2 
/0.63 
1059.77±428.82 
/0.51 
41.43±0.81 
/0.31 
10.57±9.56 
/0.74 
25.05±1.35 
/0.082 
FVII-
deficient 
11.71±7.96 
/0.13 
967.91±244 
/0.81 
70.43±31 
/0.76 
18.53±9.62 
/0.39 
11.29±7.19 
/0.99 
TF 
Standard 
NormTrol 2.64±0.064 1399±174.82 254±6.14 5.37±0.11 93.54±3.65 
FXII- 
deficient 
2.05±0.017 
/0.95 
2011±164 
/*0.0014 
328±8 
/*0.016 
4.98±0.08 
/0.99 
111.64±0.6 
/0.37 
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FVII-
deficient 
14.32±1.83 
/***0.0001 
1722±70 
/0.102 
219±24 
/0.31 
18.52±1.96 
/**0.0013 
53.633±11.25 
/*0.019 
MVs from tumour cells at concentration of 0.6 x 10*6/ml were concentrated in PBS to induce TG in 3 different platelet-free plasma (NormTrol, 
Factor XII-deficient and Factor VII-deficient). TG parameters include Lag time, ETP, Peak, TTP and Velocity Index. Results are mean of n=4 ± S.D 
performed in duplicates. P values from two-way ANOVA multiple comparisons with NormTrol as baseline compared with Factor VII-deficient 
plasma and Factor XII-deficient plasma. Significance is at *p< 0.05, **p<0.01, ***p<0.001. 
168 
 
 
A) 
 
B) 
 
  
A S
P C
-1
 M
V
U M
S C
C 8
8 1
B  
M
V
P A
N C
-1
 M
V
M
IA
 P
aC
a -
2  
M
V
U 9
3 7
 M
V
T F
 s
ta
n d
a r
d
0
1 0
2 0
3 0
L
a
g
 T
im
e
 (
m
in
u
te
s
) N o rm T ro l
F a c to r  X II-d e f ic ie n t P la s m a
F a c to r  V II-d e f ic ie n t P la s m a
A S
P C
-1
 M
V
U M
S C
C 8
8 1
B  
M
V
P A
N C
-1
 M
V
M
IA
 P
aC
a -
2  
M
V
U 9
3 7
 M
V
T F
 s
ta
n d
a r
d
0
5 0 0
1 0 0 0
1 5 0 0
2 0 0 0
2 5 0 0
E
n
d
o
g
e
n
o
u
s
 t
h
ro
m
b
in
 p
o
te
n
ti
a
l 
(n
M
/m
in
u
te
)
N o rm T ro l
F a c to r  X II-d e f ic ie n t P la s m a
F a c to r  V II-d e f ic ie n t P la s m a
169 
 
C) 
 
D) 
 
  
A S
P C
-1
 M
V
U M
S C
C 8
8 1
B  
M
V
P A
N C
-1
 M
V
M
IA
 P
aC
a -
2  
M
V
U 9
3 7
 M
V
T F
 s
ta
n d
a r
d
0
1 0 0
2 0 0
3 0 0
4 0 0
P
e
a
k
 t
h
ro
m
b
in
 (
n
M
) N o rm T ro l
F a c to r  X II-d e f ic ie n t P la s m a
F a c to r  V II-d e f ic ie n t P la s m a
A S
P C
-1
 M
V
U M
S C
C 8
8 1
B  
M
V
P A
N C
-1
 M
V
M
IA
 P
aC
a -
2  
M
V
U 9
3 7
 M
V
T F
 s
ta
n d
a r
d
0
1 0
2 0
3 0
4 0
5 0
T
im
e
s
-t
o
-p
e
a
k
 (
m
in
u
te
s
) N o rm T ro l
F a c to r  X II-d e f ic ie n t P la s m a
F a c to r  V II-d e f ic ie n t P la s m a
170 
 
E) 
 
Figure 4.6 Influence of coagulation factors on thrombin generation in cancer MVs.  
A) Lag times B) ETP C) Peak thrombin D) Times-to-peak. E) Velocity Index. TG in MVs 
(per 20µl of PBS) were obtained from cancer cell lines of PC (ASPC-1, PANC-1, MIA 
PaCa-2), UMSCC81B and haematologic U937 and was measured on the CAT assay. 
Results are mean of n=3 ± S.D performed in duplicates.  
 
4.2.5  Influence of tissue factor on cell-induced thrombin generation from 
solid tumours and haematological malignancy cell lines in platelet-free 
plasma 
 
As a measure of the influence of cell TF expression on TG of cell lines, mean TF cell 
surface expression was assessed by flow cytometry and plotted against average TG 
parameters using data generated at 0.63 x 106 cells/ml. There was variability in TF 
expression as expected across the cell lines however; the solid cancer cell lines 
expressed higher TF values than haematological cells (Figure 4.7). While UMSCC81B 
expressed the highest TF amongst solid cancer cells overall, CFPAC-1 expressed the 
highest TF amongst PC cells and JJN3 the lowest of all cell lines. An inverse correlation 
was seen upon correlation of TF expression with TG parameters Lag time (r2=-0.78, 
p=0.036) (Figure 4.7A)  and TTP (r2=0.78, p=0.002) (Figure 4.7B). Upon Log10/Log10 
transformation of data with regression, a near linear relationship of these 2 TG 
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parameters in NormTrol with TF expressed per 105 cells was displayed. Correlation 
with TG parameters obtained from factor VII-deficient conditions showed weak 
correlations of low significance (r2< 0.5) and no relationship with factor XII-deficient 
conditions. Also, the TG parameters ETP, Vel.Index and peak height correlated weakly 
with TF cell surface expression (r²=0.65, p=0.000000009, r²=0.61, p=0.004 and 
r²=0.69, p=0.0000079 respectively).  
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B)  
 
Figure 4.7 Influence of Tissue Factor (TF) on Thrombin generation in cell lines. 
A) TF:Lag times B) TF:Times-to-peak. Following 24 hour cell culture, flow cytometry 
was used to assess mean TF surface expression of cell lines at 0.63 x 10*6/ml cell 
concentration. There was an inverse correlation of TF expression with averaged TG 
parameters such that as TF expression increases, Lag times and times-to-peak 
decreases. There existed a near linear relationship of TG parameter (Lag times, Times-
to-peak) in NormTrol with TF expressed per 105 cells on Log10/Log10 transformed data 
using regression where R2 values are 0.78 and 0.75 respectively. Results are mean of 
n=3 performed in triplicates. 
 
  
R² = 0.78
0
1
2
3
4
5
6
7
0 5 10 15 20 25
Ti
ss
ue
 Fa
ct
or
 
M
ea
n 
Fl
uo
re
sc
en
ce
In
te
ns
ity
Times-to-Peak (minutes)
SKOV-3
PC9
UMSCC881B
CFPAC-1
ASPC-1
MIAPaCa-2
PANC-1
H929
U266B
MM1.S
JJN3
U937
Solid cancer cells Haematologic cells
173 
 
4.3  Discussion 
 
Cancer cell lines exhibit TG in a cell concentration dependent manner. Of the five TG 
parameters, lag time and time-to-peak highlighted the differences between solid and 
haematological tumours and were dependent on TF expression. Coagulation driven 
by solid tumour was also more TF-FVII dependent than for haematological cells, 
which was both factors VII and XII dependent, which suggests that there is a role for 
factor XII in the absence of factor VII in non-solid malignancies.  
 
An ETP of 30% or higher has been linked to clinical situations where bleeding 
tendencies were absent or low, and therefore to the severity of observed bleeding(Al 
Dieri et al., 2002). In plasma, several studies suggest that the peak thrombin height 
and ETP are considered most important (Duchemin et al., 2008), but none has been 
conclusively determined for other substrates. Lag times reported here were defined 
as the time in which 20nM of thrombin is formed (Hemker et al., 2003) and the 
importance of this initiation phase has been previously described in coagulation 
studies with limited factor V component (Butenas et al., 1997). Peak thrombin may 
reflect the ability of the cell lines to generate thrombin; and it also correlated with a 
one-step clotting assay (Figure 4.3). This could mean that although the height of 
thrombin produced may reflect clotting time, it may not necessarily indicate the 
absolute capacity of the cell lines to generate thrombin. 
 
Pancreatic cancer displays a TF-driven coagulation process when compared to MM 
that is not as dependent on TF-related coagulation (Yates et al., 2011; Welsh et al., 
2012). As to be expected, PC and other solid cancer cell lines exhibited a stronger 
overall TG profile in this study with larger volumes of thrombin produced than MM 
cells (Table 4.1). TG parameter differences characterize cancer cell lines, which may 
reflect how thrombin is formed in vivo and potential response to therapy. In this 
study, MM cells generally have slower lag times and may continuously generate 
thrombin for a longer period (Figure 4.5). A further distinction could also be made 
between the PC cell lines, where the fastest lag times and times-to-peak of those such 
as ASPC-1 and CFPAC-1 may be explained by increased cell surface mucin, unlike for 
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PANC-1 and MIA PaCa-2 (Lieber et al., 1975; Chen et al., 1982; Deer et al., 2010) have 
less Mucin and which are slower to initiate TG. Although UMSCC81B has the highest 
TF cell surface expression this did not necessarily translate into the cell line with the 
highest total amount of thrombin produced, as only a little TF is needed to produce 
the initial thrombin necessary for amplification to the propagation phase of the 
clotting haemostatic cascade (Monroe & Hoffman, 2006). 
 
Compared to low TF control, factor VII exerted more influence on TG than factor XII 
in both PC and MM. However, factor XII had a greater influence on TG in the MM cells 
and almost none in PC (Figure 4.4). Factor VII and factor XII are members of the 
extrinsic and intrinsic contact-activated coagulation pathways involved in thrombus 
formation(Kuijpers et al., 2014). They may also be involved in other functions such as 
inflammation and angiogenesis in vivo (Ruf et al., 2011; Woodruff et al., 2011). Lack 
of both factors caused changes in TG parameters, which was consistent across cell 
lines. Solid tumour cells, such as PC express more TF, compared to haematological 
cell lines.TF-factor VII complex has been suggested to drive coagulation from a 
damaged vessel wall while factor XII may act at more distant locations (Nickel et al., 
2015) and may modulate stability of thrombus independent of thrombin 
generation(Konings et al., 2011). TF-dependent pathways are known to utilise factor 
VII which activates the PAR-2 pathway and leads to a TF-FVII complex that activates 
the extrinsic clotting pathway (Rickles et al., 2003; Ruf et al., 2011). Although, TF-
factor VII removal from the assay caused the most profound change in the TG 
kinetics, it is interesting to note that there was no complete abolishment in both cell 
groups, highlighting the possibility of an alternative pathway being utilized in these 
situations. Marchetti et al also reported a similar observation upon blocking of TF 
activity with anti-TF antibody during TG (Marchetti et al., 2012). Moreover, our study 
implies that although TF cell expression correlates with some particular TG 
parameters, it does not singularly determine the level of thrombin produced. 
 
Haematological cells under factor XII-deficient conditions behaved differently from 
solid cancer cells by generating less thrombin in a longer time with slower initiation. 
It could be suspected from this result that some level of inhibition of the contact 
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pathway is lifted, such that though lower levels of thrombin height is reached, there 
is continuous thrombin production beyond 60 minutes. Although factor XII-deficiency 
is not associated with excessive bleeding its involvement in stabilising thrombus clot 
may contribute to increased risk of emboli formation (Kuijpers et al., 2014). It has 
also been suggested that some reduction in the levels of factor XII may result in higher 
cardiovascular risk and thrombotic complications (Woodruff et al., 2011; Renné et al., 
2012). Also, though it can be bypassed by other coagulation cascade members, factor 
XII may still be essential and its importance comes to prominence in myeloma-related 
thrombosis in the absence of other constituents(Woodruff et al., 2011), as seen here 
when TG persisted in smaller quantities after factor VII absence. Moreover, 
continuing TG may be responsible for persistent initiation of the clotting cascade 
leading to continuous clotting formation in clinical scenarios as suggested by 
Duchmein et al (Duchemin et al., 2008). This study has indicated a possible large 
intrinsic pathway reserve for haematological cells and to a lesser extent solid cancer 
cells, and highlights differential contributions to TG by both the intrinsic and extrinsic 
coagulation pathways. This is supported by a previous study that has highlighted the 
possibility of a large intrinsic pathway reserve in human plasma samples of different 
origins (Rice et al., 2016). 
 
The absence of factor XII in plasma may allow coagulation through an alternative TG 
pathway. For example, a recent study found that in some solid cancers such as 
prostate and pancreatic cancer, TG might be triggered by polyphosphate exposure 
on their plasma membranes in a factor XII-dependent manner (Nickel et al., 2015). 
Therefore, the importance of the role of the intrinsic pathway may not be restricted 
to non-solid cancers alone. Furthermore, a switch from one factor-dependency to 
another might be possible in other cell lines and substrates.  
 
To conclude, this chapter has shown that cells from solid tumours exhibit greater 
thrombin generation potential and are faster to initiate coagulation than 
haematological cells.  The use of factor VII deficient plasma had a greater influence 
in thrombin generation in the solid tumour cells suggesting a greater reliance on the 
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extrinsic, TF-driven pathway in these cells, which may persist when evaluated in 
cancer patients in vivo.  
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Chapter:5  Thrombin generation (TG) and Tissue 
factor (TF) involvement in Multiple Myeloma 
and Pancreatic Cancer  
 
 
PART A 
 
5.1   Introduction of Clinical Studies 
 
In order to study the thrombin generation (TG) patterns in Multiple myeloma (MM) 
and Pancreatic cancer (PC), two main clinical studies were conducted, and the work 
demonstrated in this thesis is a sub study of these pre-existing studies. The main 
studies were both prospective cohort trials; one involved MM patients and was titled 
‘Study of apoptosis related changes and endothelial responses of multiple myeloma 
patients treated with chemotherapy’ and the other involved PC patients entitled ‘A 
Study of the effect of resection of localized Pancreatic Cancer on tissue factor (TF)- 
promoted pathways of Thrombosis and Angiogenesis markers’. These studies were 
commenced from previous PhD projects in our laboratory at different time points 
over the past 9 years; Dr Hussein Echrish was the initial Principal investigator (PI) of 
PC study from 2008, which was taken over by Dr Jessica Hall in 2011 who also 
commenced the MM study. This thesis project started during 2014, and during this 
period, the ongoing PC study was amended substantially from a surgical-only 
treatment to include a separate arm for PC patients on chemotherapy treatment, and 
compare this with chemotherapy effects on TG in the MM study. Further details on 
both studies are described below. 
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5.2  Design and Patient groups 
 
The recruitment process included identification of eligible patients by the Chief 
Investigator -Professor Anthony Maraveyas or by the co-investigator Dr Hazem Sayala 
at Multidisciplinary team meetings (MDT) held at the Queen’s centre for Oncology 
and Haematology, Castle Hill Hospital (CHH) at Hull and East Yorkshire (HEY) Trust in 
the National Health Service (NHS). Good clinical practice (GCP) guidance was followed 
in the consent process; briefly, the research nurse or doctor approached these 
patients for detailed explanation of the study objectives. If interested, they were 
provided with pertinent information (Patient information sheets and consent forms; 
(see appendix A and B for MM and localized PC respectively) to recruit them to the 
study. Patients could reject participation or opt out during the study. Once written 
and informed consent is given, the data managers registered their clinical and 
demographic data onto the trial database, and scheduled hospital visits were 
recorded.  
 
While the surgical arm of the PC study has been completed, the other studies are all 
ongoing with a target to recruit 50 MM patients, 50 PC in the chemotherapy arm, as 
well as 20 Myeloproliferative disorders (MPD), 20 Cholecystitis as inflammatory 
controls for MM and localized PC respectively. During the tenure of this studentship 
as from 2014 10 MM (6 newly diagnosed and 4 relapsed), 7 PC surgery, 9 PC on 
chemotherapy patients were recruited and used for data collection, along with 6 
MPD and 12 Cholecystitis controls. For overall data collection, samples obtained by 
the previous investigators mentioned above that remained in long term storage were 
also used (Figure 5.1), as the actual number of samples received after 2014 was less 
than expected due to several logistic issues. TG from CAT assay was prioritized over 
others for these analyses, when sample volumes were low. In addition, all patients 
recruited during this thesis project were link-coded and anonymized according to 
study protocols so as to maintain ‘blinding’ of the laboratory experiments to avoid 
bias and ‘unblinding’ occurred only prior to data analysis.  
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Figure 5.1 FLOW DIAGRAM of patients in both MM and PC clinical studies.  
The 4 main patient groups assessed were MM, Myeloproliferative disorder (MPD) 
control, PC and Cholecystitis control 
 
5.3  Clinical methods: Blood sample collection and processing 
 
At the scheduled visits, pre-treatment baseline and non-baseline samples of all 
patients in the study (MM, MPD, PC and Cholecystitis) were collected as per the 
schedules of events (on each visit before any treatment or surgery was administered, 
listed in Table 5.1 and Table 5.2) for assays, which included haematological tests 
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where the haemoglobin level, white blood cells and platelet counts that were 
checked by the CHH laboratory. Paraprotein levels were also assessed for MM 
patients before, during and after the chemotherapy courses, and the MM disease 
immunophenotype categorized in bone marrow aspirates at the Haematological 
Malignancy Diagnostic Service (HMDS) in Leeds, UK. Using standard venepuncture 
techniques, venous blood samples were taken from the antecubital vein of the 
patients arm into sample BD Vacutainer tubes (BD biosciences, UK); a yellow serum-
separator bottle, and two blue 3.8% tri-sodium citrated bottles for plasma. All 
samples were treated and processed the same way into serum and platelet-free 
plasma (PFP). As described in section 2.8.3, fresh PFP was obtained by immediate 
centrifugation of the citrated blood collection tubes in serial steps; first at 180xg for 
10 minutes at room temperature (to prevent cold-induced platelet activation) to 
obtain platelet rich plasma (PRP) and then at 12,000xg for an additional 10 minutes 
to obtain plasma free of platelets (PFP). All PFP samples were used fresh in further 
analysis within 4 hours of blood collection or aliquoted and stored in an -800C freezer. 
Serum samples were obtained by leaving the serum-separator bottle to stand upright 
for 30 minutes to allow clot formation. Serum was also processed within 4 hours of 
collection stored and stored same as PFP. Frozen PFP was used for CAT assays 
(section 2.7), while fresh PFP was used for PCA assessment with a prothrombin time 
clotting assay as described in METHODS section 2.5, although the fresh PFP results 
were not evaluated further due to low numbers. Serum was used for TF antigen level 
estimation by ELISA (section 2.8) as illustrated in figure 5.2.  
 
Table 5.1 Blood sampling schedule for MM patients and MPD controls enrolled in 
the study 
Timepoints Newly diagnosed 
MM patients 
Relapsed MM 
patients 
Myeloproliferative 
group (control) 
Baseline (T1) X X X 
day 8, cycle 1 - X - 
day 1, cycle 2 (T2) X X - 
day 1, cycle 3 (T3) X X - 
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8 weeks post 
chemotherapy(T4) 
X X - 
 
 
Table 5.2 Blood sampling schedule for localized PC patients (surgical and 
chemotherapy arms) and Cholecystitis controls enrolled in the study. 
Timepoint Resected Unresected Laproscopic -
Cholycystectomy 
Cholecystitis 
(Control) 
Baseline X X X X 
Post-surgery/ Pre-
chemotherapy 
X X X X 
8-12 week 
Chemotherapy 
X X - - 
24 week 
Chemotherapy 
X X - - 
8 weeks post 
chemotherapy 
X X - - 
 
 
Figure 5.2 Serological experiments performed in both MM and PC clinical studies. 
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Abbreviations: PFP is platelet free plasma. CAT is Calibrated automated 
thrombogram assay. ELISA is Enzyme-linked immunosorbent assay. sCD142 is serum 
Tissue Factor/CD 142 antigen. TFMVs is Tissue Factor Microvesicles (Appendix C) 
 
5.4  Clinical studies description 
 
5.4.1  Clinical History of MM patients 
 
The current study was initially authorized as a clinical trial of an investigational 
medicinal product (CTIMP) by the Medicines and Healthcare products Regulatory 
Agency in 2012, and granted approval by the Research Ethics Committee/REC (ref 
12/YH/0328) and the Hull and East Yorkshire (HEY) Research and Development (R&D) 
department. It was approved for reopening in 2014. The study initially studied the 
effects of novel chemotherapy treatment of MM on the clotting pathways, platelets 
and the endothelium. These patients received an induction chemotherapy of either 
CTD (Cyclophosphamide, Thal, DEX) given as a 28 day or an intensified 21 cycle 
regimen, or a LCD (LEN, Cyclophosphamide, DEX) or LD (LEN+DEX) therapy. 
 
Eligibility criteria for the study included patient’s age ≥ 18 years, ability to give 
informed written consent and a confirmed diagnosis of symptomatic MM through 
the presence of a paraprotein in serum and/or urine, organ damage (such as renal 
insufficiency, osseous appearances) or symptoms considered by the clinician to be 
MM-related. Patients that required treatment for their myeloma either at 
presentation or at the time of relapse were included. Those excluded included 
patients with other conditions known to elevate MV levels such as active infection, 
uncontrolled hypertension, diabetes mellitus with HBA1C indicative of poor diabetic 
control, recent myocardial infarction <3 months, rheumatoid arthritis or other 
inflammatory process in active phase (e.g. psoriasis). Also excluded were patients 
treated with long-term anti-coagulants (e.g. warfarin for DVT or AF) and those with 
recent thrombosis still on secondary prophylaxis. A control group for this study was 
included as patients with intrinsic thrombotic potential in myeloproliferative 
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disorders (MPD) such as chronic myeloid leukaemia, myelofibrosis, polycythaemia 
rubra vera. 
 
Blood samples were collected at baseline pre-chemotherapy T1, after first cycle T2, 
after second cycle T3, and at end of chemotherapy T4 according to table 5.1 schedule. 
In addition, samples were not collected at all the time points for several reasons such 
as patient withdrawal from the study, severe illnesses and other adverse events. 
Overall, total number of newly diagnosed and relapsed patients recruited was 32; the 
samples collected for various assays and analysed at T1 was 28 (10 after 2014), while 
there were 20 in T2 (8 after 2014), 18 in T3 (7 after 2014) and 12 after end of 
treatment T4 (3 after 2014). One patient sample at baseline T1 haemolysed and was 
the sample excluded from analysis. Only one patient entered a 3rd cycle of 
chemotherapy and this, as well as the 4 from end of week 1 timepoint collected from 
relapsed patients, was excluded from analysis due to low numbers. In total, 12 
patients were recruited for the MPD control and only the baseline bloods were 
processed (METHODs section 5.3) and analysed. 
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Figure 5.3 FLOW DIAGRAM of patients in MM study 
 
5.4.2  Clinical History of PC patients 
 
The study was initially approved by the REC (ref: 08/H1305/59) and by the NHS Trust 
research and development (R&D) / NHS Trust organization (number RO721) in 2008. 
This study initially titled ‘Pancreatectomy and Tissue Factor’ was started to study the 
effects of tumour removal from PC patients on TF-related thrombotic pathways. To 
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facilitate one of the secondary objectives of this thesis the ongoing PC study was 
amended substantially to include a separate arm to study the effects of 
chemotherapy on localized PC patients undergoing non-surgical treatment, and 
compare this with chemotherapy effects in the MM study (Version 3.0, August 2016). 
This amendment of the PC study was granted a favourable opinion by the REC in 
September 2016 and approved by Health Research Authority (IRAS 3284) at end of 
October 2016. Recruitment commenced shortly afterwards and included PC patients 
on palliative treatment, as well as those on adjuvant and neo-adjuvant 
chemotherapy. 
 
5.4.2.1  Surgical Arm of PC study: 
For the surgical arm, eligibility criteria included all patients fit for surgical resection 
and overall 88 patients were recruited into the study over a period of 9 years as these 
all had attempted surgery for malignant conditions and non-malignant ones, which 
were detected and excluded after histology was performed on the resections. 3 
patients proceeded after surgery to week 8 of adjuvant chemotherapy and these 
were included in the chemotherapy arm analysis below. In this study, 29 patients 
were available overall but due to incomplete and missing samples, TG assays were 
performed on 21 patients (including those obtained by previous PI’s) with confirmed 
pancreatic adenocarcinoma (PDAC), pre-cancerous malignant pancreatic conditions 
and cholangiocarcinoma (shown in Figure 5.4) while non-malignant conditions (n=4) 
were excluded. Most patients received either a Whipple’s total or partial pancreatic 
resection (Resected group in Table 5.2) while others judged to be unresectable 
(Unresected group in Table 5.2) had either a bypass or palliative chemotherapy to 
relieve symptoms. A cholecystitis group was recruited as age and sex-matched 
controls and their pre and post-operative blood samples processed as described in 
section 5.3.  
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Figure 5.4 FLOW DIAGRAM of patients in Surgery arm of PC study 
 
5.4.2.2  Chemotherapy Arm of PC study: 
For the PC chemotherapy arm, the sampling schedule in the study protocol (see Table 
5.3) involved obtaining pre-chemotherapy baseline bloods at the initial patient visits, 
then twice during chemotherapy at weeks 8 or 12 and weeks 24, and finally at 8 
weeks after the end of the chemotherapy regimen. 12 patients were placed on 
chemotherapy before the end of this thesis study, however due to inadequate, 
haemolysed or missed samples, only 9 of these had enough samples at the different 
timepoints to be analysed. Also included for in this group were the 3 patients from 
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the surgical arm that had adjuvant or palliative chemotherapy, as shown in figure 5.5. 
The cholecystitis group recruited above remained the controls for this group. Most 
of these PC chemotherapy patients were placed on Gemcitabine (GEM)-based 
chemotherapy regimen (monotherapy or combined with Paclitaxel) or Modefied de 
Gramont 5-Fluorouracil (5-FU)-based therapy. Due to low recruitment numbers of 
study population, data analysis was performed on the TG results from overall 9 
patients on chemotherapy (resected and non-resected) only at baseline and 6 at 
week 8-12. There were less than 3 patients in week 24 and at end of chemotherapy 
during this study; therefore, these data were not included in the final analysis. 
 
 
Figure 5.5 FLOW DIAGRAM of patients in Chemotherapy arm of PC study 
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5.5  Clinico-pathologic details 
 
The clinico-pathologic details of the 4 independent patient groups (MM, PC, MPD and 
Cholecystitis) in both studies are summarized in Table 5.3 below. The data obtained 
from both clinical studies in this chapter was analysed on GraphPad software, version 
7 (GraphPad Software, Inc., California, USA) where the median (Interquartile 
range/IQR) haematological parameters in both MM and PC patient groups and the 
respective controls were calculated. Student t-tests or one-way analyses of variance 
(ANOVA) were used to compare values within independent patient groups. P values 
of <0.05 were assumed as statistically significant. 
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Table 5.3 Summary of clinico-pathological details at baseline pre-treatment for patients recruited into PC and MM studies 
Patient 
characteristics  
MM 
(n=28) 
MPD 
Control 
(n=10) 
PC 
(Surgery) 
(n=29) 
PC 
(Chemotherapy) 
(n=12) 
Cholecystitis 
Control 
(n=12) 
P value at baseline  
(one-way ANOVA) 
Male/female  15/13 7/3 16/13 5/7 5/7 0.47 
Age 71.14 ± 
1.65 
71.91 ±-
2.43 
64.86 ± 
1.87 
69.64  
± 2.16 
71.25  
± 2.31 
0.039 
Paraprotein 
concentration 
(mean ± SD; 
g/l)  
27.10 
±15.40 
- - - - - 
Ig Myeloma 
type:  
      
        IgG   12 - - - - - 
        IgA  5 - - - - - 
       Others 10 - - - - - 
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Haematological 
parameter 
(mean ± SD) 
      
Haemoglobin 
(g/dl)  
11.29±0.30 14.01 ±1.36 12.35±0.37 12.21 ± 0.59 13.92 ± 0.30 <0.0001 
Platelet count 
(x109/l)  
201.10 
±14.42 
291.30 
±45.53 
284.80 ± 
22.88 
287± 36.54 
 
243.40  
± 12.81 
0.0155 
 
WCC count 
(x109/l)  
6.41±1.99 7.27±3.06 9.02 ± 0.75 8.96 ± 0.70 6.92 ± 0.39  0.0022 
N.B. P values between the 4 patient groups (MM, PC, MPD and Cholecystitis) was obtained by one-way ANOVA tests and values of <0.05 were 
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5.5.1  MM Patient characteristics 
 
 
5.5.1.1  Age and Sex of MM patients 
 
The average age of the MM and MPD control patients analysed are similar (p=0.803) 
with no difference on analysis 71.14 +/- 1.65 years for MM while those for MPD 
patients is 71.91 ± 2.43, n=10. The male to female ratio for MM patients was 1.15:1 
(15 males to 13 females) while those for MPD was 2.3:1 (3 out of 10 were females), 
as shown in table 5.3.  
 
5.5.1.2  Demographics 
 
Out of the 26 MM patients analysed for Thrombin generation (TG), 4 patients were 
hypertensive. All patients received anti-thrombotic treatment of Dalteparin 
(Fragmin®) from prophylactic doses of 5,000 units and above, and there were no 
symptomatic DVT or PE recorded during treatment. There were no serious adverse 
events (SAEs) observed during the collection of samples for this thesis project, 
although it should be noted that prior to 2014, 2 patients suffered from 
cerebrovascular accidents (CVAs) and both were newly diagnosed patients receiving 
CTD within the T1 cycle (associated with progressive disease). Another 2 patients 
were withdrawn from the study due to adverse events of suspected respiratory tract 
infection or pulmonary oedema and placed on alternative chemotherapy regimens. 
Furthermore, as determined by the treating physician, patients also received 
antibiotics and antiemetic prophylaxis during treatment according to local hospital 
protocols. 
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5.5.1.3  Haematological parameters in MM patients 
 
Table 5.4 Summary of haematological parameters in MM patients over the duration 
of treatment 
Mean +/- S.D 
 
T1 
(n=28) 
T2 
(n=20) 
T3 
(n=18) 
T4 
(n=12) 
P value vs. T4*  
(Student t-test) 
Haemoglobin 
level (g/dl) 
11.29 
±0.30 
10.79 
±0.34 
10.92 
±1.18 
12.05 
±1.94 
0.992 
0.272 
0.367 
- 
Platelet count 
(x109/l) 
201.1 
±14.42 
247.1 
±81.54 
251.9 
±83.9 
259.5 
±95.09 
0.3147 
0.9571 
0.9893 
- 
 
WCC (x109/l) 6.41 
±1.99 
5.96 
±2.16 
6.1 
±1.75 
6.04 
±1.65 
0.9059 
0.9993 
0.9999 
- 
 
Paraprotein 
concentration 
(g/l) 
27.10 
±15.40 
17.98 
±12.96 
14.0 
±10.16 
12.51 
±6.35 
0.0050 
0.6283 
0.9854 
- 
 
 
 
It is known that a pre-chemotherapy Haemoglobin (Hb) level of <10.0 g/dl, platelet 
count of ≥ 350 x109/l and White cell counts (WCC) > x109/l have all been individually 
correlated with an increased cancer VTE risk(Khorana et al., 2008b). In this thesis, 
although VTE endpoints were not studied, all the Hb values obtained at different time 
points except at T4, were below the normal reference range (men=13.5 to 17.5 g/dl 
and women 12.0 to 16.0 g/dl) as provided by the Castle Hill Hospital laboratory that 
performed the tests. Platelet counts and WCC counts obtained were all however 
within normal reference ranges. In table 5.4, the average Hb level of MM patients 
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pre-treatment at T1 was 11.29+/-0.3g/dl while after the first, second, and end of 
chemotherapy it was 10.79+/- 0.34, 10.92+/-1.18, and 12.05+/-1.94g/dl respectively. 
There was a slight decrease from T1 of 11.29g/dl after the first cycle was 
administered to T2 10.79 g/dl (mean difference 0.5 +/- 0.53, p=0.99) and this 
reduction remained until a return to pre-treatment levels at the end of 
chemotherapy. Overall, when compared to T4 values, Hb values at different 
timepoints were not significantly different (p=0.253; one-way ANOVA). However, the 
Hb values at baseline were significantly lower than the MPD control group at 14.01 
+/- 1.36g/dl (p=0.0001), which was within normal reference range (Table 5.3). 
 
The platelet counts show no significant variation across time during chemotherapy 
(p= 0.0753). As seen in table 5.3, platelet counts of MM patients at baseline 201.10+/-
14.42 x109/l (n=28) were 31% lower compared to MPD control 291.30± 45.53, n=10), 
and this difference was of significance (p= 0.0166). This result was similar to that 
observed for WCC, with significant variances between MPD control and baseline MM 
(p=0.0022), but none observed during the duration of chemotherapy (p=0.123).  
 
The mean paraprotein levels for MM patients were 27.17 +/-15.4g/l at T1, which 
declined significantly (p= 0.0023; one-way ANOVA) in a downward trend with 
administration of chemotherapy in figure 5.6, indicating reduction in paraprotein 
plasma viscosity as a treatment response. This mean paraprotein level at T1 was 
higher than at T4 (12.51+/-6.35g/l), and this difference highly statistically significant 
(p=0.005). In addition, IgG was found to be the most frequent subtype (12 out of 20; 
60%) and kappa the major light chain (10 out of 20; 50%) out of the paraproteins. 
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Figure 5.6 Total Paraprotein (g/l) in patients with MM before, during, and after 
chemotherapy.  
MM patients prior to chemotherapy administration (T1, n= 28), after the first cycle 
of chemotherapy but before start of the second (T2, n=20), after second cycle but 
before start of the third (T3, n=18), and 6-8 weeks after the end of chemotherapy 
treatment at minimum 3 cycles (T4, n=12). 
 
5.5.2  PC Clinical characteristics 
 
5.5.2.1  Age and Sex of PC patients 
 
The mean +/- SD age of the 29 localized PC patients included in this thesis project was 
64.86 ± 1.87 years, while that of the Cholecystitis control group of 12 patients is 71.25 
± 2.31 years, and there was no statistical difference in these groups at p=0.0582. 
Furthermore, out of the PC patients, 16 were male and 13 females with a male:female 
ratio of 1.23:1. The cholecystitis group had 5 males out of 12 cases with a 0.71:1 
male:female ratio. 
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5.5.2.2  Demographics 
 
Out of the 29 PC cases analysed, 9 patients were hypertensive, while 11 drank alcohol 
in frequent amounts (2 units per week and above). In the study, 9 patients were 
diabetic, and while 2 were current cigarette smokers, another 2 were ex-smokers 
having quit over 20 years ago. Also 5 of these patients received anti-thrombotic 
Dalteparin at 5,000 units subcutaneously prophylactically, and one of these patients 
already had a thrombotic event (DVT). 
 
5.5.2.3  Haematological parameters of PC patients 
 
The mean Hb concentration for PC patients at baseline was 12.35 ± 0.37 g/dl, and this 
is statistically significantly less than the control group of 12 Cholecystitis patients 
13.92 ± 0.30 g/dl taken at pre-surgery time points (p= 0.0107; student t-test).  
 
The platelet count in blood samples of PC patients at baseline was 284.8 ± 22.88 per 
109/l which was 14.4% higher than the counts for Cholecystitis control cases at 
243.40± 12.81, n=12 (p=0.24; t-test) table 5.3. However, this difference did not reach 
any significance. 
 
The WCC of PC and Cholecystitis patient groups were significantly different; with 
23.28% higher counts in PC 9.02 ± 0.75 x109/l, relative to control 6.92 ± 0.39 x109/l at 
a statistical difference of (p= 0.017; t-test). 
 
5.5.3  PC on Chemotherapy Clinical characteristics 
 
5.5.3.1  Age and Sex of PC chemotherapy patients 
 
The patients recruited and ultimately analysed for the chemotherapy arm (including 
those on adjuvant therapy from the surgical arm) had a mean age group of 69.64 ± 
2.16 years; n=12 (Table 5.3). This value was similar (p= 0.6162, t-test) to the mean 
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age of the cholecystitis control cases, which was 71.25 ± 2.31; n=12. Out of these PC 
chemotherapy patients, 5 were male and 9 were female (male:female ratio is 0.55:1).  
 
5.5.3.2  Demographics 
 
Of the overall PC patients (n=12) placed on chemotherapy (including those on 
adjuvant therapy from the surgical arm of n=3), 3 were hypertensive, and one drank 
alcohol only socially. In addition, 5 of these patients had Diabetes and 1 smoked 11-
20 packs of cigarette per day while the other was an ex-smoker. 
 
5.5.3.3  Haematological parameters of PC chemotherapy patients 
 
On the average, the mean +/- SD Hb concentration of patients analysed in the 
chemotherapy arm of PC study was 12.21 ± 0.59g/dl (n=12), while that of the control 
cholecystitis group before treatment was 13.92 ± 0.30g/l (n=12). This lower 
concentration of Hb in PC on chemotherapy patients was significant at p=0.0104; t-
test. 
 
The mean platelet counts in PC on chemotherapy was 287.0 ± 36.54 x 109/l and was 
higher compared to the values for cholecystitis control patients at 243.40 ± 12.81 x 
109/l, although this difference held no significance (p=0.193; t-test) as seen in table 
5.3. 
 
The number of white cells present in PC chemotherapy patients baseline blood was 
8.96 ± 0.70 x109/l, and was significantly higher (p=0.0127; t-test) than those found in 
Cholecystitis control 6.92 ± 0.39 x109/l. 
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PART B 
 
5.6  The Assessment of Thrombin generation (TG) and Tissue Factor (TF) 
involvement using the Calibrated Automated Thrombogram (CAT) assay in 
Cancer patients 
 
Patients with Multiple myeloma (MM) and Pancreatic cancer (PC) are known to be 
affected by severe antineoplastic treatment-related thrombophilia that manifests as 
a high incidence of clinical VTE events, with up to a third of these patients 
experiencing VTE in the absence of thromboprophylaxis(Khorana et al., 2007b). An 
important factor that has been associated with increased VTE risk is the use of 
chemotherapy, especially immunomodulatory (IMiD)-based therapies in MM 
(Zangari et al., 2010)and mostly Gemcitabine (GEM) in PC(Khorana & Fine, 2004). In 
both cancers, the development of thrombosis before and during treatment involves 
the generation of thrombin as part of the coagulation process. There is little 
knowledge of the dynamics of thrombin activation in the context of cancer 
coagulopathies driven by various malignancies and their treatments and whether 
markers of this state as measured by in vitro tests vary between different cancers. In 
chapter 4, it was shown how thrombin generation (TG) differs between solid cancers 
cell lines and haematological ones in vitro, with specific emphasis on the various 
kinetic parameters that correlated positively with tumour-derived Tissue Factor (TF) 
in PC, which distinguished it from MM cell lines. The hypothesis therefore generated 
by these findings was that the CAT assay, as a real time measurement of thrombin as 
it is formed in substrates, may be able to identify similar differences in the dynamics 
of thrombin production between these two malignancies (MM and localized PC) in 
the clinical setting. In this chapter, this hypothesis is tested by exploring baseline TG 
differences between the two malignant states before, during and after treatment for 
the effect of treatment on the production of thrombin, and to explore the 
relationship of TF to thrombin development in both malignancies. 
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5.7  Aims 
 
The preceding subchapter part A describes the two main clinical trials from which 
MM and PC patients and their respective control groups of Myeloproliferative 
disorders (MPD) and Cholecystitis patients were recruited. In this part B, platelet-free 
plasma (PFP) samples obtained from the processing of whole blood of both cancer 
patients and controls were assessed on the CAT assay; detailed in METHOD section 
2.8.3. Here, the aims were to: 
 
§ assess characteristics of TG through 4 main parameters (Lag times, ETP, Peak 
thrombin, TTP) from the TG curves generated from fluorescence emitted from 
thrombin-cleaved conjugates formed per test well in the assay (METHODS 
section 2.8)  
§ evaluate serum samples for soluble TF antigen with quantitative ELISA kits 
(METHODS 2.9).  
 
5.8  Statistics 
 
The data obtained from both clinical studies was analysed on GraphPad software, 
version 7 (GraphPad Software, Inc., California, USA) where the median (Interquartile 
range/IQR) haematological parameters in both MM and PC patient groups and the 
respective controls were calculated. Then further statistical analysis on acquired data 
from CAT and ELISA assays was performed by Dr Eric Gardiner on SPSS computer 
software (version 20.0 (IBM Corp.) using a SPSS MIXED procedure (with no random 
effects) that accommodated for missing data points across time. Two correlation 
structures for the variable measurement within a patient were used; the first 
assumed covariances per patient with an unstructured correlation matrix with no 
predetermined pattern, while the second is a heterogenous first order autoregressive 
covariance structure that assumes that the variances of the measurements at each 
time point can differ. For both structures, the marginal means (+/- standard error 
(S.E)) were used to compare variations over time points and cancer type with paired 
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student’s T-tests. One-way ANOVA tests such as the non-parametric Kruskal-Wallis 
(KS) tests based on medians was used for comparing the pre-treatment baseline 
results of the 4 independent patient groups (MM, PC, MPD and Cholecystitis). P 
values of <0.05 were assumed as statistically significant. 
 
 
5.9  Results 
 
5.9.1  Longitudinal study of the TG parameters in MM patients before, 
during, and after chemotherapy  
 
Whole blood samples were collected and processed into frozen PFP (methods section 
2.8.3 and 5.3) for assessment on the CAT assay from patients at different timepoints 
of treatment (Table 5.5); baseline pre-chemotherapy T1, after the first cycle of 
chemotherapy T2, after the second cycle T3, and at 8 weeks after the end of 
chemotherapy T4. Only 2 MM patients entered a 3rd cycle of chemotherapy and only 
1 patient into a fourth cycle, and both were not included in analysis. A mixed marginal 
model (as described in section 5.8 above), which accommodated missing time points 
per patient, was used to estimate mean values. Tests of significance of differences 
between T1, T2, T3 with T4 as a reference time point, were performed using t-tests 
on these mean TG values. T4 was chosen as a reference time point to demonstrate 
differences between patients with disease in-situ (T1, T2 and T3) and those in which 
the disease is cured or in remission (which it represents), and to align with previously 
published results recorded in our laboratory(Hall et al., 2016). P values of <0.05* were 
deemed significant statistically. The main significant results were observed between 
Lag times and TTP at T3 and T4, as explained in detail below. Velocity index was not 
evaluated in this chapter, as in previous chapter 3 and 4 it gave similar results to Peak 
thrombin and added no new information. 
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Table 5.5 Summary of CAT parameters for MM PFP before, during and after 
chemotherapy.  
Time-points 
during 
chemotherapy 
Patient 
numbers 
Lag times- *P 
value vs.  
T4  
ETP- *P 
value vs. 
T4  
Peak- *P 
value vs. 
T4  
TTP- *P 
value vs. 
T4  
T1 26 0.40 0.18 0.79 0.70 
T2 20 0.11 0.81 0.59 0.09 
T3 18 *0.04 0.89 0.65 *0.03 
T4 12 - - - - 
Each parameter obtained at various time points (T1, T2 and T3) were compared to T4 
at end of chemotherapy treatment. Significant *P values was at < 0.05. 
 
5.9.1.1  Lag times 
The lag time (the time to start of maximum TG), of each time point was measured in 
MM PFP samples. In table 5.6 and figure 5.7, the median (IQR) lag times in MM PFP 
before chemotherapy was 3.12 (1.67-9.83) minutes. This duration was faster than lag 
times at T2 of 3.60 (1.67-9.5), and at T3 of 3.67(2-17), before returning to baseline 
levels once chemotherapy ceased at T4 of 3.17 (1.67-4.33) minutes.  
 
Statistical analysis using a marginal model (an autoregressive covariance structure) 
for the 26 MM patients showed that the mean lag times at T3 are 1.85 minutes (S.E 
= 0.824 minutes; (*p=0.037)) significantly higher than T4. This difference in mean lag 
time between T3 and T4 was also of borderline significance under an unstructured 
covariance model (p=0.05). Although lag times at T2 seemed higher than at T4 as 
well, however no other differences were statistically relevant. 
 
Table 5.6 Lag times of PFP of MM patients before, during, and after chemotherapy 
showing the statistical difference in the 4 timepoints on a covariance model.  
Time-points during 
chemotherapy 
Patient 
numbers 
Median (IQR) 
Lag times  
*P value vs. T4  
T1 26 3.12(1.67-9.83) 0.40 
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T2 20 3.60(1.67-9.5) 0.11 
T3 18 3.67(2-17) *0.04 
T4 12 3.17(1.67-4.33) - 
N.B. Prior to statistical analysis, a marginal covariance model that estimated missing 
data patterns was fitted to all values obtained for each patient. Under a specified 
assumption, this model facilitated the estimation of the marginal means for each 
time point, which was analysed by Student’s t tests to determine significant 
variations. P values of <0.05 were assumed as statistically significant. 
 
 
Figure 5.7 Lag times of PFP of MM patients before, during, and after 
chemotherapy.  
Lag times of PFP in newly diagnosed and relapsed MM patients prior to 
chemotherapy administration (T1, n= 26), after first cycle of chemotherapy and 
before start of the second (T2, n=20), after second cycle and before start of the third 
(T3, n=18) and 6-8 weeks after the end of chemotherapy treatment at minimum 3 
courses (T4, n=12). The horizontal bar represents the median levels and the error 
bars represent the IQR. 
 
5.9.1.2  Endogenous thrombin potential (ETP) 
The endogenous thrombin potential or area under the curve, corresponding to the 
total amount of thrombin formed (ETP in nM/min) was measured for all analysed MM 
PFP. Over the duration of treatment, the median (IQR) was T1 1429 (676-2843) 
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nM/minute and was similar to that of T2 1442 (27-2526) and T3 of 1459 (25-2272) 
nM/minute. This trend changed at T4 when the ETP was reduced to 1234 (803-2124) 
units, as shown in figure 5.8. However, as seen in table 5.7, when inserted into a 
mixed marginal model, there were no statistically significant differences between 
time points for either covariance structure model (autoregressive or unstructured) 
used. 
 
Table 5.7 ETP of PFP of MM patients before, during, and after chemotherapy 
showing no statistical difference in the 4 timepoints on a covariance model. 
Time-points during 
chemotherapy 
Patient 
numbers 
Median (IQR) 
ETP  
*P value vs. T4  
T1 26 1429(676-2843) 0.18 
T2 20 1442 (27-2526) 0.81 
T3 18 1459 (25-2272) 0.89 
T4 12 1234(803 -2124) - 
N.B. Prior to statistical analysis, a marginal covariance model that estimated missing 
data patterns was inserted to all values obtained for each patient. Under a specified 
assumption, this model facilitated the estimation of the marginal means for each 
time point, which was analysed by Student’s t-tests to determine significant 
variations. P values of <0.05 were assumed as statistically significant. 
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Figure 5.8 ETP of PFP of MM patients before, during, and after chemotherapy.  
ETP of PFP in newly diagnosed and relapsed MM patients before chemotherapy 
administration (T1, n= 26), after first cycle of chemotherapy and before start of the 
second (T2, n=20), after second cycle and before start of the third (T3, n=18) and 6-8 
weeks after the end of chemotherapy treatment at minimum 3 courses (T4, n=12). 
The horizontal bar represents the median levels and the error bars represent the IQR. 
 
5.9.1.3  Peak thrombin  
The peak height or maximum amount of thrombin formed (in nM thrombin) was 
measured for MM patient samples. As shown in figure 5.9, the median (IQR) values 
for peak thrombin at T1 of 243 (112-448) nM was similar to that of T2 at 263 (1-375) 
and T3 and T4 at 241 (4-388) and 264 (90-404) nM respectively. However, there were 
no statistically significant trend was observed between time points using a mixed 
modelling covariance structure to analyse the mean (Table 5.8). 
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Table 5.8 Peak of PFP of MM patients before, during, and after chemotherapy 
showing no statistical difference in the 4 timepoints on a covariance model.  
Time-points during 
chemotherapy 
Patient 
numbers 
Median (IQR) 
Peak  
*P value vs. T4 
  
T1 26 243(112-448) 0.79 
T2 20 263(1-375) 0.59 
T3 18 241 (4-388) 0.65 
T4 12 264(90-404) - 
N.B. Prior to statistical analysis, a marginal covariance model that estimated missing 
data patterns was fitted to all values obtained for each patient. Under a specified 
assumption, this model facilitated the estimation of the marginal means for each 
time point, which was analysed by Student’s t-tests to determine significant 
variations. P values of <0.05 were assumed as statistically significant. 
 
 
Figure 5.9 Peak thrombin of PFP of MM patients before, during, and after 
chemotherapy.  
Thrombin Peak measured from PFP in newly diagnosed and relapsed MM patients 
prior to chemotherapy administration (T1, n= 26), after the first cycle of 
chemotherapy but before start of the second (T2, n=20), after second cycle but 
before start of the third (T3, n=18), and 6-8 weeks after the end of chemotherapy 
treatment at minimum 3 cycles (T4, n=12). The horizontal bar represents the median 
levels and the error bars represent the IQR. 
T 1 T 2 T 3 T 4
0
1 0 0
2 0 0
3 0 0
4 0 0
5 0 0
P
e
a
k
 t
h
ro
m
b
in
 (
n
M
)
205 
 
 
5.9.1.4  Time-to-peak (TTP) 
The time until the peak thrombin height is reached (TTP) in minutes was measured in 
MM samples. Median (IQR) TTP at baseline T1 was 6.06 (3.56-13.83) minutes which 
increased over time to T2 of 6.66 (3.44-19.67) and peaked at T3 of 6.85 (4-32.33) 
minutes (Figure 5.10). This value decreased to 5.84 (3.67-9.44) minutes after the last 
course of chemotherapy T4.  
 
Similar to Lag times, statistical analysis was performed using a mixed marginal model 
(an autoregressive covariance structure) in order to accommodate for missing time 
points for the 26 MM patients. This covariance marginal model confirmed that the 
mean TTP was 3.18 (S.E = 1.33) minutes longer at T3 relative to T4 at end of 
chemotherapy. This difference between T3 and T4 was of significance under the 
autoregressive covariance structure model (p=0.026), shown in table 5.9. Other 
differences observed were not found as significant. These two variables of the CAT 
assay (Lag times and TTP) also showed a strong correlation > 0.9 after analysis with 
Pearson tests. 
 
Table 5.9 TTP of PFP of MM patients before, during, and after chemotherapy 
showing the statistical difference in the 4 timepoints on a covariance model.  
Time-points during 
chemotherapy 
Patient 
numbers 
Median (IQR) 
TTP 
*P value vs. T4  
T1 26 6.06(3.56-13.83) 0.704 
T2 20 6.66(3.44-19.67) 0.096 
T3 18 6.85(4-32.33) *0.026 
T4 12 5.84(3.67-9.44) - 
N.B. Prior to statistical analysis, a marginal covariance model that estimated missing 
data patterns was fitted to all values obtained for each patient. Under a specified 
assumption, this model facilitated the estimation of the marginal means for each 
time point, which was analysed by Student’s t-tests to determine significant 
variations. P values of <0.05 were assumed as statistically significant. 
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Figure 5.10 TTP of PFP of MM patients before, during, and after chemotherapy.   
TTP of PFP in newly diagnosed and relapsed MM patients before chemotherapy 
administration (T1, n= 26), after first cycle of chemotherapy and before start of the 
second (T2, n=20), after second cycle and before commencement of the third (T3, 
n=18) and 6-8 weeks after the end of chemotherapy treatment at minimum 3 courses 
(T4, n=12). The horizontal bar represents the median levels and the error bars 
represent the IQR. 
 
5.9.2  Baseline studies of TG parameters in Multiple Myeloma (MM) patients 
and Myeloproliferative disorders (MPD) control with localized Pancreatic 
Cancer (PC) patients and Cholecystitis control, before treatment 
administration. 
 
The median values for all TG parameters obtained by CAT assay for the MM and the 
MPD control at baseline pre-treatment, with localized PC and Cholecystitis control 
before surgical treatment are shown in table 5.10. For all four TG variables, data from 
66 patients were used: n=21, n=12, n=26 and n=7 from the PC pre-surgery, 
cholecystitis pre-surgery control, MM pre-treatment baseline T1 and MPD baseline 
control groups respectively. Overall, differences observed between the four groups 
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were not statistically significant except for variances of the ETP parameter (Kruskal-
Wallis statistic = 10.28, df=3, p=0.016) and this is described further below.  
 
Table 5.10 Summary of median (IQR) TG parameters in 4 independent patient 
groups; MM and the MPD control, PC and Cholecystitis control before treatment.  
 Group 1: 
MM (n=26) 
median 
(IQR) 
Group 2: 
MPD 
(n=7) 
median 
(IQR) 
Group 3: 
PC 
(n=21) 
median 
(IQR) 
Group 4: 
Cholecystitis 
pre-surgery 
(n=12) 
median (IQR) 
Overall P 
value 
between 
groups 
(ANOVA) 
Lag times 
(minutes) 
3.12(1.67-
9.83) 
2.67(2.11-
4.17) 
3.33(2.4
0-10.89) 
3(1.67-4.00) 0.083 
ETP 
(nM/minute) 
1429(676-
2843) 
1162 
(645-
1356) 
1214(74
5-1782) 
1276(673-
1795) 
0.016 
Peak(nM) 243(112-
448) 
177(80-
292) 
223(73-
346) 
210(82-290) 0.078 
 
TTP 
(minutes) 
6.06(3.56-
13.83) 
6(4.56-
10.17) 
6(4.11-
16.33) 
6.33(4.33-
8.67) 
0.899 
TG parameters between groups were compared with one-way ANOVA (Kruskal-
Wallis tests). P values of <0.05 were assumed as statistically significant. 
 
5.9.2.1  Lag times 
The median (IQR) Lag times in MM patients before treatment commenced T1 seemed 
slightly higher at 3.12 (1.67-9.83) minutes than MPD controls at 2.67 (2.11-4.17), 
shown in figure 5.11. This value also seemed lower than that of PC, which had the 
longest lag times before surgery at 3.33 (2.4-10.89) minutes, and was 33 seconds 
longer than the lag times for Cholecystitis pre-surgery control at 3.00 (1.67-4) 
minutes. None of these differences however reached statistical significance when 
Kruskal-Wallis (KS) tests (p=0.083) were used to assess differences in estimated 
medians between these four independent groups.  
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Figure 5.11 Lag times comparison between PFP of patient groups. 
Lag times of MM patients (n=26) and MPD control (n=7) prior to treatment; Lag times 
of PC patients (n=21) and Cholecystitis control (n=12) before surgery, measured by 
the CAT assay. The horizontal bar represents the median levels and the error bars 
represent the IQR. 
 
5.9.2.2  Endogenous Thrombin Potential (ETP) 
There was an overall significant trend found amongst groups for the ETP (p=0.016). 
The median (IQR) for MM before treatment at T1 of 1429 (676-2843) nM/minute was 
higher than that of the MPD control 1162 (645-1356), shown in figure 5.12. Pairwise 
comparisons adjusting for multiple testing by a Bonferroni correction showed that 
this difference was significant (p=0.025). This median value for MM at T1 was also 
higher than PC before surgery of 1214 (745-1782) nM/minute, which was slightly 
lower than Cholecystitis pre-surgery control group with 1276(673-1795) nM/minute, 
however no statistical difference was found in these 3 groups. 
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Figure 5.12 ETP comparison between PFP of patient groups  
ETP of MM (n=26) and MPD control (n=7) prior to treatment; ETP of PC patients 
(n=21) and Cholecystitis control (n=12) before surgery, measured by the CAT assay. 
The horizontal bar represents the median levels and the error bars represent the IQR. 
 
5.9.2.3  Peak thrombin 
In the samples studied, the median peak thrombin reached for MM at T1 243(112-
448) nM was higher in quantity than the 7 MPD controls of 177.30 (80-292) nM, 
shown in figure 5.13. This MM median was similar to that of PC before surgery of 223 
(73-346) nM, which was slightly higher than that of the Cholecystitis pre-surgery 
control at 210(82-290) nM. The median Peak values for these 4 groups showed no 
statistical significance when analysed further (p=0.078). 
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Figure 5.13 Peak thrombin comparison between PFP of patient groups. 
Peak thrombin levels of MM patients (n=26) and MPD control (n=7) prior to 
treatment; PC patients (n=21) and Cholecystitis control (n=12) before surgery, 
measured by the CAT assay. The horizontal bar represents the median levels and the 
error bars represent the IQR. 
 
5.9.2.4  Times-to-Peak (TTP) 
The median (IQR) TTP of MM at T1 6.06 (3.56-13.83) minutes was similar to that in 
the MPD controls at 6 (4.56-10.17) minutes, which was in turn similar to that of PC 
before surgery 6.0 (4.11-16.33) and that of the Cholecystitis pre-surgery control 
6.33(4.33-8.67) minutes), shown in figure 5.14. There were no statistically significant 
differences also observed upon further analysis (p=0.899). 
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Figure 5.14 TTP comparison between PFP of patient groups. 
TTP of MM patients (n=26) and MPD control (n=7) prior to treatment; PC patients 
(n=21) and Cholecystitis control (n=12) before surgery, measured by the CAT assay. 
The horizontal bar represents the median levels and the error bars represent the IQR. 
 
5.10  Estimation of serum TF antigen (sCD142) measured in MM, localized 
PC patients and Healthy Volunteers (Normal control) 
 
TF antigen (sCD142) levels was measured in serum by ELISA and for this assay, a 
healthy (Normal control) group was designated from the Cholecystitis group 8 weeks 
to 1 year after surgery. Out of the 12 cholecystitis patients, only 9 volunteered to 
return for post-surgery sample collections. For MM patients, 25 pre-treatment 
samples were analysed instead of 26 (one exception after cycle 2 for one patient as 
a serum-separating blood tube was not collected). 29 PC patient serum samples 
taken before surgery were available for use. Overall, the differences in TF (sCD142) 
measurements between the three groups were statistically significant (Kruskal-Wallis 
statistic = 10.037, df=2, p=0.007). Unexpectedly, sCD142 levels was found to be lower 
in PC pre-surgery patients than in Normal Control (p=0.013), as shown in table 5.11. 
The Normal control group have a significantly higher sCD142 median value of 53.92 
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(37.04-97.02) ng/ml than the PC pre-surgery group of 38.09 (15.91-69.22)ng/ml 
(Figure 5.15). 
 
Table 5.11 TF (sCD142) levels found in serum of MM and PC before treatment and 
Healthy Volunteers (Normal control) group.  
 Group 1: MM 
(n=25) pre-
chemotherapy 
median (IQR) 
Group 2: PC 
(n=29)  
pre-surgery 
median (IQR) 
Group 3: 
(n=9) Normal 
Control 
median (IQR) 
*P value between 
groups 
Group1/Group2 
Group2/Group3 
Group1/Group3 
sCD142 
(ng/ml) 
47.24(25.65-
113.17) 
38.09(15.91 -
69.22) 
53.92(37.04-
97.02) 
0.068 
*0.013 
0.672 
Variances within groups were compared with one-way ANOVA tests (Kruskal-Wallis 
or KS). P values of <0.05 were assumed as statistically significant. 
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Figure 5.15 Serum analysis of TF (sCD142) levels in patient samples 
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Serum TF antigen (sCD142) measured by ELISA in MM (n=25) and PC (n=29) prior to 
treatment and Normal control (n=9) patient samples. The horizontal bar represents 
the median levels and the error bars represent the IQR. 
 
5.11  Relationship between TG parameters in PFP with soluble TF antigen in 
serum in MM, localized PC patients and Healthy Volunteers (Normal 
control)  
 
Correlations were sought between serum TF measured with ELISA (sCD142) and the 
TG variables in PFP measured by the CAT assay (Lag times, ETP, Peak and TTP) in MM, 
PC and Normal control samples. Overall, this TF (sCD142) marker mostly showed no 
significant associations between each group when compared with each TG 
parameter, except for a negative correlation with Peak thrombin in pre-treatment 
MM patients, which was significant (r=-0.41, p=0.04) such that TF antigen level 
increases in serum as Peak thrombin levels declines. In each group, although the 
correlations between variable pairs were different, however when Fisher’s z-test was 
used to test the corresponding correlations, non-significant p-values (Table 5.12) 
were obtained in most of the parameters.  
 
Table 5.12 Statistical correlation of serum TF (sCD142) levels measured by ELISA 
with TG parameters obtained by CAT assay. 
 
1) MM before treatment 
ELISA Patient 
numbers 
Pearson Correlation 
coefficient (r) 
P value 
(2-tailed) 
Lag times, sCD142 25  0.18 0.38 
ETP, sCD142 25 -0.34 0.10 
Peak, sCD142 25 -0.41 *0.04 
TTP, sCD142 25 0.22 0.30 
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2.) PC before surgery 
ELISA Patient 
numbers 
Pearson 
Correlation 
coefficient (r) 
P value 
(2-tailed) 
Lag times, sCD142 29  -0.02 0.93 
ETP, sCD142 29 0.26 0.28 
Peak, sCD142 29 0.09 0.72 
TTP, sCD142 29 0.04 0.89 
 
3.) Healthy volunteers (Cholecystitis post-surgery) control 
ELISA Patient 
numbers 
Pearson 
Correlation 
coefficient (r) 
P value 
(2-tailed) 
Lag times, sCD142 9  -0.54 0.13 
ETP, sCD142 9 -0.35 0.35 
Peak, sCD142 9 -0.07 0.74 
TTP, sCD142 9 -0.46 0.45 
 
 
5.12  Comparison of the TG parameters in PC patients before and during 
chemotherapy  
 
Of the nine patients studied for these four TG variables at baseline before 
chemotherapy and after week 8 of chemotherapy cycle, 2 patients provided data at 
week 12 and 2 at week 24, however these were not included in analysis. Furthermore, 
there were no statistically significant difference in any variable between baseline and 
week 8 of treatment (Table 5.13). 
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Table 5.13 Summary of median (IQR) TG parameters in PC on chemotherapy patient 
group before and at week 8 of treatment.  
Time-points 
during 
chemotherapy 
Patient 
numbers 
Lag times-  
Median 
(IQR) 
/*P value  
ETP-  
Median 
(IQR) 
/*P value  
Peak-  
Median 
(IQR) 
/*P value  
TTP-  
Median 
(IQR) 
/*P value  
Baseline 9 2.4 (2.18-
3.33) 
/0.34 
1089 (937-
1782) 
/0.34 
278(153-
346) 
/0.34 
5.5(4.11-6) 
/0.11 
Week 8 6 2.78(2.11-
6.74) 
1276(787-
1746) 
190(115-
367) 
6.76(4.67-
10.41) 
Variances within groups were compared with one-way ANOVA tests (Kruskal-Wallis 
or KS). P values of <0.05 were assumed as statistically significant. 
 
All TG parameters; Lag times, ETP, TTP with the exception of Peak thrombin seemed 
slightly elevated after week 8 of chemotherapy. Peak thrombin in PC patients 
reduced by approximately 33% from 278(153-346) to 190(115-367) nM after 8 weeks 
in the chemotherapy cycle. However, none of these changes reached significance 
during analysis. 
 
 
5.13  Summary of results: 
 
§ Changes within time in MM patients’ sample under chemotherapy treatment 
showed that Lag times became progressively slower from 3.12 minutes at T1 
to 3.67 minutes at T3 after which it returned to pre-treatment values at T4 at 
the end of chemotherapy courses. 
§  TTP (Times to reach peak thrombin height) also became progressively slower, 
similar to Lag times, from 6.06 minutes at T1 to 6.85 minutes at T3, before 
declining below baseline levels of 5.84 minutes at T4. 
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§ However, only the difference between T3 and T4 in both Lag times and TTP 
were statistically significant (p=0.04 and p=0.03 respectively), once all data 
was fitted into a mixed modelling statistical model that allowed for missing 
values. 
§ Lag times and TTP results showed a very strong positive correlation (r>0.9)to 
each other in MM patients PFP during treatment. 
§ Median ETP obtained in MM samples pre-treatment at T1 (1429(676-2843) 
nM/minute) was higher than that of the other groups, although only the 
difference relative to its MPD control was significant (p=0.025). 
§ Overall, comparisons between the ELISA sCD142 measurements of MM, PC 
and healthy volunteers (Normal control) showed a statistically significant 
difference between the three groups (Kruskal-Wallis statistic = 10.037, df=2, 
p=0.007). Here, the amount of serum TF (sCD142) found in PC before surgery 
was lesser than in the healthy volunteers’ Normal controls (p=0.013). 
§ In the MM pre-chemotherapy treatment group, peak thrombin correlated 
negatively with serum TF (sCD142) antigen levels (r=-0.41, p=0.04). 
 
 
5.14  Discussion  
 
MM and PC are cancers of different origins and aetiology. Although the existing 
clinical data in the literature reveal a high incidence of thrombosis in both 
malignancies in patients whilst receiving antineoplastic treatment, there are distinct 
differences that are apparent and can be highlighted. Firstly, the type of 
antineoplastic treatments used are different, with chemotherapy consisting of 
classical cytotoxics (GEM) being the mainstay of treatment for PC while MM is treated 
with a combination of immunomodulatory (IMiD) agents (Thal, LEN or BOR), 
chemotherapy (alkylating agents Cyclophosphamide or Mephalan) and hormonal 
therapies (DEX or Prednisolone). Secondly, the impact of these antineoplastic agents 
is much more pronounced upon commencement in MM than in PC, as PC patients 
often present with thrombotic signs in the absence of systemic treatments and even 
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before cancer diagnosis is made. Furthermore, the thrombotic effects of increments 
in the chemotherapy used in PC is also rather modest; whereas the classical baseline 
of VTE incidence in MM before IMiD-containing combinations became standard was 
typically recorded as approximately 5%(Carrier et al., 2011), but may increase by 17% 
to 75% based on the combinations used during treatment(Rajkumar et al., 2006) 
(Zonder et al., 2006). Thirdly, the treatment response rate in these two malignancies 
varies widely. In MM over 70% response rates occur on current 1st line options such 
as Thal/DEX combination therapy(Cavo et al., 2005; Rajkumar et al., 2006; Rajkumar 
et al., 2008) and there has been about 50% improvement in median survival in the 
past decade due to advent of IMiD-based therapies(Kumar et al., 2008). On the other 
hand, in PC there are practically no complete treatment responses (between 7-12%) 
and even partial responses are limited to a 1-year survival rate of 18% with the typical 
agent used-GEM (Burris et al., 1997). Therefore, the malignancy-related 
thrombophilic drivers from MM abate early and substantially, when compared to PC 
where they tend to be continuously present and contribute to a more aggressive 
malignancy.  
 
As MM and PC are both known to have high VTE risks, any differences or similarities 
that exist may be distinguishable through products and substrates of the coagulation 
pathway that may highlight potential thrombotic markers. However, few studies 
have successfully linked VTE risk to the increase of any MV-associated coagulation 
biomarker, even though numerous cancers exhibit them, except for PC where the 
release of TFMVs are seen to be specifically associated with coagulation activation 
and thrombotic enhancement(Wang et al., 2012). Although VTE occurrence is known 
to depend on various factors such as imbalance between prothrombotic agents and 
antithrombotic deficiencies (Hisada et al., 2015), and use of chemotherapy, thrombin 
formation underpins clot development processes and therefore could be a valid 
means of comparatively assessing VTE pathways in cancer patients. In a large 
multicentre prospective study of 254 patients, high values of TG parameters (Lag 
times, ETP and Peak thrombin) were useful in the identification of patients at 
increased risk of recurrence after a symptomatic VTE episode (Tripodi et al., 2008). 
In this study however, the results obtained from TG were not compared to VTE risk 
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as patients involved in the study received thromboprophylaxis and no symptomatic 
VTE events were recorded before, during and 8 weeks post-chemotherapy.  
 
In this chapter, while most changes measured by the assays in MM and PC did not 
reach significance, it is notable that of the few that did, Lag times and TTP were 
among the CAT parameters that showed prominence. In assessing the difference 
between MM PFP thrombin produced over time, both parameters highlighted higher 
values in T3 when compared to T4. This interesting result shows a significant (p=0.04; 
Table 5.6, Figure 5.7), progressive increase (lengthening) of lag times of the CAT assay 
as the time it takes to start the thrombin burst in MM patients across the 
chemotherapy cycles. A marked increase is also observed in the TTP parameter 
(p=0.03; Table 5.9, Figure 5.10), which means that it takes a progressively longer time 
to reach peak height of thrombin production from T1 toT3. One possibility from the 
resulting change in these TG parameters may be due to the compilation of damages 
to the endothelium from cycles of chemotherapy, which returns to pre-treatment 
values once chemotherapy treatment ended. An explanation for this observation 
may be that it is due to a concerted rise in endothelial MVs (EMVs) and other MVs in 
MM patients under treatment. This has been suggested by past data from our 
laboratory that showed a 2.4 fold EMVs increase at the third cycle of chemotherapy 
compared to baseline values in MM samples, although this remained elevated at 
T4(Hall et al., 2016). A damaged endothelium may actively prevent clot formation 
and TG by production of anti-thrombotic particles, including Nitric Oxide (NO) and 
prostacyclin and prevent fibrin deposition by production of tissue-type plasminogen 
activator (t-PA)(van Hinsbergh, 2012; Yau et al., 2015). An opposing view can also be 
argued that a damaged endothelium may likely release more apoptotic vesicles and 
procoagulant phospholipids into circulation resulting in faster thrombin clot 
formation and therefore cause Lag times and TTP to shorten. Further studies would 
be needed to explore these views, which reflect the functional heterogeneity of the 
endothelium during chemotherapy treatment, and to verify the TG kinetics that exist 
in these patients, although it is also important to note that there exists a flaw in this 
study whereby all MM patients unlike PC (5 patients only) were routinely placed on 
thromboprophylaxis (the LMWH Dalteparin) which may contribute to the prolonged 
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Lag times and TTP. Dalteparin acts by potentiating the actions of antithrombin III, 
which leads to the active inhibition of thrombin (through prevention of the 
propagation and growth of thrombi) and factor Xa and ultimately results in prolonged 
clotting times(Nutescu et al., 2016). It is these prolonged clotting times that may be 
reflected in the elongation of the Lag times and TTP observed in this chapter. 
 
In previous studies in literature such as (Marchetti et al., 2012), as well as in chapter 
4, Lag times and TTP have demonstrated marked differences in various established 
cancer lines in vitro, pointing to marked variability in mechanisms underlying 
coagulation pathways in PC and MM. In both the in vitro work and the in vivo study 
here in this chapter, both TG parameters show a strong correlation (r>0.9) to each 
other. A possibility may exist that since these 2 CAT assay parameters are wholly 
time-dependent, both may also be more sensitive to longitudinal studies that involve 
a measure of time, as seen in this chapter when the changes in TG was measured 
over the duration of chemotherapy cycles administered to MM patients. Here, 
changes in time to the thrombin burst and to reach maximum peak production, 
rather than the actual amount of thrombin formed may be more important. 
However, none of the published studies in literature have yet to report this 
observation, therefore the implications of these speculation remain to be seen and 
many studies are required to divulge additional insight and clarity.  
 
In this chapter, apart from the ETP (total amount of thrombin producible over time) 
of MM being higher than the other patient groups especially the MPD control (Figure 
5.12), there were no other significant differences between CAT parameters for PC 
and MM and the normal controls chosen for each. This ETP result suggests that there 
is a higher TG potential in MM, which may reflect the summary in chapter 4 that MM 
cells have a larger, intrinsic non-TF pathway reserve than PC cells (from their ability 
to generate thrombin during TF-FVII inhibition in the absence of factor VII from 
plasma) and therefore may be able to exhibit thrombotic features indefinitely. A 
recent 2017 study by Leiba et al has shown that in MM patients, those that have VTE 
during treatment are preceded by a rise in ETP of statistical significance (2896 
nM/minute; p<0.001) which is higher than an ETP of 2028 nM/minute in those 
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without thromboembolic events (Leiba et al., 2017). Furthermore, ETP has been 
identified to be a potential predictive marker for VTE in metastatic patients, in a large 
prospective multicentre trial (n=831)(Falanga et al., 2015). Before treatment it would 
be expected that PC as a solid cancer with more of a TF-driven thrombin production 
pathway, would have shorter lag times (time to initiation of thrombin burst) and be 
generally faster as seen in the solid cancer cell lines in the chapter 4. However, this 
was not the case here, as there were no other significant differences in TG 
parameters obtained between MM and PC patient groups.  
 
ETP has been useful in several studies in published literature. As main parameters of 
the CAT assay, ETP and peak thrombin have been reported in normal healthy 
individuals where they have been shown to be useful markers of TG ability(Dielis et 
al., 2008) and they also increase through pregnancy(McLean et al., 2012). In people 
with genetic susceptibilities to VTE, both are linked to single nucleotide 
polymorphisms and corresponding proteins such as F5 Leiden, F2 G20210A(Segers et 
al., 2010), indicating their sensitivity to genetic determinants and usefulness 
potential as screening tools. In relation to VTE occurrence, a few studies have 
reported weak associations with risk of first occurrence VTE; the Leiden 
Thrombophilia Study (LETS) associated ETP produced with a 1.5 fold increased risk of 
a first time DVT, although no link could be demonstrated with risk of recurrence (van 
Hylckama Vlieg et al., 2007). Another study associated peak thrombin of 349.2 (+/-
108) nM with reduced risk of recurrence when compared to higher peaks of 419.5 
(+/-110.5) nM (Hron et al., 2006). Presumably, it may be possible that these main 
parameters of the CAT assay have various analytical strengths that varies with 
substrates used; as suggested by one study that found higher sensitivity of ETP and 
Peak thrombin in whole blood analysis of patients with historical VTE than in their 
PFP or PRP samples (Tappenden et al., 2007).  
 
In the results of this chapter, PFP peak thrombin correlated significantly with TF 
antigen(sCD142) measured in MM pre-treatment serum with ELISA, indicating that 
as TF levels increases the peak thrombin proportionally reduces. This may mean that 
although TF is present, it may exist in a different configuration in serum, such that 
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the amount of thrombin produced in relation is significantly reduced in MM patients, 
at least in peak height. This conflicting result may be understood in view of several 
reports in literature that shows that TF exists in various configurations and cryptic 
isoforms in circulation, and not all of these may be functional in different conditions 
(Bogdanov et al., 2003; Bach, 2006; Chen & Hogg, 2013). Yates et al, have also 
suggested that freely soluble TF may have limited activity in cell-free media from PC 
cell lines (Yates et al., 2011). Furthermore, some methods of measuring TF in 
substrates do not necessarily correlate with each other (van Doormaal et al., 2012; 
Tatsumi et al., 2014). For instance, studies using TF antigen and TFMV activity have 
been shown to not only contradict each other but also confound assessments of 
thrombosis risk in patients (Zwicker et al., 2013), an observation that contributes to 
difficulties in measurement and also to making comparisons across various studies, 
and may confound the results described here. 
 
The view of different TF configurations may also explain the observation in this 
chapter that serum TF (sCD142) in localized PC patients was significantly less 
(p=0.013) than that measured in Normal controls from healthy volunteers. This may 
be because TF isoforms that exist in malignancies with established inflammatory 
component such as PC may be different to those in normal individuals. However, this 
result is in marked contrast to studies in literature that have found higher TF levels in 
PC than in controls, and attribute this to be associated with the high VTE incidents of 
this solid malignancy in particular. For example, the CATCH (Comparison of Acute 
Treatments in Cancer Hemostasis) study was a large randomized, multicenter trial 
that analysed about 900 patients and successfully showed that the highest VTE 
reoccurrence was found amongst patients with solid tumours such as PC that have 
the largest circulating serum TF levels, as measured by the same ELISA assay used in 
this study (Khorana et al., 2017). In addition, Maraveyas et al used a similar ELISA 
method in the FRAGEM study to demonstrate that the level of soluble circulating TF 
in PC patients on chemotherapy before administration of VTE prophylaxis correlated 
with the level of serum-induced invasion of PC cells (Maraveyas et al., 2010). 
However, none of these studies included a normal control group, as used in this 
chapter, as both had different end points. Khorana et al compared soluble TF levels 
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in serum to recurrent VTE events in the CATCH study, while Maraveyas et al studied 
the effects of LMWH on levels of serum TF before and after commencing 
anticoagulants compared to a group that did not receive anticoagulants in the 
FRAGEM study. Furthermore, it has been suggested by Echrish et al that most of TF 
activity is found associated with MVs (TFMVs) in plasma(Echrish et al., 2014), and is 
a component that may have clotted out from plasma given the process of obtaining 
serum. These may explain the observations in this chapter; although another 
possibility could be the varying durations of storage of the samples used (for example 
some had been stored for over 7 years). However, the CATCH study also recruited 
over a period of 3-4 years and the FRAGEM study samples were also accrued over a 
recruitment period of 7 years. It is unknown how TF antigen in serum may degrade 
over time, or under prolonged storage conditions as occurred in this project. The 
process of its disassembly and the type of conditions that could induce 
biodegradation in different substrates have not yet been studied extensively, and 
could be an interesting addition to published research. 
 
The other correlations between TG parameters measured in PFP by the CAT assay 
and TF values (sCD142) in serum measured by ELISA in this project were mostly weak 
or insignificant, a fact that may be due to the use of serum as ELISA substrate. Ideally, 
patients plasma, which contains the full complement of clotting factors as was used 
in the CAT assay according to the thrombinoscope manufacturer’s instructions 
(Hemker et al., 2006; Giesen, 2012), should also be utilized in the ELISA assay for 
consistency and to align with measurements from plasma. However, plasma volumes 
available were low and serum was therefore used for ELISA, as studies such as the 
FRAGEM and CATCH trials discussed above have already shown that ELISA assays on 
serum samples could significantly distinguish between patient groups with 
thrombotic issues. Moreover, in studies of other tumours, TF measured in serum can 
also be useful as biomarkers for the presence of cancers such as renal cell 
carcinoma(Silva et al., 2017) and as prognostic indicators for ovarian cancer(Han et 
al., 2006).  
 
223 
 
There are weaknesses that exist in this study, the main one being the low numbers 
of patients particularly for the localized PC study where chemotherapy was 
administered. This PC clinical project has been designed to study two groups of non-
metastasized patients; one with PC in situ (non-resected) and the other post-
pancreatectomy surgery (resected) to shed light on the impact of the tumour 
presence but also ‘isolate’ the effect of chemotherapy alone (without the tumour 
present). Unfortunately, the chemotherapy arm of the PC study was still on going at 
completion of the experimental work of this thesis, hence the numbers of patients 
were too low for meaningful analysis during this period and comparative evaluation 
with MM during treatment time points could not be achieved. As a compromise the 
data for this section was analysed for all patients with PC at baseline and week 8 of 
chemotherapy cycle, which may explain the lack of any meaningful conclusion at this 
point in time.  
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Chapter:6  General Discussion 
 
 
 
A better understanding of the molecular mechanisms that underlie cancer-related 
venous thromboembolism (VTE) is of vital importance for the development of better 
screening, treatment and prevention strategies. The mechanisms through which 
cancer induces or influences prothrombotic activity are many and varied and still not 
well understood. There are some biomarkers of this activity including Tissue Factor 
(TF), the selectins, D-dimers (Ay et al., 2009; Pabinger & Ay, 2009) that have been 
shown to demonstrate variable degrees of clinical correlation with CAT but robust 
markers and causative stimuli are yet to be identified and developed. This study 
concentrated on thrombin generation (TG), a key constituent of coagulation, and it 
was demonstrated that thrombin production can potentially show haemostatic 
differences in cancer cells of varied aetiology in vitro as well as in blood obtained from 
patients in the clinical setting. This project has also contributed to the understanding 
of thrombin activity under various conditions, including the presence of freely soluble 
TF, circulating TF microvesicles (MVs) and coagulation factors of the intrinsic (factor 
XII) and extrinsic (factor VII) pathways. In addition, it has shown the acquisition of 
procoagulant characteristics in the endothelium through prothrombotic mechanisms 
such as TFMV uptake, TF expression and thrombin generation.  
 
It is known that the vascular endothelium is prominently involved in clot formation, 
and can contribute to clinical VTE complications including DVT in malignancies(Blom 
et al., 2005). Several reports have described increased levels of procoagulant 
molecules including active TF produced from disruption of the endothelial wall 
(Moore et al., 1987; Mackman, 2009; 2012). Increasing TF levels in endothelial cells, 
delivered through uptake of TFMVs (often circulating at increased levels in cancer 
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patients) can lead to endothelial transformation through activation of PAR-2 and 
induction of a pro-apoptotic state that leads to cumulative damage and denudation 
of the endothelial layer. This endothelial dysfunction results in a decrease in 
production of anti-coagulant factors such as TF pathway inhibitor [TFPI], 
thrombomodulin (Moore et al., 1987) compounding the pathologic conditions that 
can initiate thrombosis clinically. However, endothelial deterioration is likely to be a 
much more complex event driven by a number of inflammatory, mechanical and 
molecular procoagulant mechanisms operative in the tumour micro and macro 
environment. As described in chapter 3, this thesis has found changes in endothelial 
behaviour positively linked to the production of TF in association with MVs (TFMVs) 
from cancer cells (Table 3.2). Here, increased TF antigen levels, were correlated with 
endothelial acquisition of procoagulant qualities such as TG in significant quantities, 
measured through parameters of the calibrated automated thrombography (CAT) 
assay. The endothelial changes also include decreased (faster) clotting times from 
previously non-clotting endothelial cells, presence of tumour MVs attachment to the 
endothelial cell membrane surface. This procoagulant activity (PCA) is a crucial 
example of endothelial heterogeneity displayed through its ability in conforming to 
different functional needs at a cellular level(Aird, 2012). It has been shown in 
published literature that TFMVs from other malignancies can have the same effect 
on human dermal blood endothelial cells (HDBECs), and a mechanism of how this 
could be induced has been proposed by Collier et al through internalization and 
recycling of circulating TF to the cell surface and associated PS exposure(Collier et al., 
2013). There are a few other studies that support this hypothesis; for example human 
glioblastoma cancer cells have been found to cause platelet aggregation and thus 
increase hypercoagulability through TFMVs shed in patients’ blood(Bastida et al., 
1984). In addition, Maiolo et al have previously described an increase in TF-like PCA 
found in tumour cell-endothelial cell co-cultures- localized on endothelial 
cells(Maiolo et al., 2002). These variations that exist in hypercoagulability of the 
endothelium may reveal therapeutically targetable ways that may be explored in 
cancer development. Potentially, anti-thrombotic strategies for VTE prevention may 
also be developed that focus on protecting the endothelium from such 
prothrombotic transformation, by reducing the PCA response to malignancies. 
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A novel finding in this study is that HUVECs that displayed new PCA from tumour MVs 
association also displayed similar TG characteristics to the parent tumour from which 
the MVs were derived. This may mean that the endothelial cells inherit similar TG 
abilities transferred by cancer MVs, which is a novel example of cross-talk between 
the tumour environment and cancer. This finding may have significant implications, 
as it provides an understanding of how tumours force not only their micro- but also 
macro-environment to be remodelled after them. Although beyond the scope of this 
study, it would be interesting to conduct intracellular studies of these endothelial 
cells using PCR techniques and proteomic assays to detect any genetic transcription 
and translation molecules that are produced as result of the change in endothelial 
phenotype reported in this thesis. A most recent discovery has been made by Ettelaie 
et al, regarding a possible post-translational modification of TF that enables its 
continued exposure on primary endothelial cells, and its release within cell-derived 
MVs(Ettelaie et al., 2018). This modification occurs in the cytoplasmic domain of TF, 
where phosphorylation of the serine 258 by protein kinase C and the ubiquitination 
of lysine 255 residues, are protected by peptidy-prolyl trans/cis isomerase 1 (Pin1), a 
multifunctional and diverse enzyme, with eventual prevention of TF release. 
Additional studies are however needed to further the understanding on the 
intracellular regulation of TF endometrial PCA.  
 
The CAT assay has been used on numerous studies to study TG mostly in vitro, and 
while informative, these studies have yet to give complete representations of clinical 
thrombotic mechanisms and possible biomarkers. Correlation of a procoagulant state 
in suspected VTE patients with TG has been shown to various degrees; one recent 
study in particular which compared in vivo and ex vivo characteristics using urine and 
plasma substrates suggested that higher levels of prothrombin 1+2 fragments in 
urine correlated with increased Lag times, times-to-peak (TTP) and endogenous 
thrombin potential (ETP) in diagnosed VTE cases(Wexels et al., 2017). However, the 
issue of acceptable substrates to use and the consistency of the results is also a factor 
preventing wide uptake of CAT assays. While thrombin can be generated in virtually 
all substrates including whole blood(Ninivaggi et al., 2012), cord blood(Rice et al., 
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2016), synovial fluid(Chang et al., 1995), urine and plasma(Wexels et al., 2017), not 
all substrates generate consistently recordable CAT parameters with the available 
Thrombinoscope calibrator, which creates potential sources of discrepancy in VTE 
assessment. Calibrator variability also occurs amongst laboratories, compounding 
the technical issues that exist(van Veen et al., 2008). In chapter 5, platelet-free 
plasma (PFP) was used, as recommended by the assay protocol developed by Hemker 
et al. As varied as these methods of assessing VTE through TG are, however inter-
laboratory variability of results has been a major deterrent to routine use in clinical 
practice. Also there are chances of high inter-individual differences in thrombin 
recorded per patient as seen in some studies(Wegert et al., 2005), which was not 
seen in this study. An attempt at standardization of TG assays with a large multicentre 
study was proposed in 2012, and although this study reported minor variability in 
acceptable limits (Dargaud et al., 2012), the study population was too small (6 
patients per centre) to be reliably utilized. Therefore, at present the CAT results 
obtained in this project are not generalizable or strictly comparable to other studies 
performed with various substrates on the assay, necessitating the need for more 
work to develop better fully standardized protocols.  
 
Several studies as discussed in the introduction section have already described the 
coagulation cascade and its numerous clotting factors involved in thrombus 
formation (Davie & Ratnoff, 1964; Macfarlane, 1964; Hoffman & Monroe, 2001; 
Ferreira et al., 2010). Thrombin is a key protease that has a multifunctional role in the 
cascade. Despite the understanding of its key importance and necessity for clot 
formation, thrombin production requires further studies to establish it as an 
independent predictor of symptomatic VTE in clinical settings. Although VTE is now 
known to be driven by anti-cancer treatments, in the context of the two malignancies 
(Multiple myeloma (MM) and Pancreatic cancer (PC)) that were the subject of this 
work, not many studies have investigated the thrombin generation kinetics, or 
explored the effect of treatment such as chemotherapy on its production. It was 
shown in the in vitro studies in chapter 4, through plasma deficient (of specific 
coagulation factors) conditions that the coagulation pathways (intrinsic and contact) 
can have variable impact on the TG parameters, which are affected significantly but 
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also variably in different cancer cells. The cytological pathology of cancer (for 
example adenocarcinoma of PC vs plasma cell malignancy of MM) therefore matters 
in TG as it was shown in chapter 4 that solid cancer cell lines of PC have a TF-
dependent thrombotic propensity over haematological lines such as MM. This 
propensity was exhibited in faster TG times and overall higher amount of thrombin 
produced in PC cell lines than MM, although MM cells may have a larger intrinsic 
pathway TG reserve than PC cells. The intrinsic reserve may result from the ability of 
MM cells to generate thrombin in both factor XII and VII absence in plasma, unlike in 
PC cells where TG was significantly reduced in factor VII absence but not factor XII. 
The observation here implies differential contributions of both cancer types to TG, 
and has also been suggested in a recent study by Rice et al(Rice et al., 2016), where 
MM may have the ability of persistent continuous, subclinical clot 
formation(Duchemin et al., 2008). Furthermore, the results in chapter 3 showed that 
tumour MVs produce similar TG patterns as their parent cell sources, which further 
implicates MVs as an important thrombotic facilitator that enhances TF PCA and a 
source of TG. The different pro-thrombotic qualities measured by CAT assay gives an 
insight into how these malignancies may behave dissimilarly inside the host by 
portrayal of differing thrombotic profiles. This assay has also proven insightful in a 
few other studies on clinical VTE. For example, an ETP of 30% or greater has been 
found in one study to reflect the severity of a bleeding tendency(Al Dieri et al., 2002). 
In the clinical setting, this could be therapeutically advantageous, as currently anti-
thrombotic medications used to prevent VTE occurrences are not tailored. Anti-TF 
therapy through TF silencing can be developed for cancers with TF-dependent 
thrombotic pathways, while inhibition of coagulation Factor XII by selective depletion 
in non-TF dependent cancer(Revenko et al., 2011), might represent an important 
therapeutic goal in cancer thrombosis management(Marchetti et al., 2012). In this 
regard, personalized VTE therapy or prophylaxis would be of utmost benefit as a 
future goal, and the determination of thrombotic phenotypes using TG may have a 
major impact on mortality from thromboembolic incidents, as has been potentially 
suggested for TF as a tumour-type specific biomarker for VTE recurrence by Fonseca 
et al (Fonseca et al., 2017) in their response to the CATCH study(Khorana et al., 2017). 
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These very interesting in vitro findings generated the hypothesis that similar 
differences may underlie the VTE phenotype of these two malignancies in vivo as well 
and that the study of TF levels and TG in human tissue (PFP in this instance) could 
mirror or parallel these findings, and also that cancer treatment could have 
differential effects on these coagulation parameters. Unfortunately, by the 
completion time of the fieldwork for this thesis not enough patients had accrued into 
the pancreatic cancer on chemotherapy cohort of this study for this comparison to 
be made, although this study is ongoing. However, in chapter 5 some interesting 
observations could be made, of the MM patient group in particular, and a few 
tentative observations could also be made across the two cohorts of cancer patients. 
In chapter 5 part A, it was shown that the paraprotein levels of MM patients 
progressively reduced across the cycles of chemotherapy treatment up to 8 weeks 
after end of treatment. This result reflects a treatment response which signifies a 
reduction in plasma viscosity that did not impact TG measurements as none of the 
TG parameters in chapter 5 part B showed a similar trend of progressive decline 
during treatment similar to the paraprotein levels. Chapter 5 part B also 
demonstrated that in MM patients the peak thrombin was the TG parameter that 
significantly correlated (r=-0.41, p=0.04) with TF antigen levels (sCD142 measured by 
ELISA) in patient samples at baseline before treatment commenced. This may signify 
that the actual amount of peak thrombin produced reduces as TF antigen levels 
increase. These correlations, though modest and at first appearing contradictory, 
may indicate the importance of studies of TF antigen configurations, as although TF 
may be available in plasma in association with MVs, in serum it may exist in a different 
isoform, one whose function decreases in relation to the amount of TF present. 
Several studies of various TF isoforms and encryptions in literature have implied that 
not all TF configurations have functional ability (Bogdanov et al., 2003; Bach, 2006; 
Chen & Hogg, 2013). Detailed studies of the mechanisms that influences and regulate 
TF isoforms in circulation with MVs, and in concert with thrombin production are 
desirable in the future to further the understanding of hypercoagulability in the 
cancer patients during treatment.  
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Another interesting result observed in chapter 5 part B, was that MM had the highest 
ETP (1429nM/minute) amongst the 4 patient groups measured for TG including PC. 
This result, and those presented in chapter 4, further highlighted the above-
mentioned intrinsic pathway reserve possible in MM, presumably due to a residual 
capacity of these cells to induce TG after TF-FVII inhibition in FVII-deficient plasma as 
previously suggested by Marchetti et al(Marchetti et al., 2012). Thus, it may be 
theorized that MM may have a larger haemostatic ability or procoagulant potential 
than previously known in literature, which may be responsible for the larger 
thrombin potential observed. Interestingly, TF antigen levels measured in PC serum 
were less than that in MM and healthy controls. This apparent paradox can be 
understood in view of the type and conditions of the serum substrate used, instead 
of plasma in which most of the TF and TFMV activity is known to be carried. Studies 
of TF isoforms have not extensively detailed the types found in different substrates, 
and approximations from in vitro studies may not accurately translate to sample 
obtained directly from patients themselves. Moreover, differing lengths of storage 
and freeze-thawing cycles may have significant effects on TF solubility and 
attachments to MVs in serum, although this has yet to be studied in detail in 
literature. In our laboratory group, Echrish et al, found that both TF antigen and 
associated MV activity of some PC cases investigated showed no significant variations 
from the control groups when measured by ELISA in frozen patient serum, inviting 
the suggestion that TFMV activity as well as reliable TF antigen detection might be 
affected by lengths of storage (unpublished work; 2008). Another possibility could be 
due at least in part, to the inhibitory effect of current thromboprophylaxis treatment 
in cancer patients. In particular, Maraveyas et al has previously described that Low 
molecular weight heparin (Dalteparin) can affect the circulating levels of TF in PC 
patient serum and serum-induced cell-invasion(Maraveyas et al., 2010), although no 
such knowledge currently exist in literature on this observation in MM patients. In 
the Maraveyas et al study, PC patients studied on Dalteparin treatment (n=39), serum 
TF antigen reduced from 336 pg/ml to 303 pg/ml as compared to controls (p=0.005). 
It would be interesting to explore this result further in view of the results from this 
chapter that showed that serum TF levels are higher in MM patients in comparison 
to PC. Therefore, more prospective studies are necessary to explore TF antigen and 
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TFMV activity in various cancers under treatment and to fully evaluate the premises 
of prolonged storage on the TF isoforms in different substrates, and the practical 
implications in assay selections. 
 
In PC, clots are known to form through highly TF-dependent mechanisms, unlike in 
MM. Several studies using various assays have measured high levels of TF in PC 
patients before treatment and correlated this to VTE risks. In the CAT assay used for 
this thesis, two TG parameters were of prominence in chapter 4; Lag times and TTP, 
which both showed consistent results differentiating TG in the solid cancers such as 
PC from the haematological ones such as MM in cell lines in vitro. Chapter 5 also 
showed that these two parameters were also of significance in highlighting 
differences seen in MM patient samples during chemotherapy treatment, although 
assessing their relationship to VTE risk was beyond the scope of this project. 
Specifically, both Lag times and TTP illustrated a progressive delay in thrombin 
formation that reached its peak at the third cycle of chemotherapy administration 
but recovered after the end of chemotherapy and returned to pre-treatment values. 
From these results, it may be hypothesized that the delay may be related to the 
concurrent administration of LMWH as anti-thrombotic in MM patients, or a rise in 
cumulative endothelial damage from chemotherapy which may be marked by a rise 
in MVs of endothelial origins that has been previously observed in a clinical study 
prior to this project(Hall et al., 2016). In support of this hypothesis is a study by 
Auwerda et al, which has identified increased levels of TFMVs in MM patients that 
develop VTE after prolonged chemotherapy treatment, compared to those that do 
not (Auwerda et al., 2011). Elevated MVs have also been recognized to reflect 
alterations in endothelial states in cancer patients from treatment(Burger & Touyz, 
2012; Hall et al., 2016), and this damage has been associated with increased cancer 
VTE(Kuenen et al., 2002). These observations all serve to strengthen the relevance of 
endothelial injury as a probable mechanism of chemotherapy-induced 
hypercoagulability in cancer patients. 
 
In summary, this thesis has provided data that has contributed to the understanding 
of thrombin and TF-associated prothrombotic mechanisms in cancers of different 
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aetiology. This project has expanded the present knowledge of endothelial 
involvement in cancer VTE development through TF and TFMV-dependent 
mechanisms, by demonstrating that procoagulant MVs shed by tumour cells induced 
a procoagulant effect in endothelial cells through increased clotting activity, TG and 
cell membrane surface expression of TF. The interplay of these main players in 
thrombus development during treatment may influence specific TG kinetics that may 
eventually aid in hospital identification of at-risk VTE patients and monitoring of 
thromboprophylaxis in cancer patients. In addition, the contribution of several lesser-
known factors in the coagulation cascade may reveal new therapeutic targets. 
However, these hypotheses need to be explored further under various haemostatic 
conditions in several other cancer types and in different clinical settings. More studies 
are also needed that reflect the in vivo thrombotic processes in cancer patients to 
fully confirm the observations made in this project.  
 
 
6.1    Future work 
 
Future work recommended for this study include the extension of both clinical 
studies most especially the PC on chemotherapy arm to maximally recruit the desired 
patient numbers. This would remove the limitations of the data reported in this thesis 
by allowing full exploration of study aims; such as the detailed comparison of TG 
kinetics in the cancer groups- PC pre-surgery baseline and after surgery, MM relapse 
and newly diagnosed patients on chemotherapy, and effects of chemotherapy on TG 
in PC over the duration of treatment. Estimation of TG in the absence of other 
coagulation factors of the clotting pathway would also be beneficial in order to obtain 
a more comprehensive and holistic profile of the coagulation cascade in various 
malignancies. Furthermore, statistically analysis of the patterns observed in TFMV 
origins with changes in treatment should be assessed to provide more information 
on MV characteristics. The contribution of other cell types to the complex 
interactions during TG should also not be underestimated. For example, how 
activated neutrophils generate MVs and also how the avulsed extracellular DNA 
produced from these neutrophils (NETs)(von Bruhl et al., 2012) interplays with the 
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endothelium in coagulation processes in vitro and in vivo are worthy of further study. 
In addition, studies that utilize cell-sorting flow cytometry to reliably isolate and 
separate the endothelial cell populations with procoagulant capacity that are induced 
by tumour TFMVs should be conducted. This will enable selection of TF-expressing 
endothelial cells from non-TF expressing cells, which may then be transfected with 
TF siRNA to knockdown TF production and demonstrate inhibition of prothrombotic 
activity such as thrombin generation. Although beyond the scope of this study, it may 
be an intriguing way to characterize these procoagulant endothelial cells populations 
further, which may propel future investigations on the inner composition of the TF-
adherent cells, the signalling mechanisms employed in PCA acquisition and the 
intracellular changes in mRNA/cDNA expression that occur as a result. It may also 
shed light on how these endothelial cells are chosen or selected for specific TFMVs 
attachment. Lastly, detailed studies should also be conducted with MVs from treated 
cancer cell lines to determine whether chemotherapy (or other treatment) effects 
can result in variable PCA transformation (TG kinetics) of the endothelium.  
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APPENDIX A: Multiple Myeloma 
 
Oncology and Haematology Centre 
Castle Hill Hospital 
Castle Road 
Cottingham 
HU16 5JQ 
 
APPENDIX A1:  
 
Patient information sheet for newly diagnosed Multiple 
Myeloma patients undergoing chemotherapy 
 
Title 
 
Study of apoptosis related changes and endothelial responses of 
multiple myeloma patients treated with chemotherapy. 
 
Introduction 
You are being invited to take part in a research study. Before you decide it is 
important for you to understand why the research is being done and what it will 
involve. Please take time to read the following information carefully. Talk to others 
about the study if you wish. 
• Part 1 tells you the purpose of this study and what will happen to you if 
you take part. 
• Part 2 gives you more detailed information about the conduct of the study. 
Ask us if there is anything that is not clear or if you would like more information. Take 
time to decide whether or not you wish to take part. 
 
Part 1 
What is the purpose of the study and why have I been chosen? 
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You have been diagnosed as having multiple myeloma, a type of bone cancer, 
which can hopefully be treated with chemotherapy. Chemotherapy is given to 
eliminate or reduce the size of the tumour in the bone marrow. Your doctor will 
have determined which combination of chemotherapy drugs is best for you. This 
will depend on the stage of the disease and your personal circumstances. Apart 
from the common symptom of persistent bone pain that this cancer causes, and 
which you may be experiencing, it can also have effects on the blood. These 
can include; increased thickness of the blood, reducucedproduction of red blood 
cells, white blood cells and platelets, and an increased capacity of the blood to clot. 
In addition, certain chemotherapy drugs such as, thalidomide and lenalidomide, which 
you may be receiving have been linked with clotting problems. To reduce this risk you 
may also receive low molecular weight heparins that thin the blood to prevent blood 
clots forming. It is currently unknown exactly how these drugs can increase the 
chance of blood clots, also known as thrombosis. However, one of the ways in which 
chemotherapy kills cancer cells, can cause the release tiny cell particles into the blood. 
These cell fragments, known as microparticles may contain factors that have the 
potential to cause thrombosis. To prove this is one of the mechanisms in which 
clotting can occur during chemotherapy, we have designed a clinical study of these 
microparticles with clotting potential before, during and after chemotherapy, in 
multiple myeloma patients. Furthermore, other factors involved in clotting (e.g. 
platelets) or those that suggest a predisposition to thrombosis (e.g. vessel damage) 
will also be assessed. 
 
Do I have to take part? 
No. It is up to you to decide whether or not to take part. If you do, you will be given 
this information sheet to keep and be asked to sign a consent form. You are still free 
to withdraw at any time and without giving a reason. A decision to withdraw at any 
time, or a decision not to take part, will not affect the standard of care you receive. 
 
What will happen to me if I take part? 
• Blood will be drawn for regular blood tests during the course of your 
treatment and at this point we would like to draw some more (about two-
three tablespoons). There will be up to a maximum of five samples taken; 
one sample taken before the start of your chemotherapy course, three 
samples during and one at the end of chemotherapy. 
• Also, a routine bone marrow biopsy will be taken at the time of diagnosis and we 
would like a small amount (approximately 1 ml) of this bone marrow aspirate, this 
will have absolutely no impact on the accuracy of your diagnosis. 
 
Therefore, we would like to ask your permission for some of your blood and bone 
marrow to be used for research purposes. This will include samples for DNA analysis 
that will be processed and stored separately using DNA preservative (Allprotect 
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Tissue Reagent, QIAGEN), which will be done to identify whether any genes (eg 
factor V leiden) may have promoted the tendency to clot. 
 
What do I have to do? 
Attend all scheduled visits so blood samples can be taken at the set timepoints. 
 
What are the side effects or risks involved when taking part?  
Blood samples:There should be no extra risks or side effects 
from the procedures as they will be part of the regularly 
planned tests that your doctors need to monitor your 
progress before, during and after chemotherapy. 
 
What are the possible benefits of taking part? 
No direct benefits to you are expected from this research. The information we get from this 
study may help us to improve the future treatment of patients with multiple myeloma. 
 
What if there is a problem? 
Any complaint about the way you have been dealt with during the study or any 
possible harm you might suffer will be addressed. The detailed information on this is 
given in Part 2. 
 
Will my taking part in the study be kept confidential? 
Yes. We will follow ethical and legal practice and all information about you will be handled 
in confidence. The details are included in Part 2. 
 
Contact details: 
Dr. Anthony Maraveyas (Chief Investigator) Queens Centre for Oncology & Haematology Hull 
& East Yorkshire NHS Trust 
Castle Hill Hospital 
Tel: 01482 461318 
 
This completes Part 1 of the Information Sheet. 
If the information in Part 1 has interested you and you are considering 
participation, please continue to read the additional information in Part 2 before 
making any decision. 
 
Part 2 
 
What will happen if I don't want to carry on with the study? 
If you withdraw from the study, we will destroy all your identifiable blood samples and any 
analysis that may have taken place. 
 
What if there is a problem?  
Complaints: 
If you have a concern about any aspect of this study, you should ask to speak to the 
researchers who will do their best to answer your questions (01482 461318). If you 
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remain unhappy and wish to complain formally, you can do this through the NHS 
Complaints Procedure. Details can be obtained from the hospital. 
Harm: 
 
In the event that something does go wrong and you are harmed during the research, no 
special compensation arrangements exist. However, if you were harmed due to someone's 
negligence then you may have grounds for legal action against the NHS Trust. The 
normal NHS complaints mechanisms will still be available to you. 
 
Will my taking part in this study be kept confidential? 
All information which is collected about you during the course of the research will be kept 
strictly confidential, and any information about you which leaves the hospital/surgery will 
have your name and address removed so that you cannot be recognised. 
 
What will happen to any samples I give? 
The blood analysis may take place immediately after collection. Stored samples will be 
coded anonymously then locked securely in locked freezers. Access to these samples 
is restricted to the research members only. 
After we complete our tests, we would like to save any left-over blood or bone marrow for 
other myeloma research projects, subject to appropriate approval. All samples will be 
destroyed after a period of five years. 
 
What will happen to the results of the research study? 
The results of this study will be kept completely confidential, and no personal details will 
be disclosed. These results will be analysed and written in a research degree thesis 
(Ph.D). The findings may be presented at learned societies or published in scientific 
journals. In such cases the information will only identify you with a number and not your 
name or other personal details. 
 
Who is organising and funding the research? 
Dr. Anthony Maraveyas is the Chief Investigator of this clinical trial that is sponsored by 
the NHS (Hull and East Yorkshire Hospitals NHS Trust). 
 
Who has reviewed the study? 
This study was given a favourable ethical opinion for conduct in the NHS by the local 
Research Ethics Committee. 
We would like to thank you for your attention so far and hopefully for your participation in 
this study. Please feel free to ask your doctors any questions about the study or about any 
of the treatments described above. You will be given a copy of the information sheet and a 
signed consent form to keep if you choose to participate. 
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APPENDIX B: Pancreatic Cancer 
 
Oncology and Haematology Centre 
Castle Hill Hospital 
Castle Road 
Cottingham 
HU16 5JQ 
 
 
APPENDIX B1:  
 
Patient Information Sheet of Pancreatic Cancer Patients 
undergoing Pancreatic Resection  
 
Title 
 
A Study of the effect of resection of localised Pancreatic Cancer on 
tissue-factor promoted pathways of Thrombosis and Angiogenesis 
markers 
 
Introduction 
 
You have been invited to take part in a research study.  Before you decide it 
is important that you understand why the research is being done and what it 
will involve.  Please take time to read the following information carefully and 
discuss it with friends, relatives and your GP if you wish.  Ask us if there is 
anything that is not clear or if you would like more information. Take time to 
decide whether or not you wish to take part.  Consumers for Ethics in 
Research (CERES) publish a leaflet called Medical Research and You. 
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This leaflet gives more information about medical research and looks at some 
questions you may want to ask. A copy can be obtained from the doctor or 
nurse inviting you to take part or from CERES, PO Box 1365, London N16 
OBW. 
 
What is the purpose of the trial? 
 
You have been diagnosed as having cancer of the pancreas, which is 
localised and can hopefully be removed.  Your surgeon therefore has offered 
you surgery with the intention of removing the tumour in your pancreas.  If 
removal is successful you may be offered more treatment called 
chemotherapy.  This will depend on the stage of the tumour and will only be 
accurately known after the pathologist has had chance to study the tumour 
under the microscope.  Chemotherapy is given to improve the effectiveness 
of the surgical treatment.  Apart from the common symptoms of blockage of 
the gut and the bile system that this cancer causes, and which you may be 
experiencing, it can also have effects on the blood.  We and others have 
found that it increases the capacity of the blood to clot and to provide 
nutrients for cancer blood vessels.  All these effects promote the growth of 
secondary cancer and are collectively called ‘cancer promoting factors’.  We 
think that the planned removal of this cancer from your pancreas may 
provide benefit by removing these ‘cancer promoting effects’ from the blood 
as well as relieving the blockage on the gut. 
To prove this we have designed a clinical study of these ‘cancer promoting 
factors’ before and after surgery and during and after chemotherapy. 
 
 
 
What will happen to me during the trial? 
 
We would want to study the concentration of these ‘cancer promoting 
factors’ in your blood before and after surgery and during and after 
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chemotherapy if it is offered to you.  We would also like to correlate these 
factors with the appearances of the tumour that has been removed.  We 
therefore would like to ask your permission for some of your blood and for a 
small portion of the tumour to be used for research purposes. 
 
Before the operation, blood will be drawn for regular blood tests and at this 
point we would like to draw some more (about two-three tablespoons) for 
the study.  The surgeon will undertake the operation as planned.  The cancer 
will be sent for histological diagnosis and with the aid of the pathologist (the 
expert who looks at cancers under the microscope) we would like a small 
portion of this tumour to be removed for research of factors that promote 
cancer.  We want the expert to do this so that the removal of this small 
portion has absolutely no impact on the accuracy of the staging of your 
cancer. 
 
About eight weeks after the operation, by which time we think that healing is 
complete, and during a regular follow-up visit, we would like a further 
sample of blood of similar quantity as before the research.  If you are not 
offered chemotherapy this will be the end of the study for you. 
 
If you are offered chemotherapy a further three blood tests will be taken, 
one during chemotherapy, at 12 weeks, one at the end of chemotherapy, at 
24 weeks, and one eight weeks after the conclusion of all the treatment.  At 
this point, your involvement with the study finishes. 
 
In the case, therefore, of you going on to chemotherapy, a total of five blood 
samples are required. 
 
Are there any side effects associated with these treatments? 
 
There should be no extra risks or side effects from the procedures as they 
will be part of the regularly planned tests that your doctors need before the 
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surgery and to monitor your progress after the surgery and during and after 
chemotherapy. 
 
Are there any other extra procedures? 
 
No extra procedures are planned.  The tissue will be taken from the tumour 
that has already been removed. 
 
 
What are the possible benefits of taking part? 
 
No direct benefits to you are expected from this research.  The information 
we get from this study may help us to improve the future treatment of 
patients with pancreatic cancer. 
 
What is something goes wrong? 
 
If you were harmed by taking part in this study, no special compensation 
arrangements exist.  However, if you were harmed due to someone’s 
negligence, then you would have grounds for legal action.  Regardless of 
this, if you have any cause to complain about any aspect of the way you 
have been approached or treated during the course of this study, the normal 
National Health Service complaints mechanisms are available to you. 
 
What if new information becomes available? 
 
Sometimes during the course of a research project, new information 
becomes available about the treatment that is being studied.  If this 
happens, your research doctor will tell you about it and discuss with you 
whether you want to continue in the study.  If you decide to withdraw, your 
research doctor will make arrangements for your care to continue.  If you 
decide to continue in the study you will be asked to sign an updated consent 
form. 
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Will my taking part in this study be kept confidential? 
 
All information which is collected about you during the course of this 
research will be kept strictly confidential.  With your permission we will 
inform your GP of your participation in the study.  Other than this, any 
information about you that leaves the hospital will have your name and 
address removed so you cannot be identified from it. 
 
Who is organising and funding the research? 
 
This is a trial sponsored and funded by the NHS (HEYNHST) & The University 
of Hull. 
 
Dr. Anthony Maraveyas is the Chief Investigator 
 
What if I do not wish to take part or change my mind? 
 
You do not have to take part in this trial if you do not wish to do so.  If you 
decide to take part you are free to withdraw at any time.  In either case you 
do not have to give a reason for your decision and this will have no influence 
over your future medical care.  If you do decide to take part in this study you 
will be asked to sign a consent form. 
 
We would like to thank you for your cooperation, Please feel free to 
ask your doctors any questions about the study or about any of the 
treatments described above. 
 
Please contact:  
Dr. Anthony Maraveyas-Castle Hill Hospital . Tel: 01482 676703    
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Dr. Mufuliat Adeola Adesanya  – Hull York Medical School, Hull 
University. Mobile Number: 07586203204. 
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APPENDIX B2 
 
Patient Information Sheet for Patients Undergoing Chemotherapy for 
resected primary pancreatic cancer (adjuvant). 
 
 
A study of the effect of chemotherapy on the Tissue-factor promoted 
pathways of thrombosis and angiogenesis in resected (adjuvant) and 
non-resected localised pancreatic cancer patients  
 
Introduction 
 
We would like to invite you to take part in a research study.  Before you 
decide whether you would like to participate, it is important that you 
understand why the research is being done and what it will involve.  Please 
take time to read the following information carefully and discuss it with 
friends, relatives and your GP if you wish.  Ask us if there is anything that is 
not clear or if you would like more information.  
 
Take time to decide whether or not you wish to take part.  Consumers for 
Ethics in Research (CERES) published a leaflet called Medical Research and 
You. 
 
This leaflet gives more information about medical research and looks at 
some questions you may want to ask. A copy can be obtained from the 
doctor or nurse inviting you to take part or from CERES, PO Box 1365, 
London N16 OBW. 
 
What is the purpose of the trial? 
 
You have been diagnosed as having cancer of the pancreas, which is 
localised and your surgeon was able to remove the cancer.  Your surgeon 
has now referred you for chemotherapy to try and reduce the risk of this 
cancer coming back (relapsing).   
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We and others have found that chemotherapy can increase the capacity of 
the blood to clot. We have also found that the same factors that promote clot 
can also promote the growth of the cancer. Collectively we call these ‘cancer 
promoting factors’.  We know that the production of a clot can make patients 
unwell (swelling of the leg or cause chest symptoms such as shortness of 
breath and chest pain). We also suspect it may also signify worse cancer 
related outcomes. We would like to find out if there are groups of patients 
more likely to be affected by these ‘cancer promoting factors’.  Being able to 
predict this could lead to better cancer treatment and better preventive 
treatments of thrombosis (clots). 
 
We are studying two major groups of pancreatic cancer patients, those in 
which the surgeon could not remove the tumour and those (like yourself) in 
whom the tumour was removable. 
 
What will happen to me during the trial? 
 
We would want to study the concentration of these ‘cancer promoting factors’ 
in your blood during and after chemotherapy, if it is offered to you and you 
decide to accept.  We therefore would like to ask your permission to collect a 
blood sample from you at specific time-points during your treatment. The 
amount of blood that will be taken for the research is about 2 to 3 
tablespoons each time. 
 
If you decide to proceed with the chemotherapy your doctor has offered then 
we would require the blood samples just before you commence 
chemotherapy, and during some of your  regular follow-up visits (at weeks 8-
12 and 24).  
 
At around 24 weeks of treatment you will have reached the planned 
completion of your chemotherapy and you are likely to be having further 
scans. After this point at week 32 (assuming your scans have shown no 
reappearance of the cancer) you will have completed your treatment with 
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chemotherapy and this will also be the date for the last sample for the study. 
We will not require any further samples for the study after this. 
 
You will therefore be having four blood samples in total if you complete the 
planned chemotherapy course in full. 
 
Are there any side effects associated with these treatments? 
 
There should be no extra risks or side effects from the procedures as they 
will be part of the regularly planned tests that your doctors need to monitor 
your progress during and after chemotherapy. 
 
Are there any other extra procedures? 
 
No extra procedures are planned.  
What are the possible benefits of taking part? 
 
No direct benefits to you are expected from this research.  The information 
we get from this study may help us to improve the future treatment of patients 
with pancreatic cancer. 
 
What is something goes wrong? 
 
If you were harmed by taking part in this study, no special compensation 
arrangements exist.  However, if you were harmed due to someone’s 
negligence, then you would have grounds for legal action.   
 
Regardless of this, if you have any cause to complain about any aspect of 
the way you have been approached or treated during the course of this 
study, the normal National Health Service complaints mechanisms are 
available to you. 
 
What if new information becomes available? 
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Sometimes during the course of a research project, new information 
becomes available about the treatment that is being studied.  If this happens, 
your research doctor will tell you about it and discuss with you whether you 
want to continue in the study.  If you decide to withdraw, your research doctor 
will make arrangements for your care to continue.  If you decide to continue 
in the study you will be asked to sign an updated consent form. 
 
 
Will my taking part in this study be kept confidential? 
 
All information which is collected about you during the course of this research 
will be kept strictly confidential.  With your permission we will inform your GP 
of your participation in the study.  Other than this, any information about you 
that leaves the hospital will have your name and address removed so you 
cannot be identified from it. 
 
 
Who is organising and funding the research? 
 
This is a trial sponsored and funded by the NHS (HEYNHST) & The 
University of Hull. 
 
Professor Anthony Maraveyas is the Chief Investigator 
 
What if I do not wish to take part or change my mind? 
 
You do not have to take part in this trial if you do not wish to do so.  If you 
decide to take part you are free to withdraw at any time.  In either case you 
do not have to give a reason for your decision and this will have no influence 
over your future medical care.  If you do decide to take part in this study you 
will be asked to sign a consent form. 
 
Please feel free to ask your doctors any questions about the study or about 
any of the treatments described above.  
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We would like to thank you for reading this information sheet. 
 
Contact for further information 
 
Professor Anthony Maraveyas- Chief Investigator, Castle Hill Hospital, 
Hull  
Tel: 01482 461245, 07772717393 
Dr Mufuliat A. Adesanya – Hull York Medical School, University of Hull.  
Mobile: 07586203204 
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APPENDIX B3 
 
Patient Information Sheet for Patients Undergoing Chemotherapy for 
non-resected primary pancreatic cancer. 
 
A study of the effect of chemotherapy on the Tissue-factor promoted 
pathways of thrombosis and angiogenesis in resected (adjuvant) and 
non-resected localised pancreatic cancer patients. 
 
Introduction 
 
We would like to invite to take part in a research study.  Before you decide 
whether you would like to participate, it is important that you understand why 
the research is being done and what it will involve.  Please take time to read 
the following information carefully and discuss it with friends, relatives and 
your GP if you wish.  Ask us if there is anything that is not clear or if you 
would like more information.  
 
Take time to decide whether or not you wish to take part.  Consumers for 
Ethics in Research (CERES) published a leaflet called Medical Research and 
You. 
 
This leaflet gives more information about medical research and looks at 
some questions you may want to ask. A copy can be obtained from the 
doctor or nurse inviting you to take part or from CERES, PO Box 1365, 
London N16 OBW. 
 
What is the purpose of the trial? 
 
You have been diagnosed as having cancer of the pancreas, which is 
localised but could not be removed.  Your surgeon therefore has either 
attempted to remove the cancer unsuccessfully or has just biopsied the 
cancer and referred you for  chemotherapy to relieve the symptoms and 
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delay the worsening of the cancer condition.   The aim of chemotherapy is to 
improve symptoms and to prevent or delay further complications of the 
cancer on your gut, such as blockages.   Apart from the common symptoms 
of blockage of the gut and the bile system that this cancer can cause, and 
which you may be experiencing, it can also have effects on the blood.  We 
and others have found that it increases the capacity of the blood to clot and 
to provide nutrients for cancer blood vessels.  All these effects promote the 
growth of secondary cancer and are collectively called ‘cancer promoting 
factors’.  To prove this we have designed a clinical study of these ‘cancer 
promoting factors’ before and during chemotherapy. We are studying two 
major groups of pancreatic cancer patients, those in which the surgeon has 
removed the tumour and those in whom this was not possible. 
 
What will happen to me during the trial? 
 
We would want to study the concentration of these ‘cancer promoting factors’ 
in your blood during and after chemotherapy, if it is offered to you.  We 
therefore would like to ask your permission to collect a blood sample from 
you at specific time-points during your treatment. The amount of blood that 
will be taken for the research is about 2 to 3 tablespoons each time. 
 
If you decide to proceed with the chemotherapy your doctor has offered then 
we would require the blood samples just before you commence 
chemotherapy, and during some of your regular follow-up visits, (weeks 8-12 
and 24). 
  
At around 12 weeks of chemotherapy you will also be due a CT scan to 
assess the response of the cancer. If your doctor decides to continue for a 
further 12 weeks then a further blood test will be taken at 24 weeks of 
treatment at which point you are likely to be having further scans. About eight 
weeks after this scan the final blood test will be required (at this point you 
may still be on chemotherapy or your doctor may have decided on a 
treatment break).  After this last sample we will not require any further 
samples for the study. 
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You will therefore be having four blood samples in total if you complete the 
full planned chemotherapy course. 
 
Are there any side effects associated with these treatments? 
 
There should be no extra risks or side effects from the procedures as they 
will be part of the regularly planned tests that your doctors need to monitor 
your progress during and after chemotherapy. 
 
Are there any other extra procedures? 
 
No extra procedures are planned.  
What are the possible benefits of taking part? 
 
No direct benefits to you are expected from this research.  The information 
we get from this study may help us to improve the future treatment of patients 
with pancreatic cancer. 
 
What is something goes wrong? 
 
If you were harmed by taking part in this study, no special compensation 
arrangements exist.  However, if you were harmed due to someone’s 
negligence, then you would have grounds for legal action.   
 
Regardless of this, if you have any cause to complain about any aspect of 
the way you have been approached or treated during the course of this 
study, the normal National Health Service complaints mechanisms are 
available to you. 
 
What if new information becomes available? 
 
Sometimes during the course of a research project, new information 
becomes available about the treatment that is being studied.  If this happens, 
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your research doctor will tell you about it and discuss with you whether you 
want to continue in the study.  If you decide to withdraw, your research doctor 
will make arrangements for your care to continue.  If you decide to continue 
in the study you will be asked to sign an updated consent form. 
 
 
Will my taking part in this study be kept confidential? 
 
All information which is collected about you during the course of this research 
will be kept strictly confidential.  With your permission we will inform your GP 
of your participation in the study.  Other than this, any information about you 
that leaves the hospital will have your name and address removed so you 
cannot be identified from it. 
 
 
Who is organising and funding the research? 
 
This is a trial sponsored and funded by the NHS (HEYNHST) & The 
University of Hull. 
 
Professor Anthony Maraveyas is the Chief Investigator 
 
What if I do not wish to take part or change my mind? 
 
You do not have to take part in this trial if you do not wish to do so.  If you 
decide to take part you are free to withdraw at any time.  In either case you 
do not have to give a reason for your decision and this will have no influence 
over your future medical care.  If you do decide to take part in this study you 
will be asked to sign a consent form. 
 
Please feel free to ask your doctors any questions about the study or about 
any of the treatments described above.  
 
We would like to thank you for reading this information sheet. 
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Contact for further information 
 
Professor Anthony Maraveyas-Chief Investigator, Castle Hill Hospital, 
Hull.  
Tel: 01482 461245, 07772717393 
Dr Mufuliat A. Adesanya- Hull York Medical School, University of Hull.  
Mobile: 07586203204 
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APPENDIX C: TFMVs in Multiple Myeloma and 
Pancreatic Cancer 
 
As a one-off experiment, TFMVs were measured by flow cytometry in MM (n=25) and 
PC (n=29) serum samples (serum obtained as described in section 2.8.3). In 5ml 
polypropylene tubes, 5 µl of FITC-conjugated mouse IgG1 isotype control antibody 
(AbD Serotec) or 5µl of FITC-conjugated mouse anti-human monoclonal anti-TF were 
added to 25 µl of serum before incubation in the dark for 30 minutes to allow binding.  
 
Although not benchmarked for serum studies, a well-known protocol for identifying 
MV subpopulations as detailed by the International Society on Thrombosis and 
Haemostasis (ISTH) Scientific and Standardization Subcommittee in Vascular Biology 
was utilized(Lacroix et al., 2010), was used here. This method allows the reproducible 
isolation of MVs with different scatter properties on a flow cytometer by addition of 
an antibody which detects specific membrane surface antigen (Robert et al., 2009) in 
plasma. In this study, the cell surface TF antigen (sCD142), expressed on membrane 
surfaces was used to detect TFMVs in serum. TFMVs from a region between 0.1-0.9 
μm in size were gated by addition of Megamix beads (Biocytex, Marseille, France) 
which contains different-sized beads of 0.5, 0.9, and 3.0 μm diameter. TFMVs are 
enumerated by AccuCheck counting beads (Invitrogen Ltd, Paisley, UK) which are 
fluorescent-labelled and contains quantities of latex beads (A and B) of known 
concentration from the supplier (approximately 1000 beads/μl).  
 
Following incubation, 350 μl of PBS was added to resuspend the antibody in the 
tubes, after which 25 μl of the counting bead mixture were added immediately prior 
to flow cytometric evaluation. On the cytometer 25,000 positive events were 
counted, where positive MV events were denoted as the difference in labelling 
between cell-specific FITC-labelled TF (sCD142) antibodies and the isotype control 
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antibody. A differential relation to the standard bead events counted by the 
cytometer allows the estimation of an absolute count of MVs in the substrate found 
in the fixed size gated region. This was calculated as: 
 
MVs Absolute count (MVs/ μl) = Number of MVs count/ Total number of beads 
counted (A + B) x known concentration of beads as supplied by manufacturer (1000 
beads μl) 
 
 
For example, if the number of TFMVs count in a sample tube is 500, and the total 
number of latex beads counted for A is 650 while B is 600, then the equation gives 
the Absolute TFMVs count as: 
 
500/ (650+600) x 1000 = 400 TFMVs present. 
 
Results: 
 
In this lone experiment, there were no significant differences (p=0.3419) in the 
median (IQR) sTFMVs in MM (2196 (842.7-11340)) and PC (1714 (593.9-13623))/µl of 
serum (Figure A.0.1) Correlations of serum TF (sCD142) measured by ELISA with 
serum TFMVs in MM and PC patients also showed no association (Figure A.0.2 and 
A.0.3 respectively). 
 
 
 
Figure A.0.1 Serum TFMVs measured by Flow cytometry in MM and PC patients 
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Figure A.0.2 Correlation of serum TF (sCD142) with serum TFMVs in MM patients 
 
 
Figure A.0.3 Correlation of serum TF (sCD142) with serum TFMVs in PC patients 
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